var title_f20_12_20672="MR due to mitral valve prolapse four chamber color Doppler echo";
var content_f20_12_20672=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/78402/4chcdmvp_conv.mp4?title=MR+due+to+mitral+valve+prolapse+four+chamber+color+Doppler+echo\" style=\"width:328px;height:248px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral valve prolapse with mitral regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 249px; height: 224px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Four chamber view from a 2-D echocardiogram with color flow Doppler shows significant mitral regurgitation due to a prolapse of the posterior leaflet of the mitral valve. As a result, the mitral regurgitation \"jet\" is directed anteriorly, toward the interatrial septum and aortic root.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_12_20672=[""].join("\n");
var outline_f20_12_20672=null;
var title_f20_12_20673="Duplication cyst";
var content_f20_12_20673=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fetal duplication cyst with debris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse view of fetal abdomen at gestational age of 31 weeks shows a cyst (arrow) with echogenic debris. Color Doppler (not shown) showed no flow in the echogenic portion. This debris moved within the cyst which showed peristalsis on real-time examination.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_12_20673=[""].join("\n");
var outline_f20_12_20673=null;
var title_f20_12_20674="Axillary freckling";
var content_f20_12_20674=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Axillary freckling in Neurofibromatosis type 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple hyperpigmented macules are present in the axilla.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_12_20674=[""].join("\n");
var outline_f20_12_20674=null;
var title_f20_12_20675="Megakaryocytes";
var content_f20_12_20675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F55409&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F55409&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bone marrow megakaryocytes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow aspirate shows two megakaryocytes with multilobulated nuclei and voluminous cytoplasm. A normal neutrophil (arrow) next to the megakaryocyte illustrates the large size of these cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David S Rosenthal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_12_20675=[""].join("\n");
var outline_f20_12_20675=null;
var title_f20_12_20676="Vulva hematoma";
var content_f20_12_20676=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar hematoma from straddle injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marc Laufer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_12_20676=[""].join("\n");
var outline_f20_12_20676=null;
var title_f20_12_20677="Renal disease in Sjgren's syndrome";
var content_f20_12_20677=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Renal disease in Sj&ouml;gren's syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/12/20677/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/12/20677/contributors\">",
"     Jai Radhakrishnan, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/12/20677/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/12/20677/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/12/20677/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/12/20677/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/12/20677/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sj&ouml;gren's syndrome is typically associated with a lymphocytic and plasmacytic infiltrate in the salivary, parotid, and lacrimal glands, leading to a sicca syndrome. This immune process can also affect non-exocrine organs, including the kidneys, producing an interstitial nephritis and defects in tubular function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=see_link\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reported prevalence of renal involvement has varied widely, ranging from 2 to 67 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20677/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This variability is due in part to different definitions of kidney involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTERSTITIAL NEPHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interstitial nephritis in Sj&ouml;gren's syndrome is characterized histologically by an interstitial infiltrate that can invade and damage the tubules [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20677/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. In some cases, granuloma formation is seen, and there may be a concurrent uveitis, suggesting the possible presence of sarcoidosis or the tubulointerstitial nephritis and uveitis (TINU syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20677/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40438?source=see_link\">",
"     \"Renal disease in sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20486?source=see_link\">",
"     \"Tubulointerstitial nephritis and uveitis (TINU syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More chronic disease is associated with tubular atrophy and interstitial fibrosis. The glomeruli are usually normal, although an immune complex-mediated glomerulonephritis has rarely been described (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Glomerular disease'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20677/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of the interstitial nephritis include a variable but generally mild elevation in the plasma creatinine concentration, a relatively benign urinalysis, and abnormalities in tubular function, including the Fanconi syndrome, distal (type 1) renal tubular acidosis (RTA), nephrogenic diabetes insipidus (tubular resistance to antidiuretic hormone), and hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20677/abstract/5,8-14\">",
"     5,8-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few data defining the optimal treatment of interstitial nephritis in Sj&ouml;gren's syndrome. In the absence of such data, it seems reasonable to prescribe a course of glucocorticoids if the interstitial nephritis is severe and active [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20677/abstract/15\">",
"     15",
"    </a>",
"    ]; stabilization or improvement in renal function have been reported anecdotally.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    , starting at 1",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    (up to 60 mg per day), has been used followed by a taper according to clinical response.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    maintenance therapy at doses of 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    can be instituted as a steroid-sparing agent in patients who appear to be steroid dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20677/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Distal renal tubular acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A defect in distal acidification occurs in up to 25 percent of patients with Sj&ouml;gren's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20677/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]. The associated metabolic acidosis is usually mild, but some patients present with a plasma bicarbonate concentration below 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and a plasma potassium concentration below 1.5 to 2",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    due to concurrent urinary potassium wasting. A brief review of the mechanisms by which distal acidification might be impaired RTA and the effect of these abnormalities on distal potassium secretion is available elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link\">",
"     \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\"",
"    </a>",
"    .) Muscle paralysis and respiratory arrest have been reported as consequences of the severe hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20677/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]; in some cases, hypokalemic paralysis has been the presenting symptom of Sj&ouml;gren's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20677/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism by which Sj&ouml;gren's syndrome leads to distal RTA is incompletely understood. Several patients have been described in whom immunocytochemical analysis of tissue obtained by renal biopsy showed complete absence of the H-ATPase pump in the intercalated cells in the collecting tubules that is largely responsible for distal proton secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20677/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. How the immune injury leads to loss of H-ATPase activity is not known. Another possible mechanism is the presence of high titers of an autoantibody directed against carbonic anhydrase II; inhibition of this enzyme would result in the generation within the cell of fewer hydrogen ions available for secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20677/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients present with a normal anion gap metabolic acidosis due to distal RTA without a prior diagnosis of Sj&ouml;gren's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20677/abstract/8\">",
"     8",
"    </a>",
"    ]. It is therefore important to consider the possible presence of this disorder in any adult with otherwise unexplained distal RTA since treatment aimed at the immunologic disease (as described above) may at least partially correct the acidification defect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link\">",
"     \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H2\">",
"     'Interstitial nephritis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Treatment of patients with distal RTA is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5860?source=see_link\">",
"     \"Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nephrogenic diabetes insipidus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyuria and polydipsia due to nephrogenic diabetes insipidus is another manifestation of impaired tubular function in Sj&ouml;gren's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20677/abstract/13\">",
"     13",
"    </a>",
"    ]. Once again, patients may present with these complaints rather than a sicca syndrome. It is therefore important to exclude Sj&ouml;gren's syndrome in any adult with symptomatic nephrogenic diabetes insipidus who does not have the two most common causes of this disorder: chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ingestion or hypercalcemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=see_link\">",
"     \"Clinical manifestations and causes of nephrogenic diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hypokalemia without renal tubular acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tubular injury induced by the interstitial nephritis indirectly leads to potassium wasting and potentially severe hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20677/abstract/8,14\">",
"     8,14",
"    </a>",
"    ]. The primary defect is thought to be sodium wasting which has two effects that augment potassium secretion: it increases sodium delivery to the potassium secretory site in the collecting tubules; and, via volume depletion, enhances the release of aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20677/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This mechanism is different from that in RTA, and these patients can acidify the urine normally and do not have metabolic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20677/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     GLOMERULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glomerular involvement is much less common than interstitial nephritis in Sj&ouml;gren's syndrome. Membranoproliferative glomerulonephritis (MPGN) and membranous nephropathy (MN) are the most common [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20677/abstract/5,17-19\">",
"     5,17-19",
"    </a>",
"    ]. The pathogenesis of the glomerular disease, including the possible etiologic relationship to Sj&ouml;gren's syndrome, is unclear but may be related to the deposition of circulating immune complexes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20677/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Optimal therapy is uncertain. Some patients with MPGN, for example, have been treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    without or with cytotoxic therapy (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) with varying reports of success [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20677/abstract/5,15,17\">",
"     5,15,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The renal findings in Sj&ouml;gren's syndrome are not specific for this disorder, as the diagnosis generally requires a sicca syndrome with objectively abnormal ocular tests and lymphocyte infiltration around the salivary glands in a biopsy specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20677/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"    </a>",
"    .) However, occasional confusion can occur since similar findings can be seen in sarcoidosis and the sensation of dry mouth can be induced by a variety of drugs. In addition, patients with IgG4-related disease may have salivary and lacrimal gland involvement as well as interstitial nephritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13178?source=see_link\">",
"     \"Overview of IgG4-related disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The autoantibodies anti-Ro (SSA) and anti-La (SSB) are relatively specific for Sj&ouml;gren's syndrome (or systemic lupus erythematosus) and, if present, can help confirm the diagnosis in the proper clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20677/abstract/13\">",
"     13",
"    </a>",
"    ]. These autoantibodies are directed against nucleoprotein antigens that are in part homologous with viral antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20677/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]; it is not clear, however, if there is a pathogenetic role for viral exposure via the mechanism of molecular mimicry [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20677/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8568?source=see_link\">",
"     \"The anti-Ro/SSA and anti-La/SSB antigen-antibody systems\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3322713\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The reported prevalence of renal involvement in patients with Sj&ouml;gren's syndrome varies from 2 to 67 percent, due in part to different definitions of kidney involvement. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal disease in Sj&ouml;gren's syndrome is usually characterized by interstitial nephritis, marked clinically by a variable but generally mild elevation in the serum creatinine, a relatively benign urinalysis, and abnormalities in tubular function (eg, distal [type 1] renal tubular acidosis [RTA], nephrogenic diabetes insipidus, and hypokalemia) (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Interstitial nephritis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A defect in distal acidification occurs in up to 25 percent of patients with Sj&ouml;gren's syndrome. The associated metabolic acidosis is usually mild, but some patients present with a plasma bicarbonate concentration below 10",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      and a plasma potassium concentration below 1.5 to 2",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      due to concurrent urinary potassium wasting. Occasionally, distal RTA may occur without a prior diagnosis of Sj&ouml;gren's syndrome. Thus, it is important to consider the possibility of Sj&ouml;gren's syndrome in any adult with otherwise unexplained distal RTA since treatment aimed at the immunologic disease may at least partially correct the acidification defect. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Distal renal tubular acidosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Polyuria and polydipsia due to nephrogenic diabetes insipidus is another manifestation of impaired tubular function that, like distal RTA, may occur without a prior diagnosis of Sj&ouml;gren's syndrome. It is therefore important to exclude Sj&ouml;gren's syndrome in any adult with symptomatic nephrogenic diabetes insipidus who does not have chronic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      ingestion or hypercalcemia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nephrogenic diabetes insipidus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The tubular injury induced by the interstitial nephritis indirectly leads to potassium wasting and potentially severe hypokalemia. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hypokalemia without renal tubular acidosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A course of glucocorticoids (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      up to 60",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      followed by tapering doses depending upon clinical response) may be prescribed in patients with severe active interstitial nephritis. In patients who appear to be steroid dependent,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg/day)",
"      </span>",
"      may be used as a steroid-sparing agent. Progression to end-stage renal disease (ESRD) is a rare event. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Interstitial nephritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glomerular involvement is much less common than interstitial nephritis in Sj&ouml;gren's syndrome. Membranoproliferative glomerulonephritis (MPGN) and membranous nephropathy (MN) are the most common. Optimal therapy in such cases is uncertain. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Glomerular disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The renal findings in Sj&ouml;gren's syndrome are not specific for this disorder; the diagnosis generally requires a sicca syndrome be present with objectively abnormal ocular tests and lymphocyte infiltration around the salivary glands in a biopsy specimen. However, similar ocular findings can be seen in sarcoidosis and the sensation of dry mouth can be induced by a variety of drugs. In addition, patients with IgG4-related disease may have salivary and lacrimal gland involvement as well as interstitial nephritis. The autoantibodies anti-Ro (SSA) and anti-La (SSB) are relatively specific for Sj&ouml;gren's syndrome and, if present, can help confirm the diagnosis in the proper clinical setting. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20677/abstract/1\">",
"      Vitali C, Bombardieri S, Moutsopoulos HM, et al. Preliminary criteria for the classification of Sj&ouml;gren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993; 36:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20677/abstract/2\">",
"      Pertovaara M, Korpela M, Pasternack A. Factors predictive of renal involvement in patients with primary Sj&ouml;gren's syndrome. Clin Nephrol 2001; 56:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20677/abstract/3\">",
"      Bossini N, Savoldi S, Franceschini F, et al. Clinical and morphological features of kidney involvement in primary Sj&ouml;gren's syndrome. Nephrol Dial Transplant 2001; 16:2328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20677/abstract/4\">",
"      Tu WH, Shearn MA, Lee JC, Hopper J Jr. Interstitial nephritis in Sj&ouml;gren's syndrome. Ann Intern Med 1968; 69:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20677/abstract/5\">",
"      Goules A, Masouridi S, Tzioufas AG, et al. Clinically significant and biopsy-documented renal involvement in primary Sj&ouml;gren syndrome. Medicine (Baltimore) 2000; 79:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20677/abstract/6\">",
"      Vidal E, Rogues AM, Aldigier JC. The Tinu syndrome or the Sj&ouml;gren syndrome? Ann Intern Med 1992; 116:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20677/abstract/7\">",
"      Moutsopoulos HM, Balow JE, Lawley TJ, et al. Immune complex glomerulonephritis in sicca syndrome. Am J Med 1978; 64:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20677/abstract/8\">",
"      Poux JM, Peyronnet P, Le Meur Y, et al. Hypokalemic quadriplegia and respiratory arrest revealing primary Sj&ouml;gren's syndrome. Clin Nephrol 1992; 37:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20677/abstract/9\">",
"      Walker BR, Alexander F, Tannenbaum PJ. Fanconi syndrome with renal tubular acidosis and light chain proteinuria. Nephron 1971; 8:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20677/abstract/10\">",
"      Pun KK, Wong CK, Tsui EY, et al. Hypokalemic periodic paralysis due to the Sj&ouml;gren syndrome in Chinese patients. Ann Intern Med 1989; 110:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20677/abstract/11\">",
"      Cohen EP, Bastani B, Cohen MR, et al. Absence of H(+)-ATPase in cortical collecting tubules of a patient with Sjogren's syndrome and distal renal tubular acidosis. J Am Soc Nephrol 1992; 3:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20677/abstract/12\">",
"      Bastani B, Haragsim L, Gluck S, Siamopoulos KC. Lack of H-ATPase in distal nephron causing hypokalaemic distal RTA in a patient with Sj&ouml;gren's syndrome. Nephrol Dial Transplant 1995; 10:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20677/abstract/13\">",
"      SHEARN MA, TU WH. NEPHROGENIC DIABETIC INSIPIDUS AND OTHER DEFECTS OF RENAL TUBULAR FUNCTION IN SJOERGREN'S SYNDROME. Am J Med 1965; 39:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20677/abstract/14\">",
"      Wrong OM, Feest TG, MacIver AG. Immune-related potassium-losing interstitial nephritis: a comparison with distal renal tubular acidosis. Q J Med 1993; 86:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20677/abstract/15\">",
"      Kaufman I, Schwartz D, Caspi D, Paran D. Sj&ouml;gren's syndrome - not just Sicca: renal involvement in Sj&ouml;gren's syndrome. Scand J Rheumatol 2008; 37:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20677/abstract/16\">",
"      Takemoto F, Hoshino J, Sawa N, et al. Autoantibodies against carbonic anhydrase II are increased in renal tubular acidosis associated with Sjogren syndrome. Am J Med 2005; 118:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20677/abstract/17\">",
"      Cortez MS, Sturgill BC, Bolton WK. Membranoproliferative glomerulonephritis with primary Sj&ouml;gren's syndrome. Am J Kidney Dis 1995; 25:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20677/abstract/18\">",
"      Baba A, Hara S, Sato Y, et al. [Three patients with nephrotic syndrome due to membranous nephropathy complicated by Sj&ouml;gren's syndrome]. Nihon Jinzo Gakkai Shi 2005; 47:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20677/abstract/19\">",
"      Stefanidis I, Giannopoulou M, Liakopoulos V, et al. A case of membranous nephropathy associated with Sj&ouml;gren syndrome, polymyositis and autoimmune hepatitis. Clin Nephrol 2008; 70:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20677/abstract/20\">",
"      Diagnosis of Sj&ouml;gren's syndrome. Lancet 1992; 340:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20677/abstract/21\">",
"      McNeilage LJ, Umapathysivam K, Macmillan E, et al. Definition of a discontinuous immunodominant epitope at the NH2 terminus of the La/SS-B ribonucleoprotein autoantigen. J Clin Invest 1992; 89:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20677/abstract/22\">",
"      Scofield RH, Harley JB. Autoantigenicity of Ro/SSA antigen is related to a nucleocapsid protein of vesicular stomatitis virus. Proc Natl Acad Sci U S A 1991; 88:3343.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7187 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-F7325097AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_12_20677=[""].join("\n");
var outline_f20_12_20677=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3322713\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTERSTITIAL NEPHRITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Distal renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hypokalemia without renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GLOMERULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3322713\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=related_link\">",
"      Classification and diagnosis of Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=related_link\">",
"      Clinical manifestations and causes of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=related_link\">",
"      Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13178?source=related_link\">",
"      Overview of IgG4-related disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=related_link\">",
"      Pathophysiology of renal tubular acidosis and the effect on potassium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40438?source=related_link\">",
"      Renal disease in sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8568?source=related_link\">",
"      The anti-Ro/SSA and anti-La/SSB antigen-antibody systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5860?source=related_link\">",
"      Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20486?source=related_link\">",
"      Tubulointerstitial nephritis and uveitis (TINU syndrome)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_12_20678="Pneumothorax in HIV-infected patients";
var content_f20_12_20678=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pneumothorax in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/12/20678/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/12/20678/contributors\">",
"     Patricia A Tietjen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/12/20678/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/12/20678/contributors\">",
"     Steven A Sahn, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/12/20678/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/12/20678/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/12/20678/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/12/20678/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumothorax is an uncommon but potentially fatal complication of human immunodeficiency virus (HIV) infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. Pneumothorax complicated 1.2 percent of all hospital admissions in a cohort of 599 HIV-infected patients followed over three years in a prospective observational study [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/1\">",
"     1",
"    </a>",
"    ]. In this report, development of a pneumothorax was associated with a significant increase in in-hospital mortality (31 versus 6 percent for patients without pneumothorax).",
"   </p>",
"   <p>",
"    Causes of pneumothorax in HIV-infected individuals include Pneumocystis jirovecii pneumonia (PCP) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/3,4,6-17\">",
"     3,4,6-17",
"    </a>",
"    ], iatrogenic pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/18\">",
"     18",
"    </a>",
"    ], Kaposi's sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/19\">",
"     19",
"    </a>",
"    ], intravenous drug abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/20\">",
"     20",
"    </a>",
"    ], toxoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/7\">",
"     7",
"    </a>",
"    ], and bacterial, fungal, viral, and mycobacterial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/1-4,21-23\">",
"     1-4,21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of pneumothorax in HIV-infected patients will be presented here. Reviews of the etiology and treatment of primary and secondary spontaneous pneumothorax are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10297?source=see_link\">",
"     \"Primary spontaneous pneumothorax in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=see_link\">",
"     \"Secondary spontaneous pneumothorax in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the cause of pneumothorax in patients with PCP is unclear, the major hypotheses have focused on tissue necrosis produced by the organism and a possible role of prophylactic treatment with aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pneumocystis jirovecii",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several investigators believe that extensive tissue invasion within the alveolar interstitium is common in severe PCP, and is an important factor in causing necrosis and subsequent pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. The following observations illustrate this point:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common sites of tissue invasion with PCP (in descending order of frequency) are the alveolar septa, pleura, and vasculature [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tissue invasion could cause necrosis as a result of the host inflammatory response [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/29\">",
"       29",
"      </a>",
"      ], direct tissue injury by toxins elaborated by Pneumocystis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/24\">",
"       24",
"      </a>",
"      ], or infarction from vascular compromise [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/24,25,27\">",
"       24,25,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Both cavitary lesions and pneumothorax are potential complications of necrosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Aerosolized pentamidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    has been implicated in the pathogenesis of cavitation, cyst formation, and pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/4,12,30\">",
"     4,12,30",
"    </a>",
"    ], but the biologic basis for this relationship is unknown. No direct toxic action of pentamidine on the lungs has been demonstrated, but an indirect effect may be present. Cavitation due to PCP may occur primarily in the upper lobes and periphery because aerosolized pentamidine is preferentially delivered to the proximal parenchyma of the lower lobes. Inadequate deposition of pentamidine in the periphery of the lung could allow a chronic, low-grade infection with Pneumocystis to persist, leading to peripheral lung destruction and pneumatocele formation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/4\">",
"     4",
"    </a>",
"    ]. Furthermore, increased survival of AIDS patients due to prophylaxis could allow additional time for development of the lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, tissue invasion, cavitary lesions, and pneumothoraces have been demonstrated in patients who are not treated with aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    , suggesting that other factors (eg, infections with other pathogens) can contribute to the development of necrotizing lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several risk factors for AIDS-related pneumothorax have been identified in addition to active or previous infection with Pneumocystis jirovecii and use of aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    . These include cigarette smoking and the presence of pneumatoceles on chest radiograph [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/31\">",
"     31",
"    </a>",
"    ]; the former is also a risk factor for spontaneous pneumothorax in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10297?source=see_link\">",
"     \"Primary spontaneous pneumothorax in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The association between cigarette smoking and AIDS-related pneumothorax could be explained by subclinical obstructive lung disease preventing adequate deposition of aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    in the lung periphery, resulting in subpleural Pneumocystis infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/31\">",
"     31",
"    </a>",
"    ]. Pulmonary tuberculosis also appears to enhance the risk of pneumothorax in AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glucocorticoid therapy, although not a cause of pneumothorax, may be associated with increased morbidity when a pneumothorax occurs. In one report, for example, patients who received glucocorticoids required longer chest tube drainage and a greater number of pleurodesis procedures than did those not receiving glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/31\">",
"     31",
"    </a>",
"    ]. Furthermore, it was rare to have AIDS-related pneumothoraces resolve with observation alone in patients receiving glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of AIDS-related pneumothorax appears to be similar to that of pneumothorax in patients without AIDS. Dyspnea and chest pain of acute onset are the most common symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=see_link&amp;anchor=H7#H7\">",
"     \"Secondary spontaneous pneumothorax in adults\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=see_link&amp;anchor=H8#H8\">",
"     \"Secondary spontaneous pneumothorax in adults\", section on 'Imaging and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic patients found to have a small pneumothorax (less than 15 to 20 percent) may be observed; some will have spontaneous resolution without further interventions. Symptomatic patients and those with a larger pneumothorax will need chest tube thoracostomy and those with a persistent air leak will likely need additional therapy with video-assistant thoracoscopy for stapling and pleurodesis. Patients who are poor operative candidates may benefit from bedside pleurodesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Chest tube thoracostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are symptomatic or who have a large pneumothorax should be treated initially with standard chest tube thoracostomy in a fashion similar to that used for secondary spontaneous pneumothorax in patients without AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients with AIDS-related pneumothorax tend to have persistent air leaks, often related to a bronchopleural fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/4,7,8,31\">",
"     4,7,8,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=see_link\">",
"     \"Placement and management of thoracostomy tubes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=see_link\">",
"     \"Secondary spontaneous pneumothorax in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another option for treatment of a small pneumothorax is attaching a Heimlich valve to a small bore chest tube [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;If an air leak persists for three days following placement of a chest tube, the patient is assessed for possible video-assisted thoracic surgery (VATS), with stapling of the blebs and pleurodesis (eg, talc, pleural abrasion, or partial pleurectomy) performed under direct video-assisted guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Traditional thoracotomy with or without pleurectomy is the last and least attractive option. It can be performed if VATS is unsuccessful or not possible because the patient cannot tolerate single lung ventilation, the lesion cannot be reached through the thoracoscope, or the lung does not collapse during the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=see_link&amp;anchor=H1032319#H1032319\">",
"     \"Secondary spontaneous pneumothorax in adults\", section on 'Persistent air leakage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several surgical series have shown that, in properly selected patients, operative therapy is virtually always successful and has acceptable morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/13,14,39\">",
"     13,14,39",
"    </a>",
"    ]. One study, for example, reported eight operations for PCP-associated pneumothorax in seven patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/39\">",
"     39",
"    </a>",
"    ]. Surgery was performed because of inability to expand the lung",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    persistent air leak. The time from insertion of the initial chest tube to surgery was 9 to 66 days (mean 33 days). The air leaks were closed with surgical staples",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sutures. Chest tubes were removed 3 to 16 days following surgery (mean 8.5 days). No patient died, and patients were discharged from the hospital 6 to 18 days following surgery.",
"   </p>",
"   <p>",
"    Another study reported 22 AIDS patients who developed 30 pneumothoraces [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/14\">",
"     14",
"    </a>",
"    ]. Fourteen of these patients had a unilateral pneumothorax, while eight had synchronous or sequential bilateral pneumothoraces. After resolution with tube thoracostomy, eight patients had one or more recurrent pneumothoraces. Tube thoracostomy was successful in the treatment of unilateral pneumothorax in 10 of the 14 patients, while two required pleurectomy and stapling for resolution. Surgery was required more frequently (six of eight cases) in patients with bilateral pneumothoraces. None of these six patients had a recurrent pneumothorax.",
"   </p>",
"   <p>",
"    A third series consisted of 44 patients treated with standard tube thoracostomy for spontaneous pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/13\">",
"     13",
"    </a>",
"    ]. Fourteen (32 percent) developed a persistent air leak for more than 10 days, and two patients had a subsequent pneumothorax on the contralateral side. Surgical therapy in 14 patients included 15 thoracotomies and one sternotomy. The bronchopleural fistula was closed directly with suture or staples in 15 procedures and resected by lobectomy in one. All 14 patients had parietal pleurectomy performed. The operative mortality was 7 percent. The fistula was closed in all survivors, and 13 patients were discharged between postoperative days 7 and 28.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H643307\">",
"    <span class=\"h2\">",
"     Bedside pleurodesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who have a persistent air leak, but are not candidates for surgery, application of a pleural blood patch (known as blood patch pleurodesis) or chemical pleurodesis at the bedside may be effective.",
"   </p>",
"   <p>",
"    Blood pleurodesis is performed by drawing approximately 100 mL of the patient&rsquo;s blood under sterile conditions and instilling it into the pleural space via the chest tube. However, empyema is a potential complication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=see_link&amp;anchor=H1032319#H1032319\">",
"     \"Secondary spontaneous pneumothorax in adults\", section on 'Persistent air leakage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chemical pleurodesis, with the sclerosing agent instilled through a chest tube, has been a successful conservative management option in preventing recurrence and closing the bronchopleural fistula; however, failures are common. Chemical agents that have been used successfully for pleurodesis in this setting include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/40\">",
"     40",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/41\">",
"     41",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/42\">",
"     42",
"    </a>",
"    ], and talc [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20678/abstract/37,43\">",
"     37,43",
"    </a>",
"    ]. Chemical and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36232?source=see_link\">",
"     \"Chemical pleurodesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30615?source=see_link\">",
"     \"Talc pleurodesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Evaluation and treatment for PCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the majority of pneumothoraces in HIV-infected patients occur in association with PCP, all such patients should undergo a diagnostic evaluation for Pneumocystis jirovecii infection. If this is not feasible, empiric antimicrobial therapy for PCP should be initiated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=see_link\">",
"     \"Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=see_link\">",
"     \"Treatment of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H643412\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of secondary spontaneous pneumothorax in HIV-infected individuals occur in conjunction with bacterial or Pneumocystis jirovecii pneumonia (PCP). Less common causes include Kaposi's sarcoma, intravenous drug abuse, toxoplasmosis, and fungal, viral, and mycobacterial infections.",
"   </p>",
"   <p>",
"    Our approach to the patient with AIDS-related pneumothorax is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a pneumothorax larger than 15 to 20 percent (&gt;2 cm between the lung and chest wall on a chest radiograph), a standard tube thoracostomy is performed. For asymptomatic patients with a small pneumothorax (&lt;2 cm between the lung and chest wall on a chest radiograph), we typically observe the patient in hospital for spontaneous resolution or enlargement of the pneumothorax. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Chest tube thoracostomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the air leak persists for three or more days, the patient is assessed for surgery. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A computer tomography (CT) scan of the chest is performed to determine the extent of underlying disease and whether it is unilateral or bilateral.",
"     </li>",
"     <li>",
"      If the patient is a surgical candidate, video-assisted thoracoscopy is usually performed with stapling, electrocautery, or laser photocoagulation followed by pleurodesis, using talc, pleural abrasion, or partial pleurectomy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Surgery'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=see_link&amp;anchor=H1032319#H1032319\">",
"       \"Secondary spontaneous pneumothorax in adults\", section on 'Persistent air leakage'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who are not surgical candidates, instillation of a blood patch (ie, blood patch pleurodesis) or chemical pleurodesis may be performed. (See",
"      <a class=\"local\" href=\"#H643307\">",
"       'Bedside pleurodesis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36232?source=see_link&amp;anchor=H9#H9\">",
"       \"Chemical pleurodesis\", section on 'Procedure via tube thoracostomy'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/1\">",
"      Afessa B. Pleural effusion and pneumothorax in hospitalized patients with HIV infection: the Pulmonary Complications, ICU support, and Prognostic Factors of Hospitalized Patients with HIV (PIP) Study. Chest 2000; 117:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/2\">",
"      Afessa B. Pleural effusions and pneumothoraces in AIDS. Curr Opin Pulm Med 2001; 7:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/3\">",
"      Beck JM. Pleural disease in patients with acquired immune deficiency syndrome. Clin Chest Med 1998; 19:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/4\">",
"      Sepkowitz KA, Telzak EE, Gold JW, et al. Pneumothorax in AIDS. Ann Intern Med 1991; 114:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/5\">",
"      Radhi S, Alexander T, Ukwu M, et al. Outcome of HIV-associated Pneumocystis pneumonia in hospitalized patients from 2000 through 2003. BMC Infect Dis 2008; 8:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/6\">",
"      Coker RJ, Moss F, Peters B, et al. Pneumothorax in patients with AIDS. Respir Med 1993; 87:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/7\">",
"      Byrnes TA, Brevig JK, Yeoh CB. Pneumothorax in patients with acquired immunodeficiency syndrome. J Thorac Cardiovasc Surg 1989; 98:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/8\">",
"      Renzi PM, Corbeil C, Chass&eacute; M, et al. Bilateral pneumothoraces hasten mortality in AIDS patients receiving secondary prophylaxis with aerosolized pentamidine. Association with a lower Dco prior to receiving aerosolized pentamidine. Chest 1992; 102:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/9\">",
"      McClellan MD, Miller SB, Parsons PE, Cohn DL. Pneumothorax with Pneumocystis carinii pneumonia in AIDS. Incidence and clinical characteristics. Chest 1991; 100:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/10\">",
"      Newsome GS, Ward DJ, Pierce PF. Spontaneous pneumothorax in patients with acquired immunodeficiency syndrome treated with prophylactic aerosolized pentamidine. Arch Intern Med 1990; 150:2167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/11\">",
"      Shanley DJ, Luyckx BA, Haggerty MF, Murphy TF. Spontaneous pneumothorax in AIDS patients with recurrent Pneumocystis carinii pneumonia despite aerosolized pentamidine prophylaxis. Chest 1991; 99:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/12\">",
"      Jules-Elysee KM, Stover DE, Zaman MB, et al. Aerosolized pentamidine: effect on diagnosis and presentation of Pneumocystis carinii pneumonia. Ann Intern Med 1990; 112:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/13\">",
"      Crawford BK, Galloway AC, Boyd AD, Spencer FC. Treatment of AIDS-related bronchopleural fistula by pleurectomy. Ann Thorac Surg 1992; 54:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/14\">",
"      Gerein AN, Brumwell ML, Lawson LM, et al. Surgical management of pneumothorax in patients with acquired immunodeficiency syndrome. Arch Surg 1991; 126:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/15\">",
"      Goodman PC, Daley C, Minagi H. Spontaneous pneumothorax in AIDS patients with Pneumocystis carinii pneumonia. AJR Am J Roentgenol 1986; 147:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/16\">",
"      Fleisher AG, McElvaney G, Lawson L, et al. Surgical management of spontaneous pneumothorax in patients with acquired immunodeficiency syndrome. Ann Thorac Surg 1988; 45:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/17\">",
"      Hoyt TL, Tarver RD. HIV, Pneumocystis carinii pneumonia, and pneumothoraces. Semin Respir Infect 2002; 17:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/18\">",
"      Cabrera-Cordero JA, Adefna-P&eacute;rez RI, Leal-Mursul&iacute; A, et al. [Pneumothorax in human immunodeficiency virus infected patients]. Cir Esp 2008; 84:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/19\">",
"      Floris C, Sulis ML, Bernascani M, et al. Pneumothorax in pleuropulmonary Kaposi's sarcoma related to acquired immunodeficiency syndrome. Am J Med 1989; 87:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/20\">",
"      Gurney JW, Bates FT. Pulmonary cystic disease: comparison of Pneumocystis carinii pneumatoceles and bullous emphysema due to intravenous drug abuse. Radiology 1989; 173:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/21\">",
"      Doppman JL, Geelhoed GW, De Vita VT. Atypical radiographic features in Pneumocystis carinii pneumonia. Radiology 1975; 114:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/22\">",
"      P&aacute;ldy L, Iv&aacute;dy G. Roentgenologic diagnosis of interstitial plasma cell pneumonia in infancy. Natl Cancer Inst Monogr 1976; 43:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/23\">",
"      Rivero A, Perez-Camacho I, Lozano F, et al. Etiology of spontaneous pneumothorax in 105 HIV-infected patients without highly active antiretroviral therapy. Eur J Radiol 2009; 71:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/24\">",
"      Murry CE, Schmidt RA. Tissue invasion by Pneumocystis carinii: a possible cause of cavitary pneumonia and pneumothorax. Hum Pathol 1992; 23:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/25\">",
"      Saldana MJ, Mones JM. Cavitation and other atypical manifestations of Pneumocystis carinii pneumonia. Semin Diagn Pathol 1989; 6:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/26\">",
"      Travis WD, Pittaluga S, Lipschik GY, et al. Atypical pathologic manifestations of Pneumocystis carinii pneumonia in the acquired immune deficiency syndrome. Review of 123 lung biopsies from 76 patients with emphasis on cysts, vascular invasion, vasculitis, and granulomas. Am J Surg Pathol 1990; 14:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/27\">",
"      Liu YC, Tomashefski JF Jr, Tomford JW, Green H. Necrotizing Pneumocystis carinii vasculitis associated with lung necrosis and cavitation in a patient with acquired immunodeficiency syndrome. Arch Pathol Lab Med 1989; 113:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/28\">",
"      Balachandran I, Jones DB, Humphrey DM. A case of Pneumocystis carinii in pleural fluid with cytologic, histologic and ultrastructural documentation. Acta Cytol 1990; 34:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/29\">",
"      Eng RH, Bishburg E, Smith SM. Evidence for destruction of lung tissues during Pneumocystis carinii infection. Arch Intern Med 1987; 147:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/30\">",
"      Gutierrez Y. The biology of Pneumocystis carinii. Semin Diagn Pathol 1989; 6:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/31\">",
"      Metersky ML, Colt HG, Olson LK, Shanks TG. AIDS-related spontaneous pneumothorax. Risk factors and treatment. Chest 1995; 108:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/32\">",
"      Bense L, Eklund G, Wiman LG. Smoking and the increased risk of contracting spontaneous pneumothorax. Chest 1987; 92:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/33\">",
"      Tumbarello M, Tacconelli E, Pirronti T, et al. Pneumothorax in HIV-infected patients: role of Pneumocystis carinii pneumonia and pulmonary tuberculosis. Eur Respir J 1997; 10:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/34\">",
"      Trachiotis GD, Vricella LA, Alyono D, et al. Management of AIDS-related pneumothorax. Ann Thorac Surg 1996; 62:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/35\">",
"      Vricella LA, Trachiotis GD. Heimlich valve in the management of pneumothorax in patients with advanced AIDS. Chest 2001; 120:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/36\">",
"      Driver AG, Peden JG, Adams HG, Rumley RL. Heimlich valve treatment of Pneumocystis carinii-associated pneumothorax. Chest 1991; 100:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/37\">",
"      Kimmel RD, Karp MP, Cascone JJ, Zinns JS. Talc pleurodesis during videothoracoscopy for Pneumocystis carinii pneumonia-related pneumothorax. A new technique. Chest 1994; 105:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/38\">",
"      Slabbynck H, Kovitz KL, Vialette JP, et al. Thoracoscopic findings in spontaneous pneumothorax in AIDS. Chest 1994; 106:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/39\">",
"      Horowitz MD, Oliva H. Pneumothorax in AIDS patients: operative management. Am Surg 1993; 59:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/40\">",
"      Busch E, Barlam BW, Wallace J, Nealon TF. Intrapleural tetracycline for spontaneous pneumothorax in acquired immunodeficiency syndrome. Chest 1991; 99:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/41\">",
"      Read CA, Reddy VD, O'Mara TE, Richardson MS. Doxycycline pleurodesis for pneumothorax in patients with AIDS. Chest 1994; 105:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/42\">",
"      Hnatiuk OW, Dillard TA, Oster CN. Bleomycin sclerotherapy for bilateral pneumothoraces in a patient with AIDS. Ann Intern Med 1990; 113:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20678/abstract/43\">",
"      Tunon-de-Lara JM, Constans J, Vincent MP, et al. Spontaneous pneumothorax associated with Pneumocystis carinii pneumonia. Successful treatment with talc pleurodesis. Chest 1992; 101:1177.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6689 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-853D91569B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_12_20678=[""].join("\n");
var outline_f20_12_20678=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H643412\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pneumocystis jirovecii",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Aerosolized pentamidine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chest tube thoracostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H643307\">",
"      Bedside pleurodesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Evaluation and treatment for PCP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H643412\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36232?source=related_link\">",
"      Chemical pleurodesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=related_link\">",
"      Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10297?source=related_link\">",
"      Primary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=related_link\">",
"      Secondary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30615?source=related_link\">",
"      Talc pleurodesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=related_link\">",
"      Treatment of Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_12_20679="Screening for asymptomatic left ventricular dysfunction";
var content_f20_12_20679=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for asymptomatic left ventricular dysfunction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/12/20679/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/12/20679/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/12/20679/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/12/20679/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/12/20679/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/12/20679/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/12/20679/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of heart failure (HF) requires the management of predisposing conditions and risk factors, such as hypertension, coronary artery disease, valvular heart disease, and diabetes, and the detection of patients with asymptomatic left ventricular (LV) systolic dysfunction before they develop overt HF [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/1\">",
"     1",
"    </a>",
"    ]. As will be noted below, less data is available on asymptomatic LV diastolic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=see_link\">",
"     \"Epidemiology and causes of heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early detection, if achievable, is important because randomized trials have shown that appropriate pharmacologic therapy can significantly improve outcomes in patients with asymptomatic LV dysfunction, defined as an LV ejection fraction (LVEF) &le;35 to 40 percent in different studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The rate of progression to symptomatic HF in the placebo group in one trial was 9.7 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential magnitude of this effect was illustrated in the SOLVD prevention trial of 4228 patients (most with a prior myocardial infarction) who had asymptomatic LV systolic dysfunction (LVEF &le;35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/2\">",
"     2",
"    </a>",
"    ]. The patients were randomly assigned to the angiotensin converting enzyme (ACE) inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    or to placebo. At a mean follow-up of just over three years, the enalapril group had a significant reduction in the incidence of death or symptomatic HF (30 versus 39 percent with placebo) (",
"    <a class=\"graphic graphic_figure graphicRef75136 \" href=\"UTD.htm?11/15/11517\">",
"     figure 1",
"    </a>",
"    ). There was a nonsignificant trend toward a lower rate of cardiovascular mortality (14 versus 16 percent, risk reduction 12 percent, 95% CI -3 to 26 percent).",
"   </p>",
"   <p>",
"    At post-trial follow-up at a median of 11 years, there was a significant reduction in cardiovascular mortality in the original",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    group (37 versus 42 percent with placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/5\">",
"     5",
"    </a>",
"    ]. No data were available on post-trial drug use.",
"   </p>",
"   <p>",
"    There are suggestive data that the addition of beta blocker therapy, which provides added benefit in patients with symptomatic HF, also may be effective in asymptomatic patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=see_link\">",
"     \"Evaluation and management of asymptomatic left ventricular systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A second rationale for screening is that outcomes are worse if effective therapy is initiated after patients develop overt HF (",
"    <a class=\"graphic graphic_figure graphicRef60648 \" href=\"UTD.htm?28/60/29645\">",
"     figure 2",
"    </a>",
"    ). In contrast to the 30 percent incidence of death or symptomatic HF in patients with asymptomatic LV systolic dysfunction with an ACE inhibitor in the SOLVD prevention trial, the SOLVD treatment trial showed that, although ACE inhibitors were beneficial in patients with New York Heart Association (NYHA) functional class II to III systolic HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ), the mortality rate alone was 20 percent at two years with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    compared to 25 percent with placebo (",
"    <a class=\"graphic graphic_figure graphicRef70015 \" href=\"UTD.htm?10/28/10701\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4058?source=see_link&amp;anchor=H10444215#H10444215\">",
"     \"Prognosis of heart failure\", section on 'Effect of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with overt systolic HF, further benefit can be achieved by adding other drugs such as beta blockers, an angiotensin II receptor blocker in addition to an ACE inhibitor, and, in selected patients, an aldosterone receptor antagonist. However, such regimens are complex, expensive, and associated with more side effects. Furthermore, the mortality rate is still higher than seen with an ACE inhibitor alone in patients with asymptomatic LV dysfunction (eg, 24 percent at 41 months in CHARM-Added compared to 14 percent in a similar time period in SOLVD prevention) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE OF ASYMPTOMATIC LV SYSTOLIC DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of pharmacologic therapy is important because of the relatively high prevalence of asymptomatic LV systolic dysfunction in the general population, particularly in older subjects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Screening studies using LVEF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence in echocardiographic screening studies varies in part with the LVEF used to define LV systolic dysfunction and with age. The normal reference limit for LVEF by echocardiography is &ge;55 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/8\">",
"     8",
"    </a>",
"    ]. The following observations illustrate the reported prevalence of asymptomatic LV systolic dysfunction in relation to LVEF; the mean age in these studies was 50 to 70 years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LVEF &le;54 percent &mdash; 12.5 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      LVEF &le;50 percent &mdash; 3.3 to 4.7 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      LVEF &le;40 percent &mdash; 0.9 to 2.1 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/10-13\">",
"       10-13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      LVEF &le;30 percent &mdash; 1.4 percent; almost all of these patients with severe LV dysfunction had evidence of coronary heart disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The trials cited above demonstrating benefit from ACE inhibitors in patients with asymptomatic LV systolic dysfunction were limited to patients with an LVEF &le;35 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The prevalence of asymptomatic disease of this severity in the general population is only 0.9 to 2.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/10-12,14\">",
"     10-12,14",
"    </a>",
"    ]. Although milder disease is more common, it is not known if ACE inhibitor therapy in these patients would be beneficial.",
"   </p>",
"   <p>",
"    Subgroups have been identified that have higher rates of asymptomatic LV systolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/9\">",
"     9",
"    </a>",
"    ]. These include men compared to women, older compared to younger patients, and those with known coronary disease in whom the reported rate has ranged from 4.8 to 8.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/9,10,14\">",
"     9,10,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Risk stratification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of having asymptomatic LV systolic dysfunction varies importantly with risk factors. The importance of this effect was illustrated in a screening study that included 734 patients &ge;45 years of age and of varying risk who were randomly selected from a general practice population and 471 selected from a group deemed to be a high risk as defined by one or more of the following risk factors: ischemic heart disease, hypertension, diabetes mellitus, peripheral arterial or cerebrovascular disease, and excessive alcohol intake [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using echocardiography as the gold standard and defining asymptomatic LV systolic dysfunction as an LVEF &lt;45 percent, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LV systolic dysfunction was present in 64 patients, 24 of whom had a general practice diagnosis or heart failure of LV systolic dysfunction or were taking look diuretics",
"     </li>",
"     <li>",
"      LV systolic dysfunction was present in 3.5 percent of patients from the general practice population; 96 percent of these patients had one or more of the above risk factors.",
"     </li>",
"     <li>",
"      LV systolic dysfunction was present in 8.5 percent of high-risk patients (one or more risk factors) compared to 0.2 percent of those at low-risk (1 of 444 with no risk factors).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Familial dilated cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been estimated that 20 to more than 50 percent of cases of idiopathic dilated cardiomyopathy are familial, usually being transmitted as an autosomal dominant trait. The potential value of screening asymptomatic relatives lies in the detection of patients who already have a dilated cardiomyopathy and of those with less pronounced abnormalities who may develop progressive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. A prospective cohort study that evaluated (by echocardiography) 767 asymptomatic first- and second-degree relatives of 189 consecutive patients with idiopathic dilated cardiomyopathy had two major findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dilated cardiomyopathy, left ventricular enlargement without systolic dysfunction, or systolic dysfunction without left ventricular enlargement was present in 23 percent of relatives.",
"     </li>",
"     <li>",
"      At a median follow-up of 53 months, 13 of the 124 relatives (10.4 percent) with left ventricular enlargement without systolic dysfunction or systolic dysfunction without left ventricular enlargement progressed to dilated cardiomyopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/59/5047?source=see_link\">",
"     \"Familial dilated cardiomyopathy: Prevalence, diagnosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Regional wall motion abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of regional wall motion abnormalities (RWMA) in adults without clinically recognized cardiovascular disease was evaluated in a report from the Strong Heart Study [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/18\">",
"     18",
"    </a>",
"    ]. Among 2864 participants (mean age 60 years, 64 percent women), RWMA were detected in 42 (1.5 percent). As with a reduced LVEF noted above, the individuals with RWMA had a higher rate of cardiovascular morbidity and mortality at eight year follow-up, independent of LVEF and other risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diastolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to the multiple studies of LVEF, data are limited on the prevalence of asymptomatic LV diastolic dysfunction. Among 2042 randomly selected residents of Olmsted County, Minnesota who were &ge;45 years of age (mean age 63), 4.7 percent of patients without symptoms of HF had a LV ejection fraction (LVEF) &le;50 percent and 1.0 percent had an LVEF &le;40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/12\">",
"     12",
"    </a>",
"    ]. In comparison, 5.6 percent had moderate to severe diastolic dysfunction with a normal LVEF, 90 percent of whom were asymptomatic. The potential value of identifying these patients is unclear, since the effect of therapy to prevent progression is not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SCREENING MODALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography is the primary modality used to assess LV function in high risk asymptomatic patients. A reduced LVEF, if present, establishes systolic dysfunction. However, other parameters also must be measured to detect patients who have only diastolic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=see_link\">",
"     \"Noninvasive methods for measurement of left ventricular systolic function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=see_link\">",
"     \"Echocardiographic evaluation of left ventricular diastolic function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of ECG abnormalities (sinus tachycardia, atrial fibrillation or flutter, ventricular ectopy, ST or T wave abnormalities, intraventricular conduction defects, pathologic Q waves, or criteria for left ventricular hypertrophy) is highly sensitive in both the general population and high risk patients (90 to 92 percent) but only moderately specific (64 to 78 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;If echocardiographic screening for asymptomatic LV systolic dysfunction were deemed appropriate, one problem is that repeated screening at periodic intervals would be required. The possible role of newer hand-held fully portable echocardiography machines remains to be determined [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cost-effectiveness of echocardiographic screening can be increased if one targets high-risk subgroups. On the other hand, screening low-risk patients with no risk factors has an extremely low yield (1 of 444 [0.2 percent] in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High-risk has been variably defined:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of one or more of ischemic heart disease, hypertension, diabetes mellitus, peripheral arterial or cerebrovascular disease, and excessive alcohol intake [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Survivors of a myocardial infarction who have anterolateral Q-waves [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypertensive persons with left ventricular hypertrophy or diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/1,20\">",
"       1,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Possibly individuals with an abnormal ECG [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using independent predictors of HF from the Framingham Heart Study, a multivariate risk formulation was devised that can be used to efficiently target high-risk HF candidates for echocardiographic examination [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/21\">",
"     21",
"    </a>",
"    ]. The required risk profile ingredients can be obtained by ordinary office procedures: an ECG for left ventricular hypertrophy, resting heart rate, blood pressure determination, weight, vital capacity, presence of significant heart murmurs, and evidence of coronary disease, cardiomegaly, or diabetes (",
"    <a class=\"graphic graphic_table graphicRef70632 \" href=\"UTD.htm?8/53/9054\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef50666 \" href=\"UTD.htm?10/55/11134\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Using this risk profile, it is possible to identify 20 percent of the susceptible population from whom 60 to 73 percent of cases of HF will arise. Those in the upper quintile of multivariate risk appear to be good candidates for both definitive diagnostic procedures and vigorous preventive measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Plasma BNP and NT pro-BNP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma concentrations of brain natriuretic peptide (BNP) and N-terminal pro-BNP (NT-pro-BNP) are elevated in patients with HF and can be used in patients with dyspnea to distinguish between HF and other causes. A big advantage of screening with BNP compared to echocardiography is the ease and low cost of serial testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation of the patient with suspected heart failure\", section on 'BNP and NT-proBNP'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The utility of plasma BNP for screening for LV dysfunction in asymptomatic persons has been evaluated in a number of studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/9,22-25\">",
"     9,22-25",
"    </a>",
"    ]. Data are more limited with plasma N-terminal pro-BNP [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/13,15,26,27\">",
"     13,15,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results with plasma BNP have not generally been encouraging when used for mass screening of the general population as illustrated by the following observations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective cohort study from the Framingham Heart Study included 3177 asymptomatic participants (mean age 58), 179 (5.6 percent) of whom had LV systolic dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/22\">",
"       22",
"      </a>",
"      ]. Plasma BNP values of 45 to 50",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      that gave 95 percent specificity (ie, low false positivity) were associated with very low sensitivities of 27 percent in men and 13 percent in women. Performance was not appreciably different for elevated LV mass, a surrogate for diastolic dysfunction.",
"     </li>",
"     <li>",
"      Suboptimal performance when testing the general population was also noted in a community-based study of 2042 randomly selected residents of Olmsted County, Minnesota who were &ge;45 years of age (mean age 63) and without a diagnosis of HF; the patients were screened with plasma BNP measurements and echocardiography [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/24\">",
"       24",
"      </a>",
"      ]. The LVEF was &le;40 percent in 2 percent (1 percent asymptomatic) and moderate to severe diastolic dysfunction was found in 7.3 percent. The discriminatory value of plasma BNP (area under the receiver operating characteristic curve) was 0.79 for any significant LV dysfunction (systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic), but optimal discriminatory values varied with age and sex.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors concluded that, considering the low prevalence of asymptomatic LV dysfunction (systolic or diastolic), screening with plasma BNP would necessitate echocardiography in 10 to 40 percent of patients, with most tests being negative, and would miss 10 to 60 percent of affected patients.",
"   </p>",
"   <p>",
"    On the other hand, others have concluded that BNP screening at age 60 (with a 1 percent prevalence of asymptomatic LV systolic dysfunction) followed by echocardiography for elevated values may be cost-effective when compared to a strategy of no screening [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/25\">",
"     25",
"    </a>",
"    ]. The cutoff values for plasma BNP were 24",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    for men (sensitivity and specificity 65 and 86 percent) and 34",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    for women (sensitivity and specificity 80 and 90 percent).",
"   </p>",
"   <p>",
"    Plasma BNP screening may be of greater value when screening higher risk groups. This was illustrated in a report in which a random sample of 1257 people in a community population was divided into three risk groups: symptomatic ischemic heart disease; blood pressure",
"    <span class=\"nowrap\">",
"     &gt;160/95",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an abnormal ECG; or none of these risk factors (low risk) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/23\">",
"     23",
"    </a>",
"    ]. The incidence of LV systolic dysfunction was 19, 6, and 0.7 percent in the three groups. Plasma BNP was not helpful in the low risk group but, in the other two groups, values above the fifth percentile would have reduced the number of echocardiograms performed and the cost of detecting LV dysfunction (by 26 percent).",
"   </p>",
"   <p>",
"    The possible role of plasma NT-pro-BNP has been less well evaluated but negative predictive values &ge;99 percent for excluding LV systolic dysfunction (compared to echocardiography) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/13,15,26,27\">",
"     13,15,26,27",
"    </a>",
"    ] and, in one report, atrial fibrillation and valvular heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/26\">",
"     26",
"    </a>",
"    ]. In the latter study of 1205 subjects from the general population, some of whom were at high risk, age- and gender-stratified normal values were determined. Although the negative predictive value was very high, the positive predictive value for detecting any cardiovascular disease was 56 percent in the general population and 62 percent in those at high risk. Among subjects with plasma NT-pro-BNP values more than four times above normal, 95 percent had significant cardiovascular disease and 5 percent had renal dysfunction.",
"   </p>",
"   <p>",
"    Plasma NT-pro-BNP does not appear to be sufficiently sensitive to screen for asymptomatic diastolic dysfunction. In a screening study cited above, the sensitivity was 29 percent in the general population and 54 percent in patients at high-risk [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography has been used to diagnose LV dysfunction in community-based studies and clinical trials. However, echocardiography is expensive and serial testing would be required if the initial test is negative. Furthermore, the yield is very low in patients with no risk factors (1 of 444 [0.2 percent] in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/15\">",
"     15",
"    </a>",
"    ]. Thus, routine screening with echocardiography is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Screening first with plasma BNP or NT-pro-BNP to determine when echocardiography would be performed is less expensive and permits serial testing over time. However, the results with these measurements are not sufficiently predictive and the values used as a trigger for echocardiography has not been well defined.",
"   </p>",
"   <p>",
"    Another problem is that the rationale for screening &mdash; that effective therapy initiated when the patient is asymptomatic improves outcomes &mdash; is only proven for patients in whom the LVEF is &le;35 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Community-based studies have shown the most individuals with asymptomatic LV systolic dysfunction have mild disease (LVEF 41 to 54 percent). The efficacy of therapy in these patients is not known. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Prevalence of asymptomatic LV systolic dysfunction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    At present, we do not recommend routine screening with echocardiography or plasma BNP or NT-pro-BNP for asymptomatic LV systolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/7\">",
"     7",
"    </a>",
"    ]. A possible approach is to use multivariable risk models to identify patients at greatest risk. Data from the Framingham Heart Study suggests it is possible to identify 20 percent of the susceptible population from which 60 to 73 percent of cases of HF will arise (",
"    <a class=\"graphic graphic_table graphicRef70632 \" href=\"UTD.htm?8/53/9054\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef50666 \" href=\"UTD.htm?10/55/11134\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/21\">",
"     21",
"    </a>",
"    ]. However, the efficacy of this strategy has not been confirmed.",
"   </p>",
"   <p>",
"    A separate issue is screening family members of patients with idiopathic dilated cardiomyopathy. As noted above, 20 to over 50 percent have familial disease and, in a representative study, 23 percent of asymptomatic relatives had evidence of cardiac disease that progressed in some affected relatives during follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/59/5047?source=see_link\">",
"     \"Familial dilated cardiomyopathy: Prevalence, diagnosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association heart failure guidelines, which concluded that the weight of evidence supported the efficacy of screening asymptomatic first-degree relatives with an electrocardiogram and echocardiography and that families with a highly positive family history should be referred to a cardiovascular genetics center [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/28\">",
"     28",
"    </a>",
"    ]. Subsequent studies supported this recommendation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20679/abstract/16,29\">",
"     16,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/59/5047?source=see_link&amp;anchor=H1365129#H1365129\">",
"     \"Familial dilated cardiomyopathy: Prevalence, diagnosis and treatment\", section on 'Diagnosis of familial disease'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/1\">",
"      Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/2\">",
"      Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992; 327:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/3\">",
"      Pfeffer MA, Braunwald E, Moy&eacute; LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/4\">",
"      K&oslash;ber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/5\">",
"      Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003; 361:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/6\">",
"      Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/7\">",
"      McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/8\">",
"      Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/9\">",
"      Wang TJ, Levy D, Benjamin EJ, Vasan RS. The epidemiology of \"asymptomatic\" left ventricular systolic dysfunction: implications for screening. Ann Intern Med 2003; 138:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/10\">",
"      Devereux RB, Roman MJ, Paranicas M, et al. A population-based assessment of left ventricular systolic dysfunction in middle-aged and older adults: the Strong Heart Study. Am Heart J 2001; 141:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/11\">",
"      Davies M, Hobbs F, Davis R, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 2001; 358:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/12\">",
"      Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/13\">",
"      Ng LL, Loke IW, Davies JE, et al. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides. J Am Coll Cardiol 2005; 45:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/14\">",
"      McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997; 350:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/15\">",
"      Galasko GI, Barnes SC, Collinson P, et al. What is the most cost-effective strategy to screen for left ventricular systolic dysfunction: natriuretic peptides, the electrocardiogram, hand-held echocardiography, traditional echocardiography, or their combination? Eur Heart J 2006; 27:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/16\">",
"      Mahon NG, Murphy RT, MacRae CA, et al. Echocardiographic evaluation in asymptomatic relatives of patients with dilated cardiomyopathy reveals preclinical disease. Ann Intern Med 2005; 143:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/17\">",
"      Baig MK, Goldman JH, Caforio AL, et al. Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease. J Am Coll Cardiol 1998; 31:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/18\">",
"      Cicala S, de Simone G, Roman MJ, et al. Prevalence and prognostic significance of wall-motion abnormalities in adults without clinically recognized cardiovascular disease: the Strong Heart Study. Circulation 2007; 116:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/19\">",
"      McMurray JV, McDonagh TA, Davie AP, et al. Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure? Eur Heart J 1998; 19:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/20\">",
"      Kannel WB. Need and prospects for prevention of cardiac failure. Eur J Clin Pharmacol 1996; 49 Suppl 1:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/21\">",
"      Kannel WB, D'Agostino RB, Silbershatz H, et al. Profile for estimating risk of heart failure. Arch Intern Med 1999; 159:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/22\">",
"      Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 2002; 288:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/23\">",
"      Nielsen OW, McDonagh TA, Robb SD, Dargie HJ. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 2003; 41:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/24\">",
"      Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation 2004; 109:3176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/25\">",
"      Heidenreich PA, Gubens MA, Fonarow GC, et al. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 2004; 43:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/26\">",
"      Galasko GI, Lahiri A, Barnes SC, et al. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur Heart J 2005; 26:2269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/27\">",
"      Goetze JP, Mogelvang R, Maage L, et al. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. Eur Heart J 2006; 27:3004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/28\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20679/abstract/29\">",
"      Burkett EL, Hershberger RE. Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 2005; 45:969.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3490 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-09444732DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_12_20679=[""].join("\n");
var outline_f20_12_20679=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE OF ASYMPTOMATIC LV SYSTOLIC DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Screening studies using LVEF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Risk stratification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Familial dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Regional wall motion abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diastolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SCREENING MODALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Plasma BNP and NT pro-BNP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3490\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3490|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/15/11517\" title=\"figure 1\">",
"      ACE inhibitor in LV dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/60/29645\" title=\"figure 2\">",
"      Survival in asymptomatic LVD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/28/10701\" title=\"figure 3\">",
"      ACE inhibitor moderate HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3490|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/53/9054\" title=\"table 2\">",
"      Probability of HF men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/55/11134\" title=\"table 3\">",
"      Probability of HF women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=related_link\">",
"      Clinical manifestations and diagnosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=related_link\">",
"      Echocardiographic evaluation of left ventricular diastolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=related_link\">",
"      Epidemiology and causes of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=related_link\">",
"      Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/59/5047?source=related_link\">",
"      Familial dilated cardiomyopathy: Prevalence, diagnosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=related_link\">",
"      Noninvasive methods for measurement of left ventricular systolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4058?source=related_link\">",
"      Prognosis of heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_12_20680="Erdheim-Chester disease";
var content_f20_12_20680=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Erdheim-Chester disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/12/20680/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/12/20680/contributors\">",
"     Eric Jacobsen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/12/20680/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/12/20680/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/12/20680/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/12/20680/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/12/20680/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H801363\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erdheim-Chester disease (ECD) is a rare non-Langerhans histiocytic disorder most commonly characterized by multifocal osteosclerotic lesions of the long bones demonstrating sheets of foamy histiocytes on biopsy with or without histiocytic infiltration of extraskeletal tissues. ECD was first described by Erdheim and Chester in 1930 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/1\">",
"     1",
"    </a>",
"    ]. Only several hundred cases have been reported in the medical literature since that time.",
"   </p>",
"   <p>",
"    Histocytic disorders are thought to be derived from mononuclear phagocytic cells (macrophages and dendritic cells) or histiocytes. This group has generally been divided into Langerhans cell histiocytosis and non-Langerhans histiocytosis. Langerhans cell histiocytosis is so named for its presumed derivation from the Langerhans cells, which are specialized dendritic cells found in the skin and mucosa. In contrast, non-Langerhans histiocytoses are thought to be derived from the monocyte-macrophage lineage.",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, pathologic features, diagnosis, and management of ECD will be presented here. The diagnosis and management of Langerhans cell histiocytosis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35592?source=see_link\">",
"     \"Pulmonary Langerhans cell histiocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32551?source=see_link\">",
"     \"Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801370\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECD is a rare histiocytic disorder and the incidence is unknown. Fewer than 500 cases have been reported in the published literature. ECD has been diagnosed in all age groups, but is most common in adults. In a series of 37 patients, the mean age at diagnosis was 52 years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/2\">",
"     2",
"    </a>",
"    ]. There may be a slightly male predominance. Although there is speculation that ECD and other histiocyte disorders may represent an aberrant response to infection, no infectious etiology has been identified. There is no evidence that ECD is an inheritable genetic disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87913025\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of ECD is poorly understood. Attempts to establish clonality have produced varied results, and although occasional clonal cytogenetic aberrations have been identified, none are characteristic or diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. A study of tissue from a single patient demonstrated inducible production of tumor necrosis factor-&alpha; (TNF-&alpha;) as well as spontaneous secretion of interleukin (IL)-6 and CXC chemokine ligand",
"    <span class=\"nowrap\">",
"     8/IL-8",
"    </span>",
"    <span class=\"nowrap\">",
"     (CXCL8/IL-8),",
"    </span>",
"    which is known to attract monocytes and polymorphonuclear cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Data from a larger series of patients demonstrated that the cellular infiltrate of ECD contains a significant number of T-cell helper 1 (Th-1) lymphocytes, and the infiltrating histiocytes express the interferon-gamma induced chemokine",
"    <span class=\"nowrap\">",
"     CXCL10/IP-10",
"    </span>",
"    as well as IL-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/8\">",
"     8",
"    </a>",
"    ]. Subsequent studies demonstrated a significant increase in the serum levels of IFN-&alpha; but not interferon-gamma in untreated ECD patients compared with controls.",
"   </p>",
"   <p>",
"    Plasmacytoid dendritic cells are a common source of interferon-alpha, but in situ immunohistochemical studies of ECD lesions did not demonstrate plasmacytoid dendritic cells, arguing that these cells are not the primary source of IFN-&alpha; production in ECD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/2\">",
"     2",
"    </a>",
"    ]. These same investigators demonstrated increased serum levels of IL-12, a cytokine that favors the Th-1 pathway and a significant decrease in IL-4, a major T-cell helper 2 cytokine in both treated and untreated patients. They also developed a 5-cytokine signature (IFN-&alpha;, IL-12, MCP-1, IL-4, and IL-7) that could distinguish ECD patients from controls and from patients with other inflammatory diseases such as rheumatoid arthritis, systemic sclerosis, and sepsis.",
"   </p>",
"   <p>",
"    BRAF is a member of the serine-threonine kinase family, which plays a part in the",
"    <span class=\"nowrap\">",
"     RAS/RAF/MEK/MAPK",
"    </span>",
"    signaling pathway leading to enhanced cell proliferation and survival. An activating point mutation of the BRAF isoform of RAF (BRAF V600E) was identified in 13 of 14 (54 percent) cases of ECD in one study and a small case series reported clinical responses to the BRAF inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Further studies are needed to investigate this potential role of BRAF in the pathogenesis of ECD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801384\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of patients with ECD varies depending upon the sites of involvement. Most patients with ECD will have osseous involvement at the time of diagnosis and the vast majority will also have at least one non-osseous site of involvement. A subset of patients is asymptomatic with bone involvement detected at the time of radiography for unrelated conditions. A retrospective case series of 37 patients reported involvement of the following sites, in order of decreasing frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Long bones (95 percent)",
"     </li>",
"     <li>",
"      Maxillary sinus, large vessels, and retroperitoneum (59 percent each)",
"     </li>",
"     <li>",
"      Heart (57 percent)",
"     </li>",
"     <li>",
"      Lungs (46 percent)",
"     </li>",
"     <li>",
"      Central nervous system (41 percent)",
"     </li>",
"     <li>",
"      Skin (27 percent)",
"     </li>",
"     <li>",
"      Pituitary gland and orbit (22 percent each)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other case series have reported a similar pattern of involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801391\">",
"    <span class=\"h2\">",
"     Bone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone involvement occurs in the majority of ECD patients. This most commonly manifests clinically as mild but persistent juxta-articular pain, particularly in the lower extremities. However, a subset of patients is asymptomatic and bone involvement is detected at the time of radiography for unrelated conditions. Bilateral and symmetric osteosclerosis of the diaphysis of the long bones is nearly universal (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77396 \" href=\"UTD.htm?23/25/23952\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85923 \" href=\"UTD.htm?6/27/6577\">",
"     image 2",
"    </a>",
"    ). Osteosclerosis of the skull bones, particularly the facial bones, is also well described [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective series of 11 patients with biopsy proven ECD who had undergone conventional radiography and bone scintigraphy reported bilateral and symmetric osteosclerosis of the diaphysis of the long bones in 98 percent of bone lesions visible on conventional radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/13\">",
"     13",
"    </a>",
"    ]. The osteosclerosis was heterogeneous in 65 percent of the patients and homogeneous in 35 percent. The diaphysis was involved in all patients, and 83 percent of the lesions also involved the metaphysis. Partial epiphyseal involvement with sparing of the subchondral bone was also common, as were periostitis and endosteitis. Bone scintigraphy depicted tracer uptake in all bone lesions visible on radiographs (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52334 \" href=\"UTD.htm?16/51/17203\">",
"     image 3",
"    </a>",
"    ). Magnetic resonance imaging (MRI) detected all abnormalities noted by plain radiograph and scintigraphy, and also depicted replacement of the normal fatty bone marrow by heterogeneous signal intensity on T1- and T2-weighted spin-echo images (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85924 \" href=\"UTD.htm?33/29/34259\">",
"     image 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801398\">",
"    <span class=\"h2\">",
"     Cardiac",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac involvement with ECD is seen in the majority of patients and is a significant source of morbidity and mortality. Cardiovascular involvement can range from valve abnormalities to conduction defects to periaortic fibrosis along the entire course of the vessel.",
"   </p>",
"   <p>",
"    In a series of 37 patients systematically screened with electrocardiogram (ECG) and imaging (cardiac MRI",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    computed tomography), 70 percent had abnormal heart imaging, and 12 of 32 had an abnormal ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/14\">",
"     14",
"    </a>",
"    ]. The most common finding was infiltration of the right heart (including pseudo-tumor) in half of the patients. Periaortic fibrosis, periarterial infiltration of the coronary arteries, and pericardial",
"    <span class=\"nowrap\">",
"     thickening/effusion",
"    </span>",
"    were also common. In another series, 31 percent of ECD-related deaths were deemed to be secondary to cardiac involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/15\">",
"     15",
"    </a>",
"    ]. The causes of death included myocardial infarction, cardiomyopathy, and symptomatic valve disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801405\">",
"    <span class=\"h2\">",
"     Pulmonary",
"    </span>",
"    &nbsp;&mdash;&nbsp;One-quarter to one-half of patients will have pulmonary involvement, either of the pleura, the lung parenchyma, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/16\">",
"     16",
"    </a>",
"    ]. Findings on computed tomography of the chest include mediastinal infiltration, pleural",
"    <span class=\"nowrap\">",
"     thickening/effusion,",
"    </span>",
"    centrilobular nodular opacities, ground glass opacities, or lung cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/17\">",
"     17",
"    </a>",
"    ]. Open-lung biopsies have demonstrated histiocytic infiltrates in a lymphangitic pattern with associated fibrosis and lymphoplasmacytic inflammatory infiltrates. Although dyspnea and progressive fibrosis leading to respiratory failure can occur, in one large series pulmonary involvement was not an independent predictor of decreased survival [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801412\">",
"    <span class=\"h2\">",
"     Retroperitoneum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retroperitoneal involvement with ECD can manifest as a mass-like infiltrative lesion or as a rind-like lesion surrounding the kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/19\">",
"     19",
"    </a>",
"    ]. This can lead to acute or, more commonly, slowly progressive renal insufficiency. Percutaneous nephrostomy tubes are often required to alleviate ureteral obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801419\">",
"    <span class=\"h2\">",
"     Central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic involvement is seen in approximately 40 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/2\">",
"     2",
"    </a>",
"    ]. Periorbital involvement is most common and can manifest as exophthalmos with or without vision changes. Xanthomas of the eyelid are frequently reported. Symptoms concerning for neurologic involvement include vision changes, excessive thirst or urination, ataxia, headache, weakness, cord compression, and loss of libido [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pituitary involvement commonly manifests as central diabetes insipidus and other endocrinopathies. Pre-existing diabetes insipidus and endocrinopathies typically persist, even with radiographic regression of disease, and require specific management. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31348?source=see_link\">",
"       \"Clinical manifestations of hypopituitarism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=see_link\">",
"       \"Diagnosis of polyuria and diabetes insipidus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cerebellar involvement and mass lesions of other parts of the central nervous system occur frequently and are often multifocal.",
"     </li>",
"     <li>",
"      ECD can infiltrate the dura, in which case it may be confused with a meningioma [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801426\">",
"    <span class=\"h2\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike Langerhans histiocytosis, which frequently affects the skin, cutaneous involvement with ECD is less common, affecting approximately one-quarter of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/22\">",
"     22",
"    </a>",
"    ]. Skin lesions are generally multifocal and papulonodular in appearance, but have few other distinguishing characteristics. Pruritus can occur, but is not a universal feature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801433\">",
"    <span class=\"h2\">",
"     Other organs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of other structures (breast, thyroid, testis, gingival, and spleen) is rare. Breast involvement usually presents as a palpable mass or nodule in one or both breasts [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/23\">",
"     23",
"    </a>",
"    ]. Liver involvement may be detected on radiographic staging or manifest with abnormalities in transaminases, bilirubin,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    alkaline phosphatase [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87912551\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsies of involved tissues are characterized by tissue infiltration by sheets of foamy (xanthomatous) histiocytes with interspersed inflammatory cells and multinucleate giant cells (Touton cells) (",
"    <a class=\"graphic graphic_picture graphicRef85925 \" href=\"UTD.htm?20/15/20727\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef80968 \" href=\"UTD.htm?36/41/37529\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef65663 \" href=\"UTD.htm?24/39/25206\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/25\">",
"     25",
"    </a>",
"    ]. ECD cells express the histiocyte marker CD68, but unlike Langerhans cell histiocytosis, do not express CD1a or S100 (",
"    <a class=\"graphic graphic_picture graphicRef64303 \" href=\"UTD.htm?29/5/29782\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef85925 \" href=\"UTD.htm?20/15/20727\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/6\">",
"     6",
"    </a>",
"    ]. Birbeck granules (an ultrastructural finding on electron microscopy in Langerhans cell histiocytosis) are absent. Attempts to establish clonality have produced varied results, and are not used routinely for diagnosis, and although occasional clonal cytogenetic aberrations have been identified, none are characteristic or diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801440\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECD is diagnosed based upon the pathologic evaluation of involved tissue interpreted within the clinical context. ECD can be difficult to diagnose since it is a very rare disease that can affect many organ systems. A biopsy of an osteosclerotic bone lesion is generally preferred, when possible.",
"   </p>",
"   <p>",
"    ECD must be distinguished histologically and immuno-phenotypically from other histiocytic and dendritic cell disorders, metastatic solid or hematopoietic neoplasms, and hemophagocytic lymphohistiocytic and macrophage activation syndromes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Langerhans cell histiocytosis &mdash; Langerhans cell histiocytosis (LCH) and ECD are both histiocytic diseases that can involve multiple sites, most commonly bones. Skin involvement is more common in LCH. The two entities can usually be distinguished by morphologic and immunohistochemical evaluation. ECD tumor cells lack central nuclear grooves and Birbeck granules typical of LCH cells, and unlike Langerhans cell histiocytosis, they do not express CD1a or S100 [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Paget&rsquo;s disease and POEMS syndrome &mdash; The osteosclerotic lesions of bone in ECD can be confused for a variety of metabolic bone disorders, including Paget&rsquo;s disease and the POEMS syndrome, the latter of which also causes endocrine abnormalities, thus adding to the confusion. While the bone abnormalities of ECD often are confined to bilateral and symmetric osteosclerosis of the diaphysis of the long bones, Paget&rsquo;s disease and POEMS syndrome generally cause less symmetric bone abnormalities with less specific localization. ECD can readily be distinguished from Paget&rsquo;s disease and POEMS syndrome by histologic and immunophenotypic findings on biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/14/35049?source=see_link\">",
"       \"POEMS syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7978?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Paget disease of bone\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemophagocytic lymphohistiocytosis &mdash; Hemophagocytic lymphohistiocytosis and the related macrophage activation syndrome are systemic disorders that demonstrate tissue infiltration by non-neoplastic histiocytes. Unlike ECD, these disorders demonstrate prominent hemophagocytic activity in the biopsy, and are also characterized by a number of other findings including fever, hypertriglyceridemia, hypofibrinogenemia, hyperferritinemia, and bicytopenia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link\">",
"       \"Hemophagocytic lymphohistiocytosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ECD of the CNS can be confused for metastatic solid or hematopoietic neoplasms or primary CNS tumors including meningioma. Cutaneous involvement is uncommon, but can mimic vasculitis, cutaneous lymphoma, or cutaneous involvement with LCH. Abdominal involvement is frequently confusing with primary or secondary retroperitoneal fibrosis, sclerosing mesenteritis, or a variety of retroperitoneal neoplasms including lymphoma and germ cell tumor. Cardiac involvement can mimic other infiltrative cardiovascular processes, including sarcoidosis, and pulmonary involvement can have the clinical appearance of any number of interstitial lung diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801447\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;To best treat patients with ECD, the initial evaluation must confirm the histologic diagnosis, the extent and sites of disease, and the performance status of the patient. In addition to a history and physical examination, it is our practice to perform the following pretreatment studies in patients with ECD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory studies include a complete blood count, serum electrolytes, chemistries with liver and renal function and electrolytes. If diabetes insipidus is suspected, urine electrolytes and urine osmolality should be measured. Patients suspected of having diabetes insipidus should also be evaluated for other manifestations of hypopituitarism, including assessments of thyroid, sex, growth, and adrenocortical hormones. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31348?source=see_link\">",
"       \"Clinical manifestations of hypopituitarism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=see_link\">",
"       \"Diagnosis of polyuria and diabetes insipidus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Imaging studies include magnetic resonance imaging (MRI) of the brain, a computed tomography (CT) scan or an MRI of the entire aorta, a cardiac MRI, a CT scan of the chest, abdomen, and pelvis (which can also be used to image the entire aorta), and a transthoracic echocardiography. An MRI of the spinal cord is only necessary if the patient has signs or symptoms of spinal cord involvement. The utility of positron emission tomography (FDG-PET) scanning is unclear and not routinely recommended at present [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Electrocardiogram (ECG) should be performed to evaluate for conduction abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801454\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all patients with ECD require treatment at the time of diagnosis. Active treatment is typically reserved for patients with symptomatic disease, symptomatic or asymptomatic central nervous system (CNS) involvement, evidence of organ dysfunction, or impending organ dysfunction. Treatment is suggested for patients with asymptomatic CNS involvement because it is an independent predictor of a worse outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who are asymptomatic without evidence of CNS involvement or organ dysfunction, we suggest a period of observation rather than immediate treatment. This is primarily because there is no known cure for ECD and some cases follow an indolent clinical course. During this observation period, we perform serial examinations similar to those used for the follow-up for patients undergoing active treatment. (See",
"    <a class=\"local\" href=\"#H87913467\">",
"     'Patient follow-up'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There is no standard treatment regimen for patients with symptomatic ECD, and patients should be encouraged to enroll in a clinical trial. Outside of a clinical trial, treatment options include interferon alpha, systemic chemotherapy, corticosteroids, and radiation therapy. Surgery has no clear role in the management of ECD except to address mechanical complications, such as ureteral obstruction. Data regarding these treatment options come primarily from retrospective case series. Interferon alpha is the preferred therapy due to a suggestion of a survival benefit in the largest retrospective analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/28\">",
"     28",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    For most patients with ECD, we recommend the use of conventional or pegylated interferon-alpha rather than systemic chemotherapy or glucocorticoids. Systemic chemotherapy can be considered for patients who either fail to respond to interferon-alpha or develop intolerable side effects. Glucocorticoids are generally reserved for patients who cannot tolerate more aggressive systemic therapies or for patients who have very mild symptoms and wish to avoid the potential side effects associated with more aggressive therapies. Radiotherapy may be used for local palliation. The following sections describe these treatment approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87913566\">",
"    <span class=\"h2\">",
"     Interferon alpha",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional or pegylated interferon alpha is our preferred treatment option for patients with newly diagnosed, symptomatic ECD outside of a clinical trial. The optimal duration of treatment is unclear, but patients are usually treated until disease progression or intolerable side effects occur. The risk-benefit ratio of interferon should be revisited periodically in patients who are on treatment for more than two years. Patients on interferon should be monitored for infection, liver function abnormalities, thyroid abnormalities, and depression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1674?source=see_link\">",
"     \"Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Treatment and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pegylated interferon alpha is started at 135 micrograms weekly and the dose is titrated upwards as tolerated if patients are not responding to the initial dose to a maximum dose of 200 micrograms weekly.",
"     </li>",
"     <li>",
"      Conventional interferon alpha is started at 3 million international units (MIU) three times a week and the dose is titrated upwards as tolerated if patients are not responding to the initial dose to a maximum dose of 9 MIU three times a week.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the largest and most comprehensive series of 53 patients with ECD, 87 percent were treated with interferon alpha for a median of 19 months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/28\">",
"     28",
"    </a>",
"    ]. Doses ranged from 3 MIU to 9 MIU three times weekly with conventional interferon, or 135 to 200 micrograms weekly with pegylated interferon. Fourteen patients (26 percent) died after a median follow-up of 56 months (range, 14 to 198 months) from symptom onset, and 27 months (range, 0.7 to 165 months) from diagnosis. The one-year and five-year survival rates were 96 and 68 percent, respectively. Treatment with interferon alpha was an independent predictor of improved survival (hazard ratio = 0.32; 95 percent CI 0.14 to 0.70). Central nervous system (CNS) involvement was an independent predictor of inferior survival. There are some reports that interferon-alpha may be less effective in patients with multisystem involvement and CNS",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiac involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/29\">",
"     29",
"    </a>",
"    ], but the preponderance of evidence still suggests that interferon alpha or pegylated interferon alpha should be considered the standard therapy for ECD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87913629\">",
"    <span class=\"h2\">",
"     Systemic chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic chemotherapy regimens have been studied in other histiocytic disorders, such a Langerhans cell histiocytosis. We consider systemic chemotherapy for patients who fail to respond to interferon alpha or who develop intolerable side effects on interferon alpha. The most commonly used regimen is a 24-week treatment consisting of weekly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    for six weeks followed by vinblastine and etoposide every three weeks until week 24 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/30\">",
"     30",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    is incorporated into this regimen, as is daily 6-mercaptopurine (starting at week nine). This regimen has demonstrated activity in other histiocytic disorders; however, patients with ECD were not included in the published reports of this regimen, and as such the response rates are unknown.",
"   </p>",
"   <p>",
"    A variety of other therapies have been utilized in ECD, though reports of their efficacy are largely restricted to single patient case reports or very small case series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IL-1-Ra production is stimulated by interferon-alpha and there is a case report of recombinant IL-1RA (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      ) inducing responses in a small group of patients who could not tolerate interferon alpha [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/31\">",
"       31",
"      </a>",
"      ]. Further studies of this agent are certainly warranted, but as of yet we have not utilized recombinant IL-1RA routinely to treat ECD.",
"     </li>",
"     <li>",
"      Several case reports have demonstrated activity of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      in ECD, though the exact role of imatinib in the treatment paradigm remains undefined [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. We consider imatinib therapy for patients who fail to respond to or are intolerant of interferon-alpha and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      based regimens.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      may have activity in ECD and has been used for other histiocyte disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/34\">",
"       34",
"      </a>",
"      ]. High dose systemic methotrexate with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      rescue may be useful in ECD with CNS involvement given the ability of methotrexate to cross the blood brain barrier, although this approach has not been studied.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"       Cladribine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      may also be active [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A report from one institution described clinical responses in two cases of ECD with cardiac involvement treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report, all three patients with multisystemic and refractory ECD carrying the BRAF V600E gene mutation demonstrated partial clinical responses following treatment with the BRAF inhibitor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"       vemurafenib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/10\">",
"       10",
"      </a>",
"      ]. Clinically significant cutaneous side effects are common with vemurafenib and include squamous cell carcinomas and keratoacanthomas. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link&amp;anchor=H100472992#H100472992\">",
"       \"Molecularly targeted therapy for metastatic melanoma\", section on 'Vemurafenib'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87913658\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids have demonstrated clinical activity in ECD, but have not demonstrated a survival benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/28\">",
"     28",
"    </a>",
"    ]. Glucocorticoids are generally reserved for patients who cannot tolerate more aggressive systemic therapies or who have very mild symptoms. For such patients we consider",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    60 mg daily for two to four weeks followed by a slow taper over three to six months. Patients on long term glucocorticoids should receive prophylaxis for Pneumocystis jiroveci (previously Pneumocystis carinii) infection and may benefit from prophylaxis for gastrointestinal ulcers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link&amp;anchor=H11#H11\">",
"     \"Major side effects of systemic glucocorticoids\", section on 'Gastrointestinal tract'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87913665\">",
"    <span class=\"h2\">",
"     Radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiotherapy has been used for local palliation, though ECD seems to be much less responsive to radiotherapy than Langerhans histiocytosis, and lack of response or in-field recurrence is fairly common [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20680/abstract/37\">",
"     37",
"    </a>",
"    ]. The optimal dose and field are unknown. We generally use doses appropriate for aggressive lymphomas (40 to 50 Gy) when feasible rather than the much lower doses utilized for LCH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87913467\">",
"    <span class=\"h1\">",
"     PATIENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be clinically assessed a minimum of every three to six months or more frequently as symptoms and organ dysfunction require. The frequency of imaging is dictated by baseline disease status, organ involvement, and requirement for ongoing treatment. Affected organs should be imaged every three to six months until stability is documented. Even if there is no baseline cardiovascular involvement, patients should undergo an electrocardiogram and echocardiogram at least annually. Our experience is that changes in radiographic imaging are often discordant with symptoms and that symptoms are the best indicator of the need for treatment and response to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87913475\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment in a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the National Cancer Institute or from",
"    <a class=\"external\" href=\"file://www.histiocytesociety.org/\">",
"     the Histiocyte Society",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801461\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Erdheim-Chester disease (ECD) is a rare histiocyte disorder most commonly characterized by multifocal osteosclerotic lesions of the long bones demonstrating sheets of foamy histiocytes infiltrates on biopsy with or without histiocytic infiltration of extraskeletal tissues. (See",
"      <a class=\"local\" href=\"#H801370\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H87913025\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation of patients with ECD varies depending upon the sites of involvement. Most patients with ECD will have osseous involvement at the time of diagnosis and the vast majority will also have at least one non-osseous site of involvement with the most common sites being the maxillary sinus, heart and great vessels, retroperitoneum, lungs, and central nervous system (including the pituitary gland and orbit). (See",
"      <a class=\"local\" href=\"#H801384\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ECD is diagnosed based upon the pathologic evaluation of involved tissue interpreted within the clinical context. ECD can be difficult to diagnose since it is a very rare disease that can affect many organ systems. A biopsy of an osteosclerotic bone lesion is generally preferred, when possible. (See",
"      <a class=\"local\" href=\"#H87912551\">",
"       'Pathologic features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H801440\">",
"       'Diagnosis and differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Not all patients with ECD require treatment at the time of diagnosis. For patients who are asymptomatic without evidence of CNS involvement or organ dysfunction, we suggest a period of observation rather than immediate treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      There is no standard treatment regimen for patients with symptomatic ECD and patients should be encouraged to enroll in a clinical trial. We use the following approach for the management of patients outside of a clinical trial (see",
"      <a class=\"local\" href=\"#H87913475\">",
"       'Clinical trials'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For most patients with ECD, we recommend the use of conventional or pegylated interferon-alpha rather than systemic chemotherapy or glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who fail to respond to or cannot tolerate interferon-alpha, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , and 6-mercaptopurine modeled after protocols used for Langerhans cell histiocytosis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Glucocorticoids are generally reserved for patients who cannot tolerate more aggressive systemic therapies. Radiotherapy may be used for local palliation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with ECD are at risk of developing potentially life-threatening complications due to the compression of normal structures. Mechanical measures such as percutaneous nephrostomy and cardiac valve replacement may also become necessary in select patients. In addition, a high percentage of patients will develop diabetes insipidus and other endocrinopathies due to hypopituitarism. Regardless of systemic therapies, endocrinopathies including diabetes insipidus should be corrected. Pre-existing diabetes insipidus and endocrinopathies typically persist, even with radiographic regression of disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31348?source=see_link\">",
"       \"Clinical manifestations of hypopituitarism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=see_link\">",
"       \"Diagnosis of polyuria and diabetes insipidus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/1\">",
"      Chester W. Uber lipoidgranulomatose. Virchows Arch A Pathol Anat Histol 1930; 279:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/2\">",
"      Arnaud L, Gorochov G, Charlotte F, et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood 2011; 117:2783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/3\">",
"      Gong L, He XL, Li YH, et al. Clonal status and clinicopathological feature of Erdheim-Chester disease. Pathol Res Pract 2009; 205:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/4\">",
"      Al-Quran S, Reith J, Bradley J, Rimsza L. Erdheim-Chester disease: case report, PCR-based analysis of clonality, and review of literature. Mod Pathol 2002; 15:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/5\">",
"      Vencio EF, Jenkins RB, Schiller JL, et al. Clonal cytogenetic abnormalities in Erdheim-Chester disease. Am J Surg Pathol 2007; 31:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/6\">",
"      Dagna L, Girlanda S, Langheim S, et al. Erdheim-Chester disease: report on a case and new insights on its immunopathogenesis. Rheumatology (Oxford) 2010; 49:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/7\">",
"      Dagna L, Corti A, Langheim S, et al. Tumor necrosis factor &alpha; as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab. J Clin Oncol 2012; 30:e286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/8\">",
"      Stoppacciaro A, Ferrarini M, Salmaggi C, et al. Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis. Arthritis Rheum 2006; 54:4018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/9\">",
"      Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012; 120:2700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/10\">",
"      Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 2013; 121:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/11\">",
"      Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D, et al. Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine (Baltimore) 1996; 75:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/12\">",
"      Drier A, Haroche J, Savatovsky J, et al. Cerebral, facial, and orbital involvement in Erdheim-Chester disease: CT and MR imaging findings. Radiology 2010; 255:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/13\">",
"      Dion E, Graef C, Miquel A, et al. Bone involvement in Erdheim-Chester disease: imaging findings including periostitis and partial epiphyseal involvement. Radiology 2006; 238:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/14\">",
"      Haroche J, Cluzel P, Toledano D, et al. Images in cardiovascular medicine. Cardiac involvement in Erdheim-Chester disease: magnetic resonance and computed tomographic scan imaging in a monocentric series of 37 patients. Circulation 2009; 119:e597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/15\">",
"      Haroche J, Amoura Z, Dion E, et al. Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review. Medicine (Baltimore) 2004; 83:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/16\">",
"      Arnaud L, Pierre I, Beigelman-Aubry C, et al. Pulmonary involvement in Erdheim-Chester disease: a single-center study of thirty-four patients and a review of the literature. Arthritis Rheum 2010; 62:3504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/17\">",
"      Brun AL, Touitou-Gottenberg D, Haroche J, et al. Erdheim-Chester disease: CT findings of thoracic involvement. Eur Radiol 2010; 20:2579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/18\">",
"      Rush WL, Andriko JA, Galateau-Salle F, et al. Pulmonary pathology of Erdheim-Chester disease. Mod Pathol 2000; 13:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/19\">",
"      Surabhi VR, Menias C, Prasad SR, et al. Neoplastic and non-neoplastic proliferative disorders of the perirenal space: cross-sectional imaging findings. Radiographics 2008; 28:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/20\">",
"      Brodkin CL, Wszolek ZK. Neurologic presentation of Erdheim-Chester disease. Neurol Neurochir Pol 2006; 40:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/21\">",
"      Lachenal F, Cotton F, Desmurs-Clavel H, et al. Neurological manifestations and neuroradiological presentation of Erdheim-Chester disease: report of 6 cases and systematic review of the literature. J Neurol 2006; 253:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/22\">",
"      Volpicelli ER, Doyle L, Annes JP, et al. Erdheim-Chester disease presenting with cutaneous involvement: a case report and literature review. J Cutan Pathol 2011; 38:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/23\">",
"      Barnes PJ, Foyle A, Hach&eacute; KA, et al. Erdheim-Chester disease of the breast: a case report and review of the literature. Breast J 2005; 11:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/24\">",
"      Gupta A, Aman K, Al-Babtain M, et al. Multisystem Erdheim-Chester disease; a unique presentation with liver and axial skeletal involvement. Br J Haematol 2007; 138:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/25\">",
"      Kim MS, Kim CH, Choi SJ, et al. Erdheim-chester disease. Ann Dermatol 2010; 22:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/26\">",
"      Steov&aacute; E, Steo B, Povinec P, et al. FDG-PET in the Erdheim-Chester disease: its diagnostic and follow-up role. Rheumatol Int 2012; 32:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/27\">",
"      Arnaud L, Malek Z, Archambaud F, et al. 18F-fluorodeoxyglucose-positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim-Chester disease. Arthritis Rheum 2009; 60:3128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/28\">",
"      Arnaud L, Hervier B, N&eacute;el A, et al. CNS involvement and treatment with interferon-&alpha; are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood 2011; 117:2778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/29\">",
"      Haroche J, Amoura Z, Trad SG, et al. Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum 2006; 54:3330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/30\">",
"      Gadner H, Grois N, P&ouml;tschger U, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 2008; 111:2556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/31\">",
"      Aouba A, Georgin-Lavialle S, Pagnoux C, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood 2010; 116:4070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/32\">",
"      Haroche J, Amoura Z, Charlotte F, et al. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood 2008; 111:5413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/33\">",
"      Janku F, Amin HM, Yang D, et al. Response of histiocytoses to imatinib mesylate: fire to ashes. J Clin Oncol 2010; 28:e633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/34\">",
"      Jeon IS, Lee SS, Lee MK. Chemotherapy and interferon-alpha treatment of Erdheim-Chester disease. Pediatr Blood Cancer 2010; 55:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/35\">",
"      Myra C, Sloper L, Tighe PJ, et al. Treatment of Erdheim-Chester disease with cladribine: a rational approach. Br J Ophthalmol 2004; 88:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/36\">",
"      Bourke SC, Nicholson AG, Gibson GJ. Erdheim-Chester disease: pulmonary infiltration responding to cyclophosphamide and prednisolone. Thorax 2003; 58:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20680/abstract/37\">",
"      Miller RC, Vill&agrave; S, Kamer S, et al. Palliative treatment of Erdheim-Chester disease with radiotherapy: a Rare Cancer Network study. Radiother Oncol 2006; 80:323.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13942 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-18C9BB78CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_12_20680=[""].join("\n");
var outline_f20_12_20680=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H801461\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H801363\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H801370\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87913025\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H801384\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H801391\">",
"      Bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H801398\">",
"      Cardiac",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H801405\">",
"      Pulmonary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H801412\">",
"      Retroperitoneum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H801419\">",
"      Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H801426\">",
"      Skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H801433\">",
"      Other organs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87912551\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H801440\">",
"      DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H801447\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H801454\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87913566\">",
"      Interferon alpha",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87913629\">",
"      Systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87913658\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87913665\">",
"      Radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87913467\">",
"      PATIENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87913475\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H801461\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/13942\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/13942|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/25/23952\" title=\"diagnostic image 1\">",
"      ECD x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/27/6577\" title=\"diagnostic image 2\">",
"      Leg CT in ECD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/51/17203\" title=\"diagnostic image 3\">",
"      ECD bone scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/29/34259\" title=\"diagnostic image 4\">",
"      Leg MRI in ECD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/13942|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/15/20727\" title=\"picture 1\">",
"      Bone curettage samples ECD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/41/37529\" title=\"picture 2\">",
"      ECD lesion biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/39/25206\" title=\"picture 3\">",
"      ECD skin biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/5/29782\" title=\"picture 4\">",
"      ECD perirenal mass biopsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7978?source=related_link\">",
"      Clinical manifestations and diagnosis of Paget disease of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31348?source=related_link\">",
"      Clinical manifestations of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=related_link\">",
"      Diagnosis of polyuria and diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32551?source=related_link\">",
"      Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=related_link\">",
"      Molecularly targeted therapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1674?source=related_link\">",
"      Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/14/35049?source=related_link\">",
"      POEMS syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35592?source=related_link\">",
"      Pulmonary Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_12_20681="Gram-negative bacillary bacteremia in adults";
var content_f20_12_20681=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gram-negative bacillary bacteremia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/12/20681/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/12/20681/contributors\">",
"     Reuben Ramphal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/12/20681/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/12/20681/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/12/20681/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/12/20681/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/12/20681/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bloodstream infection is a major cause of morbidity and mortality despite the availability of potent antimicrobial therapy and advances in supportive care. Bacteremia due to gram-negative rods is a significant problem in hospitalized and community-dwelling patients. Although the percentage of hospital-acquired bloodstream infections (BSIs) associated with gram-negative bacilli has decreased, these organisms now pose serious therapeutic problems because of multidrug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/1\">",
"     1",
"    </a>",
"    ]. Gram-negative bacillary sepsis with shock has a mortality rate of 30 to 50 percent; mortality varies depending, in part, on whether the patient receives timely and appropriate antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, microbiology, clinical manifestations, and treatment of gram-negative bacillary bacteremia will be reviewed here. The epidemiology, clinical manifestations, and treatment of infections due to specific gram-negative bacilli are discussed separately in the appropriate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the 1980s, gram-negative bacilli were the predominant organisms associated with nosocomial bloodstream infections in the United States. Since then, gram-positive aerobes (eg, coagulase-negative staphylococci, Staphylococcus aureus, and enterococcus), and Candida species have increased in relative importance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/4\">",
"     4",
"    </a>",
"    ]. In 1975, hospitals that participated in the National Nosocomial Infections Surveillance (NNIS) System reported that gram-negative bacilli were responsible for 55 percent of bacteremia hospitalwide. By 2003, NNIS hospitals reported that gram-negative bacilli were responsible for 24 percent of nosocomial bacteremias in intensive care units (ICUs) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a surveillance study of hospital-wide primary health care-associated bloodstream infections in a large tertiary care hospital in the United States found a significant increase in the rate of gram-negative bacillary bloodstream infections in 2003 which may represent either a reemergence of gram-negative infections over the preceding five years or changes in patient demographics in that institution [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/5\">",
"     5",
"    </a>",
"    ]. The proportion of gram-negative organisms identified in bloodstream infections increased significantly from 15.9 percent in 1999 to 24.1 percent in 2003. No specific gram-negative species contributed disproportionately to the increase and with few exceptions there were no significant increases in antimicrobial resistance to explain this trend. This study excluded bloodstream infections that were community-acquired or were secondary to infection at another site.",
"   </p>",
"   <p>",
"    In Latin America, and some areas of Europe and the Far East, the proportion of bacteremia caused by gram-negative bacilli is greater than that identified in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/6\">",
"     6",
"    </a>",
"    ]. This geographic difference in etiology of bacteremia is illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective study of bloodstream infections in hematologic malignancy patients from Brazil hospitalized between January 2000 and June 2001 identified gram-negative bacteria in 81 of 133 (61 percent) episodes [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/7\">",
"       7",
"      </a>",
"      ]. In contrast, studies from North America have generally shown a predominance of gram-positive bacteria [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective multicenter study in Italy conducted between 1999 and 2000 found 46 percent of bacteremias were due to gram-negative bacilli [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/8\">",
"       8",
"      </a>",
"      ]. In this study, gram-negative bacilli were the etiologic agent in 42 percent of hospital-acquired bacteremia and 55 percent of community-acquired bacteremia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A retrospective review of 238 episodes of bacteremia in patients &ge;65 years of age in the United States identified gram-negative bacilli as the etiologic agent in 36 percent of cases; 81 percent of patients were admitted with bacteremia from home [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/9\">",
"     9",
"    </a>",
"    ]. The rate of gram-negative bacteremia in patients &ge;65 years is even higher in nursing home residents as illustrated by a retrospective review of 169 episodes of bacteremia identified between January 1997 and April 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/10\">",
"     10",
"    </a>",
"    ]. Of the 132 episodes of monomicrobial bacteremia, 78 (59 percent) were caused by gram-negative organisms. Thus, even within North America, there are subpopulations of patients in whom gram-negative bacteremia occurs more frequently than does gram-positive bacteremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H78470229\">",
"    <span class=\"h2\">",
"     Seasonal patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. aeruginosa and Acinetobacter infections appear to occur in a seasonal pattern, with a 17 percent increase in their occurrence for each 10&deg;F increase in external temperature [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/11\">",
"     11",
"    </a>",
"    ]. The implications for this observation are that the incidence of these infections is likely to be higher in warmer climates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most hospitalized patients with gram-negative bacteremia have at least one comorbid condition [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. A study of 326 episodes of gram-negative bacteremia at two university-affiliated medical centers identified comorbid conditions in 315 (97 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/12\">",
"     12",
"    </a>",
"    ]. Conditions identified in this and other studies included [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/7,12-17\">",
"     7,12-17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hematopoietic stem cell transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Liver failure [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Serum albumin &lt;3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Solid organ transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/12,13,16,18\">",
"       12,13,16,18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/12,19\">",
"       12,19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pulmonary disease [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hypotension [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Chronic hemodialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      HIV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hematologic malignancy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/7,13\">",
"       7,13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Treatment with glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Elderly [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/10,17\">",
"       10,17",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these risk factors, combat injured military personnel and patients injured during natural disasters involving trauma in water are also at increased risk for infections caused by gram-negative bacilli [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. Acinetobacter baumannii infection has been reported in military personnel in Vietnam, World Wars I and II, the Gulf conflicts, and the Afghanistan and Iraq wars [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Whether this is due to particular environmental conditions in the battlefield is unclear. Infections present very early after injuries have occurred, excluding long term broad-spectrum antibiotic usage as a risk factor.",
"   </p>",
"   <p>",
"    Other host factors related to the primary source of infection may also affect the development of secondary bacteremia. As an example, one prospective study identified urinary retention and recent urogenital surgery as host factors independently associated with the risk of bacteremia in 156 hospitalized patients with E. coli bacteriuria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unusual organisms such as Pantoea agglomerans (renamed from Enterobacter agglomerans) observed on cotton and cotton plants [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/23,25,26\">",
"     23,25,26",
"    </a>",
"    ] have emerged as pathogens under specific conditions, causing \"Cotton fever,\" a syndrome of acute fever following intravenous injection of heroin that has been filtered through cotton [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/25,26\">",
"     25,26",
"    </a>",
"    ] has also been implicated as a cause of bacteremia due to contaminated intravenous solutions and stored blood products [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Source of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The source of infection differs depending on the patient population studied as illustrated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the retrospective review of nursing home residents noted above, the following were identified as the most common sources of infection in the cases of gram-negative bacteremia [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/10\">",
"       10",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Urinary tract &ndash; 81 percent",
"     </li>",
"     <li>",
"      Gastrointestinal tract &ndash; 9 percent",
"     </li>",
"     <li>",
"      Respiratory tract &ndash; 4 percent",
"     </li>",
"     <li>",
"      Unknown &ndash; 5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of gram-negative bacteremia in the elderly (eg, &gt;70 years), the most common sources of infection in community-acquired infection were [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/29\">",
"       29",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Urinary tract &ndash; 50 percent",
"     </li>",
"     <li>",
"      Gastrointestinal tract &ndash; 27 percent",
"     </li>",
"     <li>",
"      Respiratory tract &ndash; 10 percent",
"     </li>",
"     <li>",
"      Skin and soft tissue &ndash; 8 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar distribution was noted for hospital-acquired infection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The source of infection differs in patients admitted to the ICU; a retrospective study found the following most common sources in this patient population [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/30\">",
"       30",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Respiratory tract &ndash; 49 percent",
"     </li>",
"     <li>",
"      Central venous catheter &ndash; 22 percent",
"     </li>",
"     <li>",
"      Surgical site infection &ndash; 16 percent",
"     </li>",
"     <li>",
"      Gastrointestinal tract &ndash; 7 percent",
"     </li>",
"     <li>",
"      Skin and soft tissue &ndash; 4 percent",
"     </li>",
"     <li>",
"      Urinary tract &ndash; 2 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Identifying the most likely source of infection impacts on empiric antibiotic treatment because the most likely microbiologic agent responsible may differ by source of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of specific gram-negative bacilli responsible for bacteremia differs by whether the infection is acquired in the hospital or community and by the geographic location of the site of care.",
"   </p>",
"   <p>",
"    Data from the NNIS system from 2003 identified that gram-negative bacilli were responsible for 24 percent of bloodstream infections in ICUs in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/4\">",
"     4",
"    </a>",
"    ]. The most common gram-negative species isolated during gram-negative bacteremia included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Enterobacter species &ndash; 18.5 percent",
"     </li>",
"     <li>",
"      Klebsiella pneumoniae &ndash; 17.8 percent",
"     </li>",
"     <li>",
"      Pseudomonas aeruginosa &ndash; 14.4 percent",
"     </li>",
"     <li>",
"      Escherichia coli &ndash; 13.6 percent",
"     </li>",
"     <li>",
"      Acinetobacter species &ndash; 10.1 percent",
"     </li>",
"     <li>",
"      Serratia marcescens &ndash; 9.7 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar results for the most common isolates were identified in a retrospective review of patients with gram-negative bacteremia from Korea [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The order of most common gram-negative bacilli in bloodstream infections in community-acquired cases differs from those responsible for hospital-acquired cases. This is illustrated by the Italian study noted above which identified the following list of the most common gram-negative organisms isolated during community-acquired gram-negative bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      E. coli &ndash; 76 percent",
"     </li>",
"     <li>",
"      P. aeruginosa &ndash; 7.9 percent",
"     </li>",
"     <li>",
"      K. pneumoniae &ndash; 5.4 percent",
"     </li>",
"     <li>",
"      Proteus mirabilis &ndash; 4.2 percent",
"     </li>",
"     <li>",
"      Enterobacter species &ndash; 3.7 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These differences are based on the fact that the urinary tract is the most common source for community-acquired gram-negative bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major clinical manifestation of gram-negative rod bacteremia is the sepsis syndrome. Sepsis is believed to result from the interaction of specific microbial ligands with human Toll-like receptors, which leads to the release of inflammatory mediators [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/32\">",
"     32",
"    </a>",
"    ]. Many of the inflammatory mediators reproduce aspects of the sepsis syndrome including shock, when given to animals [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5449?source=see_link\">",
"     \"Pathophysiology of sepsis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The virulence factor thought to be primarily responsible for this syndrome is lipopolysaccharide (LPS) or endotoxin of gram-negative organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/34\">",
"     34",
"    </a>",
"    ]. However, other bacterial products are also able to stimulate the sepsis syndrome including membrane lipoproteins [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/35\">",
"     35",
"    </a>",
"    ], flagellin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/36\">",
"     36",
"    </a>",
"    ], and CpG DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/37\">",
"     37",
"    </a>",
"    ], constituents that are common to most gram-negative bacteria.",
"   </p>",
"   <p>",
"    P. aeruginosa, among common gram-negative bacteria, produces the largest number of \"toxins\", but a few non-Pseudomonas gram-negative rods produce unique putative virulence factors that have the potential to injure host cells and thus, could be involved in sepsis. Among the few are the metalloproteases in Serratia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/38\">",
"     38",
"    </a>",
"    ], hemolysins in E. coli and Proteus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], and type III secreted toxins in E. coli [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/41\">",
"     41",
"    </a>",
"    ]. Other factors in gram-negative bacilli that may play a role in disease are pili and capsules [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/42\">",
"     42",
"    </a>",
"    ]. Secreted virulence factors have not yet been identified in Acinetobacter spp. [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27145?source=see_link\">",
"     \"Epidemiology and pathogenesis of Pseudomonas aeruginosa infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with gram-negative rod bacteremia typically present with fever, with or without chills. The fever is not usually sustained, except in the presence of an underlying abscess or during a disease such as typhoid fever. Disorientation, hypotension, and respiratory failure may complicate bacteremia and are usually signs that the patient may be developing septic shock, which is seen in about 25 percent of patients on presentation with gram-negative rod bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients may rarely present with evidence of disseminated intravascular coagulation, such as petechiae and purpura, although this finding is more frequently seen in meningococcemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gram-negative rod bacteremia rarely occurs spontaneously without infection at another site. Thus, clinical clues should be sought to determine the site of infection and thus the likely identity of the infecting bacterium, which is of potential use in selecting empiric therapy. Manifestations of infection may be apparent at the primary site of infection. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Source of infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are two exceptions to this rule, the neutropenic patient in whom cytotoxic chemotherapy has caused mucosal injury allowing bacteria to cross mucosal membranes and enter the bloodstream and the splenectomized patient. These patients may not have an obvious primary site of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link\">",
"     \"Overview of neutropenic fever syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9895?source=see_link\">",
"     \"Clinical features and management of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic resistance among gram-negative bacteria is generally believed to increase mortality. However, it is often difficult to measure the impact of antibiotic resistant versus nonresistant gram-negative bacillary infections because of underlying illnesses (host related issues) and methodologic problems.",
"   </p>",
"   <p>",
"    The following findings illustrate these difficulties:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective case-control study of bacteremia due to gram-negative bacilli in neutropenic cancer patients found that attributable mortality was similar in patients with gram-negative bacteremia whether they were infected with susceptible or multiresistant strains (15.7 versus 13.8 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inappropriate empiric therapy (eg, treatment with an antibiotic that does not have activity against the causative organism due to antibiotic resistance) may result in increased mortality in gram-negative bacteremia (eg, 30 day mortality 38 versus 27 percent with appropriate initial therapy in a series of 286 cases of antibiotic-resistant gram-negative bacillary bacteremia) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonetheless, we suspect that gram-negative resistance influences mortality in most situations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Impact of antibiotic resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of gram-negative bacteremia is increasingly complicated by the occurrence of multidrug resistant gram-negative bacilli strains. Normally susceptible bacteria may become resistant to antimicrobial agents through mutation and selection or acquisition from other bacteria of genetic information that encodes resistance. In addition, overproduction of chromosomal beta-lactamases by Enterobacter spp. has become one of the most common mechanisms of resistance to third generation cephalosporins [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30553?source=see_link\">",
"     \"Extended-spectrum beta-lactamases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    According to the NNIS System report in 2004, nonsusceptibility to third generation cephalosporins from patients in intensive care units in the United States was found in [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/46\">",
"     46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      20.6 percent of K. pneumoniae isolates",
"     </li>",
"     <li>",
"      31.1 percent of Enterobacter spp. isolates",
"     </li>",
"     <li>",
"      5.8 percent of E. coli isolates",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence and nature of resistance among these bacteria have changed dramatically, as we have witnessed the emergence and dissemination of new ESBLs, particularly CTX-M beta lactamases and more carbapenemases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30553?source=see_link\">",
"     \"Extended-spectrum beta-lactamases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9754?source=see_link\">",
"     \"Carbapenemases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Extended-spectrum beta-lactamases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extended-spectrum beta-lactamases (ESBL) confer resistance to beta lactam agents. These organisms are frequently multidrug resistant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30553?source=see_link\">",
"     \"Extended-spectrum beta-lactamases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ESBL producing E. coli is an important cause of both nosocomial and community onset bacteremia. In one series these organisms accounted for 7.3 percent of cases of community-onset bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/47\">",
"     47",
"    </a>",
"    ]. Independent risk factors included health care, urinary catheter use and previous antimicrobial therapy.",
"   </p>",
"   <p>",
"    In a prospective, observational study of 85 episodes of K. pneumoniae due to ESBL-producing organisms bacteremia, the following findings were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/48\">",
"     48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Failure to treat with any antibiotic with in vitro activity against the isolate recovered during the five day period after the first positive blood culture result was associated with a significantly higher mortality than was treatment with active antibiotics (63.6 versus 14.1 percent, odds ratio [OR], 10.7; 95% CI, 2.2-57.0).",
"     </li>",
"     <li>",
"      Patients who were treated with a carbapenem (primarily imipenem) either as monotherapy or in combination therapy in the five day period after the first positive blood culture had a significantly lower 14-day mortality than patients treated with a noncarbapenem antibiotic (4.8 versus 27.6 percent, OR, 0.17; 95% CI, 0.04-0.76).",
"     </li>",
"     <li>",
"      Carbapenem monotherapy was significantly superior to fluoroquinolone or noncarbapenem beta-lactam therapy (3.7 versus 36.3 versus 44.4 percent mortality, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Carbapenem resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The widespread use of carbapenems for suspected cases of ESBL bacterial infection has contributed to the development of carbapenem resistance in many species of bacteria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9754?source=see_link\">",
"     \"Carbapenemases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of gram-negative bacillary bacteremia requires urgent empiric antibiotics, good supportive care, careful monitoring of patients, and control of the source of infection, which may require surgical drainage, or removal of an intravascular catheter. A retrospective study of 2731 adult patients with septic shock demonstrates the urgency of appropriate antibiotic therapy: for each hour of delay of appropriate therapy following the onset of hypotension, survival decreased by 7.6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Empiric antimicrobial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous antibiotic therapy should be initiated immediately after obtaining blood cultures and cultures of the suspected source of infection or upon a call from the microbiology laboratory reporting positive blood culture results. The choice of antibiotics should consider the patient's history, comorbidities, clinical syndrome, Gram's stain data, and previous culture results.",
"   </p>",
"   <p>",
"    No recent randomized controlled studies have evaluated empiric antibiotic regimens for gram-negative bacillary bacteremia. Treatment recommendations are based on retrospective or observational case series and on the knowledge of the patient or hospital's prior gram-negative bacillary sensitivity data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Immunocompetent patient without sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For immunocompetent patients without signs of severe sepsis or septic shock, we recommend broad-spectrum antibiotic coverage with one of the following antibiotics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antipseudomonal cephalosporin (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      2 g every 8 hours or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      2 g every 12 hours)",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Beta-lactam/beta-lactamase",
"      </span>",
"      inhibitor (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"       piperacillin-tazobactam",
"      </a>",
"      4.5 g every six hours,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/45/42710?source=see_link\">",
"       ticarcillin-clavulanate",
"      </a>",
"      3.1 g every four hours)",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      Carbapenem (eg, imipenem 500 mg every six hours,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      1 g every eight hours,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/42/6822?source=see_link\">",
"       doripenem",
"      </a>",
"      500 mg every eight hours, preferably by a prolonged infusion of four hours or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"       ertapenem",
"      </a>",
"      1 g once daily).",
"     </li>",
"     <li>",
"      For patients with multiresistant gram-negative bacteremias not susceptible to the above agents,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"       colistin",
"      </a>",
"      may be an alternative option, depending on susceptibility (100 and 200 mg every 8 to 12 hours).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     When to consider combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considerable controversy surrounds the need for one or two drugs for treatment of Pseudomonas bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39528?source=see_link\">",
"     \"Treatment of Pseudomonas aeruginosa infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No such controversy accompanies the therapy of other gram-negative rod bacteremias. Two meta-analyses have concluded that the addition of an aminoglycoside to a beta-lactam for the management of gram-negative bacteremia does not provide any advantage over the beta-lactam alone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. One of the meta-analyses concluded that toxicity is increased with inclusion of an aminoglycoside.",
"   </p>",
"   <p>",
"    However, the use of two drugs is supported by findings that mortality is increased in patients with gram-negative bacteremia when patients receive inappropriate initial antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/2,52\">",
"     2,52",
"    </a>",
"    ]. In the retrospective review of 286 patients from Korea with antibiotic-resistant gram-negative bacteremia, the mortality rate was significantly higher in patients who received initial inappropriate therapy compared to those who received at least one antimicrobial agent to which the causative microorganism was susceptible (38.4 versus 27.4 percent mortality) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, the role of a second agent may be to cover possible resistant pathogens when resistance rates to the primary agent are high.",
"   </p>",
"   <p>",
"    Thus, for any patient with severe sepsis or septic shock or when the level of resistance among the most common gram-negative pathogens in a hospital is &gt;20 to 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/2,53\">",
"     2,53",
"    </a>",
"    ], we recommend a broad-spectrum combination antibiotic regimen. In addition, if culture results are not available, gram-positive therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (1 g every 12 hours, adjusted for renal insufficiency) should be added pending culture results.",
"   </p>",
"   <p>",
"    Typical combination antibiotic regimens include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       Amikacin",
"      </a>",
"      (7.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours)",
"      <strong>",
"       PLUS",
"      </strong>",
"      one of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Antipseudomonal cephalosporin (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      2 g every 12 hours or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      2 g every 8 hours)",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      Antipseudomonal",
"      <span class=\"nowrap\">",
"       beta-lactam/beta-lactamase",
"      </span>",
"      inhibitor (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"       piperacillin-tazobactam",
"      </a>",
"      4.5 g every six hours or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/45/42710?source=see_link\">",
"       ticarcillin-clavulanate",
"      </a>",
"      3.1 g every four hours)",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      Carbapenem (eg, imipenem 500 mg every six hours or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      1 g every eight hours)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Pathogen-directed therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once culture results and antimicrobial susceptibility data are available, we recommend that therapy be pathogen-directed based upon the susceptibility results. Narrowing the antimicrobial spectrum based on culture results preserves the most broad-spectrum agents for treatment of multidrug resistant pathogens. Thus, once susceptibility results are available, patients should only receive the most broad-spectrum agents (eg, carbapenems, third and fourth generation cephalosporins, or beta-lactam, beta-lactamase inhibitors) if their particular isolate is resistant to more narrow spectrum antibiotics.",
"   </p>",
"   <p>",
"    The importance of using a narrower spectrum agent is due to the concern that the use of carbapenems for the treatment of the hospitalized patient on an empiric basis will lead to the selection of carbapenem-resistant P. aeruginosa [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/54\">",
"     54",
"    </a>",
"    ], K. pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/55,56\">",
"     55,56",
"    </a>",
"    ], or Acinetobacter spp. [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/57\">",
"     57",
"    </a>",
"    ]. Continued resistance surveillance will be crucial to monitor the effectiveness of these antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, if the isolate is an Enterobacter spp., we recommend treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    or a carbapenem even if the isolate appears sensitive to a third generation cephalosporin or a beta-lactam, beta-lactamase inhibitor, because of the high rate of resistance that may develop during treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/48,59\">",
"     48,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized controlled studies have evaluated the optimal duration of antibiotic therapy for gram-negative bacteremia; the duration of therapy should be determined by the clinical response of the patient and the source and extent of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/10999?source=see_link\">",
"     \"Acute complicated cystitis and pyelonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most cases, the duration of antibiotic therapy is 7 to 14 days. Initially antibiotics should be given parenterally, but once the patient has defervesced and has remained afebrile for 48 hours, the antibiotics may be switched to an oral agent with in vitro activity and excellent bioavailability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Control of the source of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to antibiotic therapy, management of gram-negative bacteremia requires the identification of the source of infection and resolution of infection at the source.",
"   </p>",
"   <p>",
"    Catheter-related gram-negative bacteremia most commonly requires removal of the catheter to prevent relapse of infection. The need for catheter removal as part of management is illustrated by a retrospective study of 72 cases of catheter-related gram-negative bacteremia that occurred between January 1990 and December 1996 at M.D. Anderson Cancer Center [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/60\">",
"     60",
"    </a>",
"    ]. In response to the bacteremia, 67 patients had their catheters removed and five patients retained their catheters. Only one patient who had their catheter removed relapsed with the same organism compared to all five of the patients who initially retained their catheters. A second retrospective study from Australia found that failure to remove the central venous catheter in patients with Stenotrophomonas maltophilia bloodstream infections was associated with increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop severe sepsis or septic shock should be managed in an ICU. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality rate of patients with gram-negative bacteremia is 12 to 38 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20681/abstract/2,61,62\">",
"     2,61,62",
"    </a>",
"    ]. In a retrospective study of 81 episodes of gram-negative bacteremia in nonneutropenic patients from Greece, factors associated with a higher death rate included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute respiratory distress syndrome (ARDS)",
"     </li>",
"     <li>",
"      Septic shock",
"     </li>",
"     <li>",
"      Disseminated intravascular coagulation (DIC)",
"     </li>",
"     <li>",
"      Anuria",
"     </li>",
"     <li>",
"      Presence of a central venous catheter",
"     </li>",
"     <li>",
"      Unknown origin of infection",
"     </li>",
"     <li>",
"      Inappropriate antibiotic treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this study, early initiation of appropriate antibiotic therapy was the most important intervention that favorably affected the outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33569?source=see_link\">",
"       \"Patient information: Sepsis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacteremia due to gram-negative rods is a significant problem in hospitalized and community-dwelling patients. While the percentage of hospital-acquired bloodstream infections (BSIs) associated with gram-negative bacilli has decreased (see below), these organisms now pose serious therapeutic problems because of multidrug resistance. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In 2003, NNIS hospitals reported that gram-negative bacilli were responsible for 24 percent of nosocomial bacteremias in intensive care units (ICUs) in the United States; higher rates occur in the elderly, particularly those in nursing homes. In Latin America, and some areas of Europe and the Far East, the proportion of bacteremia caused by gram-negative bacilli is greater than that identified in the United States. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most hospitalized patients with gram-negative bacteremia have at least one comorbid condition. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with gram-negative rod bacteremia typically present with fever, with or without chills. Disorientation, hypotension, and respiratory failure may complicate bacteremia and are usually signs that the patient may be developing septic shock, which is seen in about 25 percent of patients on presentation with gram-negative rod bacteremia. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gram-negative rod bacteremia rarely occurs spontaneously without infection at another site. An exception to this rule is the neutropenic patient in whom cytotoxic chemotherapy has caused mucosal injury allowing bacteria to cross mucosal membranes and enter the bloodstream. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of gram-negative bacteremia is increasingly complicated by the occurrence of multidrug resistant gram-negative bacilli strains. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Impact of antibiotic resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of gram-negative bacillary bacteremia requires urgent empiric antibiotics, good supportive care, careful monitoring of patients, and control of the source of infection, which may require surgical drainage, or removal of an intravascular catheter. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of antibiotics should consider the patient's history, comorbidities, clinical syndrome, Gram's stain data, and previous culture results. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Empiric antimicrobial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In hospital-acquired gram-negative bacteremia, when local resistance rates are low and the patient is immunocompetent without signs of severe sepsis or septic shock, we recommend broad-spectrum antibiotic coverage with a single antibiotic (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Acceptable regimens include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Antipseudomonal cephalosporin (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      2 g every 8 hours or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      2 g every 12 hours)",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Beta-lactam/beta-lactamase",
"      </span>",
"      inhibitor (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"       piperacillin-tazobactam",
"      </a>",
"      4.5 g every six hours or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/45/42710?source=see_link\">",
"       ticarcillin-clavulanate",
"      </a>",
"      3.1 g every four hours)",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      Carbapenem (eg, imipenem 500 mg every six hours,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      1 g every eight hours,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/42/6822?source=see_link\">",
"       doripenem",
"      </a>",
"      500 mg every eight hours, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"       ertapenem",
"      </a>",
"      1 g once daily)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Empiric antimicrobial therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For any patient with severe sepsis or septic shock or when the level of resistance among the most common gram-negative pathogens in a hospital is &gt;20 to 25 percent, we recommend a broad-spectrum combination antibiotic regimen (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Typical combination antibiotic regimens include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       Amikacin",
"      </a>",
"      (7.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours)",
"      <strong>",
"       PLUS",
"      </strong>",
"      one of the following:",
"     </li>",
"     <li>",
"      Antipseudomonal cephalosporin (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      2 g every 12 hours or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      2 g every 8 hours)",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      Antipseudomonal",
"      <span class=\"nowrap\">",
"       beta-lactam/beta-lactamase",
"      </span>",
"      inhibitor (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"       piperacillin-tazobactam",
"      </a>",
"      4.5 g every six hours or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/45/42710?source=see_link\">",
"       ticarcillin-clavulanate",
"      </a>",
"      3.1 g every four hours)",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      Carbapenem (eg, imipenem 500 mg every six hours,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      1 g every eight hours,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/42/6822?source=see_link\">",
"       doripenem",
"      </a>",
"      500 mg every eight hours, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"       ertapenem",
"      </a>",
"      1 g once daily)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H15\">",
"     'When to consider combination therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once culture results and antimicrobial susceptibility data are available, we typically narrow coverage so that therapy is pathogen-directed based upon the susceptibility results. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Pathogen-directed therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The duration of therapy should be determined by the clinical response of the patient and the source and extent of infection. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to antibiotic therapy, management of gram-negative bacteremia requires the identification of the source of infection and resolution of infection at the source. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Control of the source of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mortality rate of patients with gram-negative bacteremia is 12 to 38 percent. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/1\">",
"      Su&aacute;rez CJ, Lolans K, Villegas MV, Quinn JP. Mechanisms of resistance to beta-lactams in some common Gram-negative bacteria causing nosocomial infections. Expert Rev Anti Infect Ther 2005; 3:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/2\">",
"      Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005; 49:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/3\">",
"      Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/4\">",
"      Gaynes R, Edwards JR, National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005; 41:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/5\">",
"      Albrecht SJ, Fishman NO, Kitchen J, et al. Reemergence of gram-negative health care-associated bloodstream infections. Arch Intern Med 2006; 166:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/6\">",
"      Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis 2004; 50:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/7\">",
"      Velasco E, Byington R, Martins CA, et al. Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in hematologic patients in a single cancer center. Eur J Clin Microbiol Infect Dis 2003; 22:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/8\">",
"      Luzzaro F, Vigan&ograve; EF, Fossati D, et al. Prevalence and drug susceptibility of pathogens causing bloodstream infections in northern Italy: a two-year study in 16 hospitals. Eur J Clin Microbiol Infect Dis 2002; 21:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/9\">",
"      Greenberg BM, Atmar RL, Stager CE, Greenberg SB. Bacteraemia in the elderly: predictors of outcome in an urban teaching hospital. J Infect 2005; 50:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/10\">",
"      Mylotte JM, Tayara A, Goodnough S. Epidemiology of bloodstream infection in nursing home residents: evaluation in a large cohort from multiple homes. Clin Infect Dis 2002; 35:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/11\">",
"      Perencevich EN, McGregor JC, Shardell M, et al. Summer Peaks in the Incidences of Gram-Negative Bacterial Infection Among Hospitalized Patients. Infect Control Hosp Epidemiol 2008; 29:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/12\">",
"      Graff LR, Franklin KK, Witt L, et al. Antimicrobial therapy of gram-negative bacteremia at two university-affiliated medical centers. Am J Med 2002; 112:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/13\">",
"      Vidal F, Mensa J, Almela M, et al. Bacteraemia in adults due to glucose non-fermentative Gram-negative bacilli other than P. aeruginosa. QJM 2003; 96:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/14\">",
"      Shmuely H, Pitlik S, Yahav J, et al. Seven-year study of bacteremia in hospitalized patients on chronic hemodialysis in a single tertiary hospital. Ren Fail 2003; 25:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/15\">",
"      Calza L, Manfredi R, Chiodo F. Stenotrophomonas (Xanthomonas) maltophilia as an emerging opportunistic pathogen in association with HIV infection: a 10-year surveillance study. Infection 2003; 31:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/16\">",
"      Abbott KC, Napier MG, Agodoa LY. Hospitalizations for bacterial septicemia in patients with end stage renal disease due to diabetes on the renal transplant waiting list. J Nephrol 2002; 15:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/17\">",
"      Baine WB, Yu W, Summe JP. The epidemiology of hospitalization of elderly Americans for septicemia or bacteremia in 1991-1998. Application of Medicare claims data. Ann Epidemiol 2001; 11:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/18\">",
"      Candel FJ, Grima E, Matesanz M, et al. Bacteremia and septic shock after solid-organ transplantation. Transplant Proc 2005; 37:4097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/19\">",
"      Thomsen RW, Hundborg HH, Lervang HH, et al. Diabetes mellitus as a risk and prognostic factor for community-acquired bacteremia due to enterobacteria: a 10-year, population-based study among adults. Clin Infect Dis 2005; 40:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/20\">",
"      Tong MJ. Septic complications of war wounds. JAMA 1972; 219:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/21\">",
"      Centers for Disease Control and Prevention (CDC). Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004. MMWR Morb Mortal Wkly Rep 2004; 53:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/22\">",
"      Davis KA, Moran KA, McAllister CK, Gray PJ. Multidrug-resistant Acinetobacter extremity infections in soldiers. Emerg Infect Dis 2005; 11:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/23\">",
"      K&auml;llman O, Lundberg C, Wretlind B, Ortqvist A. Gram-negative bacteria from patients seeking medical advice in Stockholm after the tsunami catastrophe. Scand J Infect Dis 2006; 38:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/24\">",
"      Marschall J, Zhang L, Foxman B, et al. Both host and pathogen factors predispose to Escherichia coli urinary-source bacteremia in hospitalized patients. Clin Infect Dis 2012; 54:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/25\">",
"      Sanders WE Jr, Sanders CC. Enterobacter spp.: pathogens poised to flourish at the turn of the century. Clin Microbiol Rev 1997; 10:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/26\">",
"      Ferguson R, Feeney C, Chirurgi VA. Enterobacter agglomerans--associated cotton fever. Arch Intern Med 1993; 153:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/27\">",
"      Wagner SJ, Friedman LI, Dodd RY. Transfusion-associated bacterial sepsis. Clin Microbiol Rev 1994; 7:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/28\">",
"      Matsaniotis NS, Syriopoulou VP, Theodoridou MC, et al. Enterobacter sepsis in infants and children due to contaminated intravenous fluids. Infect Control 1984; 5:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/29\">",
"      McCue JD. Gram-negative bacillary bacteremia in the elderly: incidence, ecology, etiology, and mortality. J Am Geriatr Soc 1987; 35:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/30\">",
"      Sligl W, Taylor G, Brindley PG. Five years of nosocomial Gram-negative bacteremia in a general intensive care unit: epidemiology, antimicrobial susceptibility patterns, and outcomes. Int J Infect Dis 2006; 10:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/31\">",
"      Friedman ND, Kaye KS, Stout JE, et al. Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/32\">",
"      Cristofaro P, Opal SM. The Toll-like receptors and their role in septic shock. Expert Opin Ther Targets 2003; 7:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/33\">",
"      Natanson C, Eichenholz PW, Danner RL, et al. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 1989; 169:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/34\">",
"      Lin WJ, Yeh WC. Implication of Toll-like receptor and tumor necrosis factor alpha signaling in septic shock. Shock 2005; 24:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/35\">",
"      Takeuchi O, Sato S, Horiuchi T, et al. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002; 169:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/36\">",
"      Szab&oacute; C. Role of flagellin in the pathogenesis of shock and acute respiratory distress syndrome: therapeutic opportunities. Crit Care Med 2003; 31:S39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/37\">",
"      Sparwasser T, Miethke T, Lipford G, et al. Bacterial DNA causes septic shock. Nature 1997; 386:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/38\">",
"      Lyerly DM, Kreger AS. Importance of serratia protease in the pathogenesis of experimental Serratia marcescens pneumonia. Infect Immun 1983; 40:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/39\">",
"      May AK, Gleason TG, Sawyer RG, Pruett TL. Contribution of Escherichia coli alpha-hemolysin to bacterial virulence and to intraperitoneal alterations in peritonitis. Infect Immun 2000; 68:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/40\">",
"      R&oacute;zalski A, Sidorczyk Z, Koteko K. Potential virulence factors of Proteus bacilli. Microbiol Mol Biol Rev 1997; 61:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/41\">",
"      Ideses D, Gophna U, Paitan Y, et al. A degenerate type III secretion system from septicemic Escherichia coli contributes to pathogenesis. J Bacteriol 2005; 187:8164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/42\">",
"      Lawlor MS, Hsu J, Rick PD, Miller VL. Identification of Klebsiella pneumoniae virulence determinants using an intranasal infection model. Mol Microbiol 2005; 58:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/43\">",
"      Joly-Guillou ML. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect 2005; 11:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/44\">",
"      Spanik S, Krupova I, Trupl J, et al. Bacteremia due to multiresistant gram-negative bacilli in neutropenic cancer patients: a case-controlled study. J Infect Chemother 1999; 5:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/45\">",
"      Goossens H, Grabein B. Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004). Diagn Microbiol Infect Dis 2005; 53:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/46\">",
"      National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/47\">",
"      Rodr&iacute;guez-Ba&ntilde;o J, Pic&oacute;n E, Gij&oacute;n P, et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 2010; 50:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/48\">",
"      Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004; 39:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/49\">",
"      Chatzinikolaou I, Abi-Said D, Bodey GP, et al. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes. Arch Intern Med 2000; 160:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/50\">",
"      Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004; 328:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/51\">",
"      Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/52\">",
"      Rodr&iacute;guez-Ba&ntilde;o J, Navarro MD, Romero L, et al. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006; 43:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/53\">",
"      Micek ST, Lloyd AE, Ritchie DJ, et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/54\">",
"      Meyer KS, Urban C, Eagan JA, et al. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993; 119:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/55\">",
"      Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005; 56:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/56\">",
"      Lomaestro BM, Tobin EH, Shang W, Gootz T. The spread of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae to upstate New York. Clin Infect Dis 2006; 43:e26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/57\">",
"      Rahal JJ, Urban C, Segal-Maurer S. Nosocomial antibiotic resistance in multiple gram-negative species: experience at one hospital with squeezing the resistance balloon at multiple sites. Clin Infect Dis 2002; 34:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/58\">",
"      Sader HS, Fritsche TR, Jones RN. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003). Diagn Microbiol Infect Dis 2005; 52:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/59\">",
"      Bhavnani SM, Ambrose PG, Craig WA, et al. Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2006; 54:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/60\">",
"      Hanna H, Afif C, Alakech B, et al. Central venous catheter-related bacteremia due to gram-negative bacilli: significance of catheter removal in preventing relapse. Infect Control Hosp Epidemiol 2004; 25:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/61\">",
"      Friedman ND, Korman TM, Fairley CK, et al. Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect 2002; 45:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20681/abstract/62\">",
"      Gikas A, Samonis G, Christidou A, et al. Gram-negative bacteremia in non-neutropenic patients: a 3-year review. Infection 1998; 26:155.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3149 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-58B3102C39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_12_20681=[""].join("\n");
var outline_f20_12_20681=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H78470229\">",
"      Seasonal patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Source of infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANTIBIOTIC RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Impact of antibiotic resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Extended-spectrum beta-lactamases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Carbapenem resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Empiric antimicrobial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Immunocompetent patient without sepsis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - When to consider combination therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Pathogen-directed therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Control of the source of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/47/10999?source=related_link\">",
"      Acute complicated cystitis and pyelonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9754?source=related_link\">",
"      Carbapenemases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9895?source=related_link\">",
"      Clinical features and management of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27145?source=related_link\">",
"      Epidemiology and pathogenesis of Pseudomonas aeruginosa infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30553?source=related_link\">",
"      Extended-spectrum beta-lactamases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5449?source=related_link\">",
"      Pathophysiology of sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33569?source=related_link\">",
"      Patient information: Sepsis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39528?source=related_link\">",
"      Treatment of Pseudomonas aeruginosa infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_12_20682="Risk factors for asthma";
var content_f20_12_20682=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Risk factors for asthma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/12/20682/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/12/20682/contributors\">",
"     Augusto A Litonjua, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/12/20682/contributors\">",
"     Scott T Weiss, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/12/20682/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/12/20682/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/12/20682/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/12/20682/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/12/20682/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/12/20682/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asthma is a condition that likely results from complex interactions between multiple environmental and genetic influences. Numerous risk factors for asthma have been identified. The best studied risk factors, including gender, airway hyperreactivity, atopy, allergens, infections, tobacco smoke, obesity, and perinatal factors, are discussed in this topic review.",
"   </p>",
"   <p>",
"    The epidemiology and natural history of asthma are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19653?source=see_link\">",
"     \"Epidemiology of asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7383?source=see_link\">",
"     \"Natural history of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are clear-cut gender differences in the prevalence of asthma. Childhood asthma tends to be a predominantly male disease, with the relative male predominance being maximal at puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/1\">",
"     1",
"    </a>",
"    ]. After age 20, the prevalence remains approximately equal until age 40, when the disease becomes more common in females. Reasons for gender differences are unclear and largely unexplored. Possible explanations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The greater prevalence of atopy (ie, evidence of IgE sensitization to allergens) in young boys.",
"     </li>",
"     <li>",
"      Reduced relative airway size in boys compared to girls [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/2\">",
"       2",
"      </a>",
"      ]. Smaller airway size may also contribute to the increased risk of wheezing after viral respiratory infections in young boys compared to girls. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2298?source=see_link\">",
"       \"Virus-induced wheezing and asthma: An overview\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Differences in symptom reporting between boys and girls [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EARLY ABNORMALITIES IN PULMONARY FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may be changes in lung function that are present in childhood or even in neonatal life in individuals who subsequently develop symptoms of asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neonatal lung function",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence for the presence of physiologic differences shortly after birth in individuals who later develop asthma. Lung function in neonates can be measured non-invasively using tidal breathing flow-volume loops and passive respiratory mechanics. Using these methods, a prospective birth cohort of 802 healthy infants underwent pulmonary function testing at an average of three days of age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/4\">",
"     4",
"    </a>",
"    ]. Ten years later, 77 percent were contacted and reevaluated for the presence of asthma by history, standard lung function testing, exercise-induced bronchoconstriction (treadmill testing),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    challenge, and skin prick testing for allergic sensitization to aeroallergens. There were statistically significant associations between values for pulmonary function testing below the median for the cohort and the presence of asthma at 10 years with odds ratios between 1.58 and 2.18, depending on the measurement examined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Airway hyperreactivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal and exaggerated airway responsiveness to noxious stimuli is a central feature in the pathophysiology of asthma, and all patients with asthma have airway hyperresponsiveness (AHR) by definition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=see_link\">",
"     \"Diagnosis of asthma in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, not all patients with AHR have symptoms of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/5\">",
"     5",
"    </a>",
"    ]. Population-based studies of both adults and children have shown that the prevalence of asthma is two to three times lower than the prevalence of AHR [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/1\">",
"     1",
"    </a>",
"    ]. Moreover, 20 to 50 percent of subjects with airway hyperresponsiveness are asymptomatic at the time of testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=see_link\">",
"     \"Bronchoprovocation testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These observations indicate that asthma and airway hyperresponsiveness are not identical phenomena. Airway hyperresponsiveness appears to be a necessary, but not sufficient condition for the development of clinical disease. Furthermore, patients with AHR are at increased risk for the development of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study in adolescents demonstrated that AHR frequently antedates and is associated with an elevated risk for wheeze onset and recurrent asthma, even after controlling for a variety of known risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/7\">",
"     7",
"    </a>",
"    ]. This study investigated 281 children, aged five to nine years at the time of entry into the study, and followed voluntarily with airway challenges for up to six years. In a logistic regression model, the odds ratio (OR) for incident wheeze among those with airways responsiveness at a previous visit was 3.91 (95% CI 1.21-12.66), after adjustment for gender, current age in years, parental atopic and asthmatic status, personal smoking, exposure to passive smoke, any lower respiratory infection before two years of age, and personal atopy.",
"   </p>",
"   <p>",
"    Another study prospectively evaluated 81 Chinese students aged 11 to 17 years who were found to have AHR in a population survey [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/8\">",
"     8",
"    </a>",
"    ]. Eighty-eight age-matched students without AHR served as controls. Fifty students with AHR were asymptomatic, of whom 10 (20 percent) developed asthma over a two year period compared to only two of 88 (2 percent) in the control group. The severity of AHR appeared to predict which subjects would become asthmatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     FAMILIAL HISTORY OF ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are clearly components of the asthma phenotype that appear strongly heritable, although these inherited components do not follow the simple Mendelian pattern and the specific genes responsible for these inherited components have yet to be identified. This topic is reviewed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10713?source=see_link\">",
"     \"Genetics of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ATOPY AND ALLERGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atopy may be defined as the state of having IgE antibodies to specific allergens, which is a prerequisite for developing allergic disease. The association between asthma and other atopic conditions is well-documented. The \"atopic march\" is a term used to describe the pattern of onset of different allergic diseases that is observed in some atopic individuals. This pattern begins with atopic dermatitis in infancy and childhood, followed by the onset of allergic rhinitis and then asthma during later childhood and adolescence. Not all atopic patients develop all three conditions (eg, only about one-third of children with atopic dermatitis subsequently develop asthma) and there are other patterns of presentation of allergic diseases; however, these conditions are clearly associated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Atopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum levels of IgE, the class of antibody responsible for the most common form of respiratory allergy, appear to be closely linked with airway hyperresponsiveness, whether or not asthma symptoms are present. Elevations in total IgE levels indicate the presence of allergic sensitization, although this measurement provides no information about the specific allergens to which an individual is sensitized.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The International Study of Asthma and Allergy in Childhood (ISAAC) found a wide variation among 22 countries in the fraction of current wheeze attributable to atopic sensitization [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/9\">",
"       9",
"      </a>",
"      ]. The association between wheeze and atopy increased in countries with higher economic development.",
"     </li>",
"     <li>",
"      The Third National Health and Nutrition Examination Survey (NHANES) found that half of the asthma cases were attributable to atopy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/10\">",
"       10",
"      </a>",
"      ]. Skin testing of 12,106 subjects with a panel of 10 allergens was performed; atopy was defined as having at least one positive skin test.",
"     </li>",
"     <li>",
"      In a study of 2657 subjects, the prevalence of asthma was closely related to the total serum IgE level, as well as the skin test reactivity [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/11\">",
"       11",
"      </a>",
"      ]. Further analysis showed that asthma correlated better with IgE levels, while allergic rhinitis correlated more closely with skin test reactivity.",
"     </li>",
"     <li>",
"      Another report evaluated 562 11-year-old children who had serum IgE levels determined from a birth cohort of 1037 New Zealand children [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/12\">",
"       12",
"      </a>",
"      ]. The prevalence of diagnosed asthma was significantly related to the serum IgE level. Even among children without a diagnosis of asthma, the prevalence and degree of AHR increased with increasing IgE levels as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      AHR was present in 1 percent at an IgE level below 32",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"     </li>",
"     <li>",
"      AHR was present in 12 percent with IgE levels of 100 to 315",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"     </li>",
"     <li>",
"      AHR was present in 30 percent with IgE levels above 315",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Allergen exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A consensus is emerging that indoor allergens play a significant role in the development of asthma, although it has been difficult to demonstrate a causative relationship, and the majority of these studies were performed on high risk groups [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. At least one prospective study of allergen exposure in early childhood, carried out with a cohort from the general population, found that although a minimum threshold level of allergen was necessary for sensitization or asthma to develop, there was no dose-response relationship above that level [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reunification of East and West Germany afforded a unique opportunity to study the effects of environmental exposure on the development of lung disease in two genetically similar populations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/18\">",
"     18",
"    </a>",
"    ]. The prevalence of asthma, atopy (assessed by skin testing), and AHR was greater in West German children than in their counterparts in East Germany. West German children had significantly greater rates of sensitization to mite, cat, and pollen allergens. In contrast, bronchitis was more prevalent in East Germany, where outdoor air pollution was greater. These investigators proposed that the difference in prevalence of asthma between East and West Germany was attributable to the increased prevalence of allergic sensitization to common aeroallergens among children in the western part of the country.",
"   </p>",
"   <p>",
"    Sources of indoor allergens include house dust mites, animal proteins (particularly cat and dog allergens), cockroaches, and fungi. Changes that have made houses more \"energy-efficient\" over the years are thought to increase exposure to these allergens, thereby playing a role in the increasing prevalence of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/13,19\">",
"     13,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      House dust mite &ndash; In many areas, sensitization to the house dust mite (HDM) appears to have an important association with asthma, potentially contributing to between 65 percent and 90 percent of cases among children and young adults [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/6,13,20\">",
"       6,13,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alternaria mold &ndash; In the middle and western United States, where levels of dust mite allergen are low, sensitization and exposure to the ubiquitous mold Alternaria appears to be important for the later development of asthma.",
"     </li>",
"     <li>",
"      Cockroach allergen &ndash; In studies of inner city asthma, sensitization to cockroach allergen has been shown to be a significant risk factor in the development of asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. In addition, morbidity from asthma in inner-city children is associated with the presence of cockroach allergy and exposure to high levels of cockroach allergen in bedroom dust [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Animal allergens &ndash; Early life exposure to indoor cat and dog allergens has been found to be both associated with and protective against the development of asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. It is possible that other exposures such as environmental tobacco smoke and pollution modulate the impact of early life animal allergen exposure, providing a partial explanation for the variation in development of asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Farm animals &ndash; Exposure to farm animals early in life is negatively associated with the development of allergic disease. Whether this is due to increased exposure to allergens or increased exposure to a wide range of microbial exposures has been the subject of a number of studies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/43/19129?source=see_link&amp;anchor=H6#H6\">",
"       \"Increasing prevalence of asthma and allergic rhinitis\", section on 'Since 1960'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Environmental control studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies examining the impact of environmental control measures for various allergens are hindered by several recurrent problems. Protocols in which a single allergen is targeted for reduction often fail to produce clinical benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. This is not entirely unexpected, because most allergic individuals are sensitized to multiple allergens, and it is possible that all relevant allergens must be controlled simultaneously. A large Canadian trial that did this found benefit for some atopic conditions, although not for airway hyperresponsiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/29\">",
"     29",
"    </a>",
"    ]. It may also be necessary to tailor the interventions to the specific sensitivities of the patients, which is technically demanding. In addition, reductions in the allergens in question may be significant compared to control groups, but it is not known to what degree most allergens must be reduced in order to prevent sensitization. Environmental control to reduced exposure to allergens is reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34569?source=see_link\">",
"     \"Allergen avoidance in the treatment of asthma and allergic rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RHINITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adults with rhinitis are at greater risk than those without rhinitis for developing adult-onset asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. This was best demonstrated in a prospective multicenter study of 6461 adults, aged 20 to 44 years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/33\">",
"     33",
"    </a>",
"    ]. Subjects were randomly chosen from the general population, and a cohort without asthma was evaluated with questionnaires, allergen skin testing, serum specific and total IgE, pulmonary function testing, and bronchial responsiveness testing. Subjects were divided into four groups and followed for a mean period of 8.8 years. The probability of developing asthma during the observation period was:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For those without evidence of atopy or rhinitis &ndash; 1.1 percent",
"     </li>",
"     <li>",
"      Atopy but no rhinitis &ndash; 1.9 percent",
"     </li>",
"     <li>",
"      No atopy but with rhinitis (ie, nonallergic rhinitis) &ndash; 3.1 percent",
"     </li>",
"     <li>",
"      With allergic rhinitis &ndash; 4 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The adjusted risk ratio for those with allergic rhinitis was 3.5 (95% confidence interval (CI) 2.1 to 5.9) and for non-allergic rhinitis, 2.1 (CI 1.6 to 4.5), after controlling for country of origin, sex, FEV1, total IgE, family history of asthma, baseline age, body-mass index, respiratory infections in childhood, and smoking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ENDOTOXIN EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endotoxins are inflammatory lipopolysaccharide molecules from gram-negative bacteria that are ubiquitous in the environment. Determinants of endotoxin in homes include both indoor sources (eg, pets, pests, humidifiers, kitchen compost bins) and outdoor air. In a nationwide study of 831 representative homes, there was an association between increasing endotoxin levels and diagnosed asthma, asthma symptoms in the past year, current use of asthma medications, and wheezing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OCCUPATIONAL EXPOSURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The European Community Respiratory Health Surveys (ECRHS and ECRHS-II) identified several occupations that are associated with an increased risk of new onset asthma; nursing and cleaning were responsible for the most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/35\">",
"     35",
"    </a>",
"    ]. Inhalational accidents (eg, fires, mixing cleaning agents, industrial spills) were also associated with an increased risk of new onset asthma.",
"   </p>",
"   <p>",
"    In the Agricultural Health Study of 25,814 adult farm women, growing up on a farm was protective against asthma, but use of certain pesticides (eg, organophosphates) was associated with an increased risk of adult-onset atopic asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     POLLUTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Outdoor",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a known correlation between levels of air pollution and lung disease, but the association between air pollution and asthma is less clear. As an example, in a study of six cities in the United States, there was a direct relationship between the levels of particulate pollution and reported rates of chronic cough and bronchitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/37\">",
"     37",
"    </a>",
"    ]. There was no association between particulate concentration and asthma, persistent wheeze, or hay fever.",
"   </p>",
"   <p>",
"    It is possible that asthma is related to specific pollutants, while other respiratory diseases are related to total air pollution.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Studies in reunified Germany have provided data on two populations exposed to different levels of pollutants [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/18,38\">",
"       18,38",
"      </a>",
"      ]. East Germany had consistently high levels of SO",
"      <sub>",
"       2",
"      </sub>",
"      and other particulates, whereas West Germany had low levels of sulfur dioxide (SO",
"      <sub>",
"       2",
"      </sub>",
"      ) but slightly higher levels of nitrogen dioxide (NO",
"      <sub>",
"       2",
"      </sub>",
"      ). The prevalence rates of asthma and atopy were higher in the West German towns, while the rates of bronchitis were higher in the East German towns, suggesting at most a minor effect of air pollution on the prevalence of asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/18,38\">",
"       18,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A large epidemiologic study examined the correlation between asthma symptoms in 990 children in eight North American cities, and the ambient concentrations of five air pollutants [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/39\">",
"       39",
"      </a>",
"      ]. There was a small positive correlation between symptoms and carbon monoxide and NO",
"      <sub>",
"       2",
"      </sub>",
"      levels, a marginal correlation with SO",
"      <sub>",
"       2",
"      </sub>",
"      levels, and no relationship with ozone levels or particulate matter.",
"     </li>",
"     <li>",
"      An eight year prospective study found an association between the risk of asthma onset and incident asthma and both greater exposure to NO",
"      <sub>",
"       2",
"      </sub>",
"      and living in close proximity to a major road [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Others studies have examined a possible role of diesel exhaust particles specifically, which are taken up by airway epithelial cells and may stimulate allergic-type immune reactions [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/41-44\">",
"       41-44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Indoor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gas stoves are the primary source of indoor NO",
"    <sub>",
"     2",
"    </sub>",
"    . It is estimated that more than half of the households in the United States use gas stoves; thus, a large number of adults and children may be chronically exposed to NO",
"    <sub>",
"     2",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 728 children (age &lt;12 years) with asthma, patients in multifamily housing with gas stoves had an increased likelihood of wheeze (OR = 2.27, 95% CI 1.15-4.47), shortness of breath (OR = 2.33, 95% CI 1.12-5.06), and chest tightness (OR = 4.34, 95% CI 1.76-10.69) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/45\">",
"     45",
"    </a>",
"    ]. The association between gas stoves and respiratory symptoms did not exist in single family housing, suggesting that the relationship is most relevant to patients in lower socioeconomic groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     RESPIRATORY INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral and bacterial respiratory infections are well-known triggers that can cause exacerbations in children and adults with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Whether respiratory infections can be a cause of asthma, however, is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. There are no conclusive epidemiologic data linking infections to causation of asthma in previously normal adults. Furthermore, certain respiratory infections may be protective in infants, not causative. In this section, respiratory infection refers to viral or unspecified infections; few studies have looked at the effect of bacterial infections.",
"   </p>",
"   <p>",
"    Epidemiologic studies performed on samples of unselected children have suggested that frequent respiratory infection during infancy may protect against the later development of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/50\">",
"     50",
"    </a>",
"    ]. An example of this effect comes from remote islands whose population has both a very low incidence of respiratory infections and strikingly high prevalence rates of asthma and atopy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/51\">",
"     51",
"    </a>",
"    ]. Similarly, the development of asthma, hay fever, or eczema has been shown to be inversely related to the number of older siblings or participation in day care [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/18,52-55\">",
"     18,52-55",
"    </a>",
"    ]. Taken together, these observations suggest that in most children, respiratory infections early in life somehow delay or prevent the expression of allergic diseases later in life [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/52,56\">",
"     52,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SMOKING AND EXPOSURE TO ENVIRONMENTAL TOBACCO SMOKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Population-based studies appear to show a relationship between smoking and airway hyperresponsiveness. However, the presence of asthma in adults has generally been unrelated to smoking history, possibly reflecting a tendency for asthmatics not to become regular smokers or to smoke less than their non-asthmatic counterparts [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Active smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have demonstrated that active smoking increases the risk for developing asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. A 1996 longitudinal study of 5801 people born in 1958 who were part of a national British cohort has implicated smoking in the development of wheeze and asthma in young adults [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/57\">",
"     57",
"    </a>",
"    ]. Subjects were followed up at the ages of 7, 11, 16, 23, and 33 years. Active smoking was strongly associated with the incidence of asthma and wheezing illnesses between the ages of 17 and 33 (OR = 4.42, 95% CI 3.31-5.92) after controlling for a variety of factors, including gender, maternal age, birth order, gestational age, hay fever, eczema, father's social class, and maternal smoking. In addition, among the 880 children who developed asthma or wheezy bronchitis by age seven, relapse at age 33 after prolonged remission of childhood wheezing was more common among current smokers. A study of adolescents found that those who smoked &ge;300 cigarettes per year had a relative risk of 3.9 for developing asthma, compared to their non-smoking peers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Secondhand smoke",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a growing body of evidence that secondhand smoke exposure is associated with the development of asthma in early life [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/25\">",
"     25",
"    </a>",
"    ]. Maternal smoking is the most important cause of secondhand smoke exposure, because of the greater exposure of the child to the mother than the father [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, a cross-sectional analysis of the relationship of maternal cigarette smoking to the incidence of asthma in the first year of life found that the children of smoking mothers were 2.1 times more likely to develop asthma than were children of non-smoking mothers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/60\">",
"     60",
"    </a>",
"    ]. Similar findings were noted in another study in which the effect of maternal smoking was found in mothers of low educational level [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In adults, data on the effects of environmental tobacco exposure on nonmalignant lung disease are sparse. The association between passive exposure to tobacco smoke and respiratory symptoms was studied in a sample of 4197 non-smoking adults as part of the Swiss Study on Air Pollution and Lung Diseases in Adults (SAPALDIA Study) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/62\">",
"     62",
"    </a>",
"    ]. Passive exposure to tobacco smoke was associated with increases in the risks of doctor-diagnosed asthma (odds ratio = 1.39), wheezing, bronchitis, and dyspnea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Prenatal exposure to maternal smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal exposure to smoking may also be important, being associated with reduced pulmonary function in the infant. One study, for example, evaluated the effect of prenatal maternal cigarette smoking on the pulmonary function of 80 healthy infants shortly after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/63\">",
"     63",
"    </a>",
"    ]. Maternal smoking was assessed by questionnaire reports and urine cotinine concentration at each prenatal visit. Pulmonary function (assessed as flow at FRC) was lower in infants whose mothers smoked compared to those whose mothers did not smoke.",
"   </p>",
"   <p>",
"    Another report evaluated the effect of early levels of lung function on the subsequent occurrence of a wheezing lower respiratory tract illness in the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/64\">",
"     64",
"    </a>",
"    ]. Infants who developed a wheezing lower respiratory tract illness in the first year of life had lower pre-illness lung function compared to infants who did not wheeze and were more likely to have mothers who smoked during pregnancy. Reduced pulmonary function early in life increases the risk for wheezing and subsequently for asthma later in life.",
"   </p>",
"   <p>",
"    It has been proposed that prenatal smoking exposes the fetus to the growth-retarding effects of tobacco and enhances airway-parenchymal dysanapsis (disproportionately small airways compared to the size of the pulmonary parenchyma). These changes may contribute to the postnatal expression of increased airway responsiveness and asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two other studies have examined the effects of prenatal and postnatal exposure to smoking on asthma and wheezing in children. The first study used a broad case definition to identify 620 schoolchildren aged seven to nine years in Cape Town with current asthma or wheeze in the last 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In bivariate analyses, maternal smoking, whether defined as ever smoking (OR = 1.80), smoking during pregnancy (OR = 1.97), smoking during the first year of the child's life (OR = 1.70), or current smoking (OR = 1.70) was significantly associated with current",
"      <span class=\"nowrap\">",
"       asthma/wheeze",
"      </span>",
"      among the children. The number of cigarettes smoked daily by the mother and the number of household smokers were also related to current",
"      <span class=\"nowrap\">",
"       asthma/wheeze.",
"      </span>",
"     </li>",
"     <li>",
"      Further strengthening these findings, the children's cotinine-creatinine ratio was significantly associated with current",
"      <span class=\"nowrap\">",
"       asthma/wheeze",
"      </span>",
"      (OR = 1.61 for the highest quartile versus the lowest quartile).",
"     </li>",
"     <li>",
"      In a multivariate logistic regression model controlling for a variety of known risk factors, maternal smoking during pregnancy (OR = 1.87, 95% CI 1.25-2.81) and the number of household smokers (OR = 1.15, 1.01, 1.30) remained significantly associated with current",
"      <span class=\"nowrap\">",
"       asthma/wheeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The second study examined the relationship between current and past exposure to maternal, paternal, and nonparental environmental tobacco smoke in the home and several measures of asthma and wheeze in a large sample of school-aged children (11,534 children) from 24 communities in the US and Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/67\">",
"     67",
"    </a>",
"    ]. Asthma was identified based on either an active diagnosis of asthma or use of medication for asthma. Wheeze outcomes were: any wheezing, wheezing with a cold, wheezing without a cold, persistent wheeze, shortness of breath with wheeze, awakening at night by wheezing, wheezing with exercise, medication for wheeze, emergency department visit for wheeze, and hospitalization for wheeze.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children who were currently exposed had a significantly increased risk of reported wheeze with a cold (OR = 1.65), emergency department visit for wheeze (OR = 1.63), persistent wheeze (OR = 1.42), shortness of breath with wheeze (OR = 1.35), wheeze with exercise (OR = 1.24), and medication for wheeze (OR = 1.23) in past year. For most of the wheeze outcomes, there was an increasing risk associated with increasing number of smokers in the home and number of cigarettes smoked in the home per day.",
"     </li>",
"     <li>",
"      Active asthma was significantly associated with exposure to environmental tobacco smoke in pregnancy only (OR = 2.70, 95% CI 1.13-6.45), and no significant association was found for currently exposed children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A European birth cohort study of more than 21,000 children examined the effects of maternal smoking exclusively during pregnancy, during pregnancy and in the first year after delivery, and exclusively for the first year after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/68\">",
"     68",
"    </a>",
"    ]. Exposure to maternal smoking exclusively during pregnancy was associated with wheeze or asthma at four to six years of age, with odds ratios of 1.39 (95% CI, 1.08&ndash;1.77) and 1.65 (95% CI, 1.18&ndash;2.31), respectively. In comparison, children exposed to maternal smoking just during the first year of life, but not during pregnancy, did not have an increased risk of wheeze or asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     OBESITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age-adjusted prevalence rates for asthma and obesity are increasing in the United States. Experimental models, prospective cohort studies, population-based case-control studies, and a meta-analysis suggest that patients with an elevated BMI are at increased risk for developing asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/69-75\">",
"     69-75",
"    </a>",
"    ]. This risk may be greater for nonallergic asthma than allergic asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective cohort study of nearly 86,000 adults followed for five years showed a linear relationship between BMI and the risk of developing asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/70\">",
"       70",
"      </a>",
"      ]. The relative risk of developing asthma was 2.7 for patients in the highest BMI group compared with nonobese counterparts.",
"     </li>",
"     <li>",
"      In a meta-analysis of seven prospective studies (333,102 subjects) that evaluated the impact of BMI on the incidence of asthma in adults, asthma was more likely in patients who were overweight or obese than in patients who had a normal body weight (odds ratio 1.5, 95% CI 1.27-1.80) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/73\">",
"       73",
"      </a>",
"      ]. The incidence of asthma increased as the BMI increased.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increased BMI may also be associated with increased asthma severity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Smaller studies have documented improved spirometry, decreased peak flow variability, reduced rescue medicine use, fewer asthma flares, and decreased subjective dyspnea in obese asthmatics who lost weight [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, it is possible that the magnitude of this risk is overstated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/78-83\">",
"     78-83",
"    </a>",
"    ]. Some studies have been based on patient reports of dyspnea or the use of inhaled beta agonists, rather than objective evidence of airflow obstruction. When data from 16,171 participants in the Third National Health and Nutrition Examination Survey (NHANES III) were analyzed, obesity was an independent risk factor for dyspnea, but",
"    <strong>",
"     not",
"    </strong>",
"    for airflow obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/82\">",
"     82",
"    </a>",
"    ]. Thus, although obesity is statistically associated with asthma, biologic causality has not been proven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88494640\">",
"    <span class=\"h1\">",
"     EARLY MENARCHE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Earlier menarche appears to increase the risk of developing asthma in young adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. As an example, asthma symptoms and bronchial hyperreactivity are more common among adult women with menarche before the age of 11 years compared with menarche at age 13 or later based on a large multinational study [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/84\">",
"     84",
"    </a>",
"    ]. In addition, both forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) are lower among women with earlier rather than later menarche. Adjustment for adult body mass index (BMI), age, height, education, and smoking status did not alter these findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     MEDICATION USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic studies have found associations between the development of asthma and both the regular use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and exposure to antibiotics during infancy. However, these studies have inadequately accounted for confounding bias. Both of these associations warrant further",
"    <span class=\"nowrap\">",
"     study.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Acetaminophen",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    /paracetamol",
"    use has been postulated to be a risk for asthma because this agent induces depletion of the antioxidant glutathione in lung tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/86-93\">",
"     86-93",
"    </a>",
"    ]. As a result, oxidative damage may occur, prostaglandin E2 production increases, and Th2 processes may be promoted. Conflicting results have been reported in population based studies of",
"    <span class=\"nowrap\">",
"     acetaminophen/paracetamol",
"    </span>",
"    use and asthma.",
"   </p>",
"   <p>",
"    Several studies have noted a dose-dependent relationship between the regular use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (or paracetamol) and the risk of developing allergic disease in general and asthma in particular [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/94-103\">",
"     94-103",
"    </a>",
"    ]. In the largest of these, parents of 205,487 children were asked retrospectively about paracetamol use in the first year of life and about current asthma symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/102\">",
"     102",
"    </a>",
"    ]. Use of paracetamol in the first year of life was associated with a small increase in risk of asthma at age six to seven; current paracetamol use was associated with a dose dependent increase in risk of asthma symptoms. The effect was also noted in both adults and in offspring of mothers taking regular acetaminophen during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/104\">",
"     104",
"    </a>",
"    ]. However, a single dose of acetaminophen does not appear to cause bronchoconstriction or airways inflammation in healthy children or those with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another population based study, regular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    use, but not",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , was linked to the risk of reporting asthma or chronic obstructive pulmonary disease, even after controlling for smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many of the studies that have described an association between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    use and asthma are retrospective and therefore subject to recall bias [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. An additional problem with studies evaluating over-the-counter medications such as acetaminophen is the possibility that the indication for the medication introduces confounding bias. As an example, asthmatics and those who are at risk for developing asthma are more likely to have co-morbidities (eg, respiratory infections) for which they may take acetaminophen for its analgesic or antipyretic effects. In a study of 1164 children enrolled in a birth cohort, intake of acetaminophen during the first year of life was associated with wheezing at two years of age; however, this association was significantly attenuated when respiratory infection was controlled for [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To reduce the risk of confounding bias, the Melbourne Atopy Cohort Study obtained frequent prospective documentation of paracetamol use and its indication in 620 children with a family history of allergic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/109\">",
"     109",
"    </a>",
"    ]. After adjustment for the frequency of respiratory infections, the association between paracetamol use and parental report of asthma at age six or seven disappeared. Paracetamol use for nonrespiratory indications was not associated with asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Antibiotics during infancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to antibiotics during infancy has been associated with the development of asthma in later childhood. The \"microflora hypothesis,\" or the dependency of the neonatal gut on the presence of normal microflora for the development of tolerance in early life, has been postulated to explain this association. In keeping with this theory, sterilization of the gut with antibiotics causes increased allergic disease in mouse models [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis of four retrospective and four prospective studies (12,082 infants), development of childhood asthma was more likely among infants exposed to antibiotics during the first year of life compared to unexposed infants (odds ratio 2.05, 95% CI 1.41-2.99) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/111\">",
"       111",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the authors stratified their analysis by type of studies, they found that the effect of antibiotics in early life was stronger in the retrospective studies (odds ratio 2.82, 95% CI 2.07-3.85) than in the prospective studies (odds ratio 1.12, 95% CI 0.88-1.42). This strongly suggests that the findings in the retrospective studies were the result of uncontrolled confounding bias or recall bias. The meta-analysis of the prospective studies suggested that exposure to antibiotics in infancy was not a major risk for the development of asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11222975\">",
"    <span class=\"h2\">",
"     Postmenopausal hormone replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies have reported a modest increase in the incidence of asthma among postmenopausal women taking hormone replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/112-116\">",
"     112-116",
"    </a>",
"    ]. Some studies have reported an increased risk associated with combination estrogen-progesterone therapy and others only with unopposed estrogen. In one study, prior histories of allergy or never-smoking appeared to enhance the risk [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PRE- AND PERINATAL FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention has increasingly been focused on the prenatal and perinatal period to identify factors which may help predict the development of asthma and wheezing lower respiratory illnesses. Prenatal exposure to maternal smoking has been discussed above. Other perinatal factors that have been studied include reduced lung function in early infancy, maternal age and diet during pregnancy, prematurity, in utero exposure to antibiotics, head circumference at birth, and mode of delivery.",
"   </p>",
"   <p>",
"    Increased IgE levels in infant cord blood, in conjunction with a family history of atopy, are associated with the development of atopic disease in childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. Increased cord blood IgE (which is believed to be of infant origin), in turn, was found to be correlated with maternal allergen sensitization, age, and maternal IgE levels, infant male sex, lower socioeconomic status, and Hispanic ethnicity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/119\">",
"     119",
"    </a>",
"    ]. The interrelationship of these factors require further study, although it suggests that both genetic and environmental factors influence the atopic diathesis, even before birth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Maternal age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infant mortality due to respiratory illnesses is inversely related to maternal age. Fewer studies have examined the relationship between infant respiratory morbidity and maternal age.",
"   </p>",
"   <p>",
"    In one study, for example, the incidence of lower respiratory tract illnesses during the first year of life was evaluated in 1246 infants enrolled at birth between 1980 and 1984 in Tucson, Arizona [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/120\">",
"     120",
"    </a>",
"    ]. The mothers were divided into five age groups: less than 21, 21 to 25, 26 to 30, 31 to 35, and greater than 35. The incidence of wheezing lower respiratory tract illnesses was inversely related to maternal age; in contrast, the incidence of nonwheezing respiratory illnesses was independent of maternal age. The odds ratio for a wheezing lower respiratory tract illness in infants was 2.4 for infants whose mothers were less than 21 years of age compared to mothers over 30 years of age.",
"   </p>",
"   <p>",
"    This study did not address the risk of asthma, which is not necessarily predicted by wheezing illnesses in infancy. Young maternal age as a risk factor for the development of asthma was studied in a case-control study of 457 newly diagnosed asthmatics among 3 to 4 year old children in Quebec [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/121\">",
"     121",
"    </a>",
"    ]. Compared to children of mothers who were older than 30 years, children born to mothers younger than 20 years had the highest risk of developing asthma, with an adjusted odds ratio of 3.48.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Maternal diet during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since most asthma has its origins in childhood, early nutrition, including prenatal exposure to nutrients, may be relevant as a risk factor for the development of asthma and allergies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/122\">",
"     122",
"    </a>",
"    ]. Conflicting results have been reported, possibly due to inherent difficulties with assessing diet and controlling for confounders [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/122-124\">",
"     122-124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Maternal intakes of the antioxidant vitamin E, zinc, and vitamin D may modulate the risk for wheezing and asthma in young children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/125-129\">",
"     125-129",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the SEATON cohort, a birth cohort of over 1,000 children in Scotland, maternal total intake (diet + supplements) of vitamin E in the highest tertile correlated to reduced development of wheezing symptoms in two year old children, compared with intakes in the lowest tertile (adjusted OR = 0. 49) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/125\">",
"       125",
"      </a>",
"      ]. These protective effects of vitamin E for wheezing at two years translated to a protective effect for asthma as the children turned five years old [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/126\">",
"       126",
"      </a>",
"      ]. In addition, maternal zinc intake was also inversely associated with active asthma in the children (adjusted OR = 0.72).",
"     </li>",
"     <li>",
"      Similarly, in an analysis of a birth cohort of over 1,000 in Massachusetts, performed by the authors, higher maternal intakes of vitamin E and zinc were inversely associated with recurrent wheezing in two year old children [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/127\">",
"       127",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An inverse association between maternal intake of vitamin D during pregnancy and risk of recurrent wheeze in young children in northern climates has also been identified [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/128-130\">",
"       128-130",
"      </a>",
"      ]. Vitamin D deficiency has become more prevalent as people spend more time indoors, particularly in northern areas, and with increasing use of sunscreen [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/131\">",
"       131",
"      </a>",
"      ]. In two cohorts, one in the northeastern United States and the other in northern Scotland, low maternal dietary and total vitamin D intakes during pregnancy were associated with increased wheezing symptoms in children at ages three to five years. These associations were independent of maternal smoking status, maternal intake of vitamin E, zinc, and calcium, and also vitamin D intake by the children. In a third cohort, studied in Finland, higher maternal vitamin D intake from food during pregnancy was associated with lower risks for asthma and allergic rhinitis in five-year old children [",
"      <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/130\">",
"       130",
"      </a>",
"      ]. Vitamin D has been implicated in immunomodulation of multiple cell types, notably dendritic and T regulatory cells. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31193?source=see_link&amp;anchor=H651669#H651669\">",
"       \"Vitamin D and extraskeletal health\", section on 'Immune system'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a prospective cohort study, high adherence to a Mediterranean diet during pregnancy was associated with a reduced risk of wheeze and atopy in the offspring at age 6.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/132\">",
"     132",
"    </a>",
"    ]. However, another study (n = 14,062 children) found no effect of dietary pattern on the development of asthma after controlling for confounders [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/133\">",
"     133",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17304?source=see_link\">",
"     \"The impact of breastfeeding on the development of allergic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Prematurity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective studies and meta-analyses have suggested that prematurity is another perinatal risk factor for asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/134-136\">",
"     134-136",
"    </a>",
"    ]. One report, for example, evaluated the significance of gestational age, birth weight, mechanical ventilation after birth, and a family history of asthma on the development of childhood asthma in a cross-sectional study of 5030 German children aged 9 to 11 years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/135\">",
"     135",
"    </a>",
"    ]. The prevalence of asthma was significantly increased in premature girls (OR = 2.6), particularly in those who required mechanical ventilation after birth (OR = 3.7). No such difference could be demonstrated for boys. Prematurity was a significant risk factor for both recurrent wheezy bronchitis and asthma in a second cross-sectional study of 1,812 primary school children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/136\">",
"     136",
"    </a>",
"    ]. Prospective studies are needed to confirm these findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28536132\">",
"    <span class=\"h2\">",
"     Neonatal jaundice",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential role of neonatal jaundice as a risk factor for childhood asthma was examined in a study of 11,321 children in the National Health Insurance Database in Taiwan [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/137\">",
"     137",
"    </a>",
"    ]. After adjustment for confounding factors (eg, prematurity, low birth rate), the rate of asthma was higher in children with neonatal jaundice than those without (OR 1.64, 95% CI 1.36 to 1.98).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Mode of delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delivery by Cesarean section may increase the risk of childhood asthma compared with vaginal delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/138-143\">",
"     138-143",
"    </a>",
"    ]. A population-based cohort study of 1.7 million singleton births found an increased risk of childhood asthma with both planned and emergency cesarean section (HR 1.52, CI 1.42 to 1.62) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/142\">",
"     142",
"    </a>",
"    ]. One possible explanation is that neonates born by vaginal delivery acquire most of their intestinal flora by swallowing their mother's vaginal fluid during birth; perinatal exposure to microbes on passage through the birth canal then influences early immune modulation. This is an extension of the \"hygiene hypothesis\" that microbial exposure and infections during early childhood (ie, postnatally) protect against the development of asthma and other allergic disease; however, data in support of this hypothesis are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/138-141,144-153\">",
"     138-141,144-153",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small study found that children born by Cesarean section had increased levels of IL-13 and IFN-gamma compared with children born vaginally [",
"    <a class=\"abstract\" href=\"UTD.htm?20/12/20682/abstract/152\">",
"     152",
"    </a>",
"    ]. Increased levels of these cytokines have been associated with the subsequent development of asthma and allergies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Childhood asthma affects boys more than girls. The incidence in females begins to rise at puberty, and by early adulthood, the prevalence is about equal. By age 40, more women than men have asthma. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Gender'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Differences in lung function may be present shortly after birth in some patients who later develop asthma. Airway hyperreactivity, the exaggerated response of asthmatic airways to noxious stimuli, is often detectable before symptoms of asthma develop. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Early abnormalities in pulmonary function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asthma is more commonly present in individuals with other atopic diseases, such as atopic dermatitis and allergic rhinitis; although only about a third of children with atopic dermatitis will go on to develop asthma. Increased total serum levels of IgE are associated with airway hyperresponsiveness (AHR). Sensitization to indoor allergens is strongly associated with asthma, although it has not been demonstrated that allergen exposure increases the risk for developing asthma. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Atopy and allergens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased levels of endotoxin, an inflammatory molecule found in gram-negative bacteria, are associated with increased asthma prevalence and severity, although endotoxin may also be protective against atopy, depending upon the timing of exposure. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Endotoxin exposure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Weiss ST, Speizer FE. Epidemiology and natural history. In: Bronchial Asthma Mechanisms and Therapeutics, 3rd, Weiss EB, Stein M (Eds), Little, Brown, Boston 1993. p.15.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/2\">",
"      Weiss ST, Gold DR. Gender differences in asthma. Pediatr Pulmonol 1995; 19:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/3\">",
"      Sennhauser FH, K&uuml;hni CE. Prevalence of respiratory symptoms in Swiss children: is bronchial asthma really more prevalent in boys? Pediatr Pulmonol 1995; 19:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/4\">",
"      H&aring;land G, Carlsen KC, Sandvik L, et al. Reduced lung function at birth and the risk of asthma at 10 years of age. N Engl J Med 2006; 355:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/5\">",
"      Toelle BG, Peat JK, Salome CM, et al. Toward a definition of asthma for epidemiology. Am Rev Respir Dis 1992; 146:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/6\">",
"      Porsbjerg C, von Linstow ML, Ulrik CS, et al. Risk factors for onset of asthma: a 12-year prospective follow-up study. Chest 2006; 129:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/7\">",
"      Carey VJ, Weiss ST, Tager IB, et al. Airways responsiveness, wheeze onset, and recurrent asthma episodes in young adolescents. The East Boston Childhood Respiratory Disease Cohort. Am J Respir Crit Care Med 1996; 153:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/8\">",
"      Zhong NS, Chen RC, Yang MO, et al. Is asymptomatic bronchial hyperresponsiveness an indication of potential asthma? A two-year follow-up of young students with bronchial hyperresponsiveness. Chest 1992; 102:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/9\">",
"      Weinmayr G, Weiland SK, Bj&ouml;rkst&eacute;n B, et al. Atopic sensitization and the international variation of asthma symptom prevalence in children. Am J Respir Crit Care Med 2007; 176:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/10\">",
"      Arbes SJ Jr, Gergen PJ, Vaughn B, Zeldin DC. Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 2007; 120:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/11\">",
"      Burrows B, Martinez FD, Halonen M, et al. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989; 320:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/12\">",
"      Sears MR, Burrows B, Flannery EM, et al. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991; 325:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/13\">",
"      Platts-Mills TA. How environment affects patients with allergic disease: indoor allergens and asthma. Ann Allergy 1994; 72:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/14\">",
"      Lau S, Illi S, Sommerfeld C, et al. Early exposure to house-dust mite and cat allergens and development of childhood asthma: a cohort study. Multicentre Allergy Study Group. Lancet 2000; 356:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/15\">",
"      Brussee JE, Smit HA, van Strien RT, et al. Allergen exposure in infancy and the development of sensitization, wheeze, and asthma at 4 years. J Allergy Clin Immunol 2005; 115:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/16\">",
"      Tovey ER, Almqvist C, Li Q, et al. Nonlinear relationship of mite allergen exposure to mite sensitization and asthma in a birth cohort. J Allergy Clin Immunol 2008; 122:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/17\">",
"      Torrent M, Sunyer J, Garcia R, et al. Early-life allergen exposure and atopy, asthma, and wheeze up to 6 years of age. Am J Respir Crit Care Med 2007; 176:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/18\">",
"      von Mutius E, Martinez FD, Fritzsch C, et al. Prevalence of asthma and atopy in two areas of West and East Germany. Am J Respir Crit Care Med 1994; 149:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/19\">",
"      Weiss KB, Gergen PJ, Wagener DK. Breathing better or wheezing worse? The changing epidemiology of asthma morbidity and mortality. Annu Rev Public Health 1993; 14:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/20\">",
"      Sporik R, Chapman MD, Platts-Mills TA. House dust mite exposure as a cause of asthma. Clin Exp Allergy 1992; 22:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/21\">",
"      Call RS, Smith TF, Morris E, et al. Risk factors for asthma in inner city children. J Pediatr 1992; 121:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/22\">",
"      Kang BC, Johnson J, Veres-Thorner C. Atopic profile of inner-city asthma with a comparative analysis on the cockroach-sensitive and ragweed-sensitive subgroups. J Allergy Clin Immunol 1993; 92:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/23\">",
"      Rosenstreich DL, Eggleston P, Kattan M, et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. N Engl J Med 1997; 336:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/24\">",
"      Kerkhof M, Wijga AH, Brunekreef B, et al. Effects of pets on asthma development up to 8 years of age: the PIAMA study. Allergy 2009; 64:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/25\">",
"      Carlsten C, Brauer M, Dimich-Ward H, et al. Combined exposure to dog and indoor pollution: incident asthma in a high-risk birth cohort. Eur Respir J 2011; 37:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/26\">",
"      Woodcock A, Lowe LA, Murray CS, et al. Early life environmental control: effect on symptoms, sensitization, and lung function at age 3 years. Am J Respir Crit Care Med 2004; 170:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/27\">",
"      Koopman LP, van Strien RT, Kerkhof M, et al. Placebo-controlled trial of house dust mite-impermeable mattress covers: effect on symptoms in early childhood. Am J Respir Crit Care Med 2002; 166:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/28\">",
"      Marks GB, Mihrshahi S, Kemp AS, et al. Prevention of asthma during the first 5 years of life: a randomized controlled trial. J Allergy Clin Immunol 2006; 118:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/29\">",
"      Chan-Yeung M, Ferguson A, Watson W, et al. The Canadian Childhood Asthma Primary Prevention Study: outcomes at 7 years of age. J Allergy Clin Immunol 2005; 116:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/30\">",
"      Guerra S, Sherrill DL, Martinez FD, Barbee RA. Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol 2002; 109:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/31\">",
"      Burgess JA, Walters EH, Byrnes GB, et al. Childhood allergic rhinitis predicts asthma incidence and persistence to middle age: a longitudinal study. J Allergy Clin Immunol 2007; 120:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/32\">",
"      Huovinen E, Kaprio J, Laitinen LA, Koskenvuo M. Incidence and prevalence of asthma among adult Finnish men and women of the Finnish Twin Cohort from 1975 to 1990, and their relation to hay fever and chronic bronchitis. Chest 1999; 115:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/33\">",
"      Shaaban R, Zureik M, Soussan D, et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 2008; 372:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/34\">",
"      Thorne PS, Kulh&aacute;nkov&aacute; K, Yin M, et al. Endotoxin exposure is a risk factor for asthma: the national survey of endotoxin in United States housing. Am J Respir Crit Care Med 2005; 172:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/35\">",
"      Kogevinas M, Zock JP, Jarvis D, et al. Exposure to substances in the workplace and new-onset asthma: an international prospective population-based study (ECRHS-II). Lancet 2007; 370:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/36\">",
"      Hoppin JA, Umbach DM, London SJ, et al. Pesticides and atopic and nonatopic asthma among farm women in the Agricultural Health Study. Am J Respir Crit Care Med 2008; 177:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/37\">",
"      Dockery DW, Speizer FE, Stram DO, et al. Effects of inhalable particles on respiratory health of children. Am Rev Respir Dis 1989; 139:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/38\">",
"      Magnussen H, J&ouml;rres R, Nowak D. Effect of air pollution on the prevalence of asthma and allergy: lessons from the German reunification. Thorax 1993; 48:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/39\">",
"      Schildcrout JS, Sheppard L, Lumley T, et al. Ambient air pollution and asthma exacerbations in children: an eight-city analysis. Am J Epidemiol 2006; 164:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/40\">",
"      Modig L, Tor&eacute;n K, Janson C, et al. Vehicle exhaust outside the home and onset of asthma among adults. Eur Respir J 2009; 33:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/41\">",
"      Bleck B, Tse DB, Jaspers I, et al. Diesel exhaust particle-exposed human bronchial epithelial cells induce dendritic cell maturation. J Immunol 2006; 176:7431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/42\">",
"      Ohtoshi T, Takizawa H, Okazaki H, et al. Diesel exhaust particles stimulate human airway epithelial cells to produce cytokines relevant to airway inflammation in vitro. J Allergy Clin Immunol 1998; 101:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/43\">",
"      Boland S, Baeza-Squiban A, Fournier T, et al. Diesel exhaust particles are taken up by human airway epithelial cells in vitro and alter cytokine production. Am J Physiol 1999; 276:L604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/44\">",
"      Jin C, Shelburne CP, Li G, et al. Particulate allergens potentiate allergic asthma in mice through sustained IgE-mediated mast cell activation. J Clin Invest 2011; 121:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/45\">",
"      Belanger K, Gent JF, Triche EW, et al. Association of indoor nitrogen dioxide exposure with respiratory symptoms in children with asthma. Am J Respir Crit Care Med 2006; 173:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/46\">",
"      Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 1995; 310:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/47\">",
"      Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ 1993; 307:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/48\">",
"      Thomsen SF, van der Sluis S, Stensballe LG, et al. Exploring the association between severe respiratory syncytial virus infection and asthma: a registry-based twin study. Am J Respir Crit Care Med 2009; 179:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/49\">",
"      Kuehni CE, Spycher BD, Silverman M. Causal links between RSV infection and asthma: no clear answers to an old question. Am J Respir Crit Care Med 2009; 179:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/50\">",
"      Illi S, von Mutius E, Lau S, et al. Early childhood infectious diseases and the development of asthma up to school age: a birth cohort study. BMJ 2001; 322:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/51\">",
"      Martinez FD. Role of viral infections in the inception of asthma and allergies during childhood: could they be protective? Thorax 1994; 49:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/52\">",
"      Strachan DP. Hay fever, hygiene, and household size. BMJ 1989; 299:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/53\">",
"      Ball TM, Castro-Rodriguez JA, Griffith KA, et al. Siblings, day-care attendance, and the risk of asthma and wheezing during childhood. N Engl J Med 2000; 343:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/54\">",
"      Celedon JC, Wright RJ, Litonjua AA, et al. Day care attendance in early life, maternal history of asthma, and asthma at the age of 6 years. Am J Respir Crit Care Med 2003; 167:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/55\">",
"      Rothers J, Stern DA, Spangenberg A, et al. Influence of early day-care exposure on total IgE levels through age 3 years. J Allergy Clin Immunol 2007; 120:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/56\">",
"      Caudri D, Wijga A, Scholtens S, et al. Early daycare is associated with an increase in airway symptoms in early childhood but is no protection against asthma or atopy at 8 years. Am J Respir Crit Care Med 2009; 180:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/57\">",
"      Strachan DP, Butland BK, Anderson HR. Incidence and prognosis of asthma and wheezing illness from early childhood to age 33 in a national British cohort. BMJ 1996; 312:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/58\">",
"      Gilliland FD, Islam T, Berhane K, et al. Regular smoking and asthma incidence in adolescents. Am J Respir Crit Care Med 2006; 174:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/59\">",
"      Polosa R, Knoke JD, Russo C, et al. Cigarette smoking is associated with a greater risk of incident asthma in allergic rhinitis. J Allergy Clin Immunol 2008; 121:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/60\">",
"      Weitzman M, Gortmaker S, Walker DK, Sobol A. Maternal smoking and childhood asthma. Pediatrics 1990; 85:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/61\">",
"      Martinez FD, Cline M, Burrows B. Increased incidence of asthma in children of smoking mothers. Pediatrics 1992; 89:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/62\">",
"      Leuenberger P, Schwartz J, Ackermann-Liebrich U, et al. Passive smoking exposure in adults and chronic respiratory symptoms (SAPALDIA Study). Swiss Study on Air Pollution and Lung Diseases in Adults, SAPALDIA Team. Am J Respir Crit Care Med 1994; 150:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/63\">",
"      Hanrahan JP, Tager IB, Segal MR, et al. The effect of maternal smoking during pregnancy on early infant lung function. Am Rev Respir Dis 1992; 145:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/64\">",
"      Tager IB, Hanrahan JP, Tosteson TD, et al. Lung function, pre- and post-natal smoke exposure, and wheezing in the first year of life. Am Rev Respir Dis 1993; 147:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/65\">",
"      Tager IB. Passive smoking--bronchial responsiveness and atopy. Am Rev Respir Dis 1988; 138:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/66\">",
"      Ehrlich RI, Du Toit D, Jordaan E, et al. Risk factors for childhood asthma and wheezing. Importance of maternal and household smoking. Am J Respir Crit Care Med 1996; 154:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/67\">",
"      Cunningham J, O'Connor GT, Dockery DW, Speizer FE. Environmental tobacco smoke, wheezing, and asthma in children in 24 communities. Am J Respir Crit Care Med 1996; 153:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/68\">",
"      Neuman &Aring;, Hohmann C, Orsini N, et al. Maternal smoking in pregnancy and asthma in preschool children: a pooled analysis of eight birth cohorts. Am J Respir Crit Care Med 2012; 186:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/69\">",
"      Shore SA, Fredberg JJ. Obesity, smooth muscle, and airway hyperresponsiveness. J Allergy Clin Immunol 2005; 115:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/70\">",
"      Camargo CA Jr, Weiss ST, Zhang S, et al. Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. Arch Intern Med 1999; 159:2582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/71\">",
"      Young SY, Gunzenhauser JD, Malone KE, McTiernan A. Body mass index and asthma in the military population of the northwestern United States. Arch Intern Med 2001; 161:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/72\">",
"      Stenius-Aarniala B, Poussa T, Kvarnstr&ouml;m J, et al. Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study. BMJ 2000; 320:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/73\">",
"      Beuther DA, Sutherland ER. Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies. Am J Respir Crit Care Med 2007; 175:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/74\">",
"      Coogan PF, Palmer JR, O'Connor GT, Rosenberg L. Body mass index and asthma incidence in the Black Women's Health Study. J Allergy Clin Immunol 2009; 123:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/75\">",
"      Castro-Giner F, Kogevinas M, Imboden M, et al. Joint effect of obesity and TNFA variability on asthma: two international cohort studies. Eur Respir J 2009; 33:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/76\">",
"      Chen Y, Dales R, Jiang Y. The association between obesity and asthma is stronger in nonallergic than allergic adults. Chest 2006; 130:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/77\">",
"      Taylor B, Mannino D, Brown C, et al. Body mass index and asthma severity in the National Asthma Survey. Thorax 2008; 63:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/78\">",
"      Sood A. Does obesity weigh heavily on the health of the human airway? J Allergy Clin Immunol 2005; 115:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/79\">",
"      Ford ES, Mannino DM, Redd SC, et al. Body mass index and asthma incidence among USA adults. Eur Respir J 2004; 24:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/80\">",
"      Schachter LM, Peat JK, Salome CM. Asthma and atopy in overweight children. Thorax 2003; 58:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/81\">",
"      Tantisira KG, Litonjua AA, Weiss ST, et al. Association of body mass with pulmonary function in the Childhood Asthma Management Program (CAMP). Thorax 2003; 58:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/82\">",
"      Sin DD, Jones RL, Man SF. Obesity is a risk factor for dyspnea but not for airflow obstruction. Arch Intern Med 2002; 162:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/83\">",
"      Clerisme-Beaty EM, Karam S, Rand C, et al. Does higher body mass index contribute to worse asthma control in an urban population? J Allergy Clin Immunol 2009; 124:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/84\">",
"      Macsali F, Real FG, Plana E, et al. Early age at menarche, lung function, and adult asthma. Am J Respir Crit Care Med 2011; 183:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/85\">",
"      Al-Sahab B, Hamadeh MJ, Ardern CI, Tamim H. Early menarche predicts incidence of asthma in early adulthood. Am J Epidemiol 2011; 173:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/86\">",
"      Micheli L, Cerretani D, Fiaschi AI, et al. Effect of acetaminophen on glutathione levels in rat testis and lung. Environ Health Perspect 1994; 102 Suppl 9:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/87\">",
"      Dr&ouml;ge W, Breitkreutz R. Glutathione and immune function. Proc Nutr Soc 2000; 59:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/88\">",
"      Balzer B. Paracetamol and asthma. Thorax 2000; 55:882; author reply 883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/89\">",
"      Etminan M, Sadatsafavi M, Jafari S, et al. Acetaminophen use and the risk of asthma in children and adults: a systematic review and metaanalysis. Chest 2009; 136:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/90\">",
"      Shaheen SO, Newson RB, Ring SM, et al. Prenatal and infant acetaminophen exposure, antioxidant gene polymorphisms, and childhood asthma. J Allergy Clin Immunol 2010; 126:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/91\">",
"      Amberbir A, Medhin G, Alem A, et al. The role of acetaminophen and geohelminth infection on the incidence of wheeze and eczema: a longitudinal birth-cohort study. Am J Respir Crit Care Med 2011; 183:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/92\">",
"      Beasley RW, Clayton TO, Crane J, et al. Acetaminophen use and risk of asthma, rhinoconjunctivitis, and eczema in adolescents: International Study of Asthma and Allergies in Childhood Phase Three. Am J Respir Crit Care Med 2011; 183:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/93\">",
"      McBride JT. The association of acetaminophen and asthma prevalence and severity. Pediatrics 2011; 128:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/94\">",
"      Shaheen SO, Sterne JA, Songhurst CE, Burney PG. Frequent paracetamol use and asthma in adults. Thorax 2000; 55:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/95\">",
"      McKeever TM, Lewis SA, Smit HA, et al. The association of acetaminophen, aspirin, and ibuprofen with respiratory disease and lung function. Am J Respir Crit Care Med 2005; 171:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/96\">",
"      Eneli I, Sadri K, Camargo C Jr, Barr RG. Acetaminophen and the risk of asthma: the epidemiologic and pathophysiologic evidence. Chest 2005; 127:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/97\">",
"      Barr RG, Wentowski CC, Curhan GC, et al. Prospective study of acetaminophen use and newly diagnosed asthma among women. Am J Respir Crit Care Med 2004; 169:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/98\">",
"      Shaheen SO, Newson RB, Henderson AJ, et al. Prenatal paracetamol exposure and risk of asthma and elevated immunoglobulin E in childhood. Clin Exp Allergy 2005; 35:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/99\">",
"      Davey G, Berhane Y, Duncan P, et al. Use of acetaminophen and the risk of self-reported allergic symptoms and skin sensitization in Butajira, Ethiopia. J Allergy Clin Immunol 2005; 116:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/100\">",
"      Newson RB, Shaheen SO, Chinn S, Burney PG. Paracetamol sales and atopic disease in children and adults: an ecological analysis. Eur Respir J 2000; 16:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/101\">",
"      Shaheen SO, Newson RB, Sherriff A, et al. Paracetamol use in pregnancy and wheezing in early childhood. Thorax 2002; 57:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/102\">",
"      Beasley R, Clayton T, Crane J, et al. Association between paracetamol use in infancy and childhood, and risk of asthma, rhinoconjunctivitis, and eczema in children aged 6-7 years: analysis from Phase Three of the ISAAC programme. Lancet 2008; 372:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/103\">",
"      Shaheen S, Potts J, Gnatiuc L, et al. The relation between paracetamol use and asthma: a GA2LEN European case-control study. Eur Respir J 2008; 32:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/104\">",
"      Allmers H. Frequent acetaminophen use and allergic diseases: is the association clear? J Allergy Clin Immunol 2005; 116:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/105\">",
"      Soferman R, Tsivion A, Farber M, Sivan Y. The effect of a single dose of acetaminophen on airways response in children with asthma. Clin Pediatr (Phila) 2013; 52:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/106\">",
"      Barr RG. Does paracetamol cause asthma in children? Time to remove the guesswork. Lancet 2008; 372:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/107\">",
"      Farquhar H, Crane J, Mitchell EA, et al. The acetaminophen and asthma hypothesis 10 years on: A case to answer. J Allergy Clin Immunol 2009; 124:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/108\">",
"      Signorello LB, McLaughlin JK, Lipworth L, et al. Confounding by indication in epidemiologic studies of commonly used analgesics. Am J Ther 2002; 9:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/109\">",
"      Lowe AJ, Carlin JB, Bennett CM, et al. Paracetamol use in early life and asthma: prospective birth cohort study. BMJ 2010; 341:c4616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/110\">",
"      Noverr MC, Falkowski NR, McDonald RA, et al. Development of allergic airway disease in mice following antibiotic therapy and fungal microbiota increase: role of host genetics, antigen, and interleukin-13. Infect Immun 2005; 73:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/111\">",
"      Marra F, Lynd L, Coombes M, et al. Does antibiotic exposure during infancy lead to development of asthma?: a systematic review and metaanalysis. Chest 2006; 129:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/112\">",
"      Jarvis D, Leynaert B. The association of asthma, atopy and lung function with hormone replacement therapy and surgical cessation of menstruation in a population-based sample of English women. Allergy 2008; 63:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/113\">",
"      Lange P, Parner J, Prescott E, et al. Exogenous female sex steroid hormones and risk of asthma and asthma-like symptoms: a cross sectional study of the general population. Thorax 2001; 56:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/114\">",
"      Troisi RJ, Speizer FE, Willett WC, et al. Menopause, postmenopausal estrogen preparations, and the risk of adult-onset asthma. A prospective cohort study. Am J Respir Crit Care Med 1995; 152:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/115\">",
"      Barr RG, Wentowski CC, Grodstein F, et al. Prospective study of postmenopausal hormone use and newly diagnosed asthma and chronic obstructive pulmonary disease. Arch Intern Med 2004; 164:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/116\">",
"      Romieu I, Fabre A, Fournier A, et al. Postmenopausal hormone therapy and asthma onset in the E3N cohort. Thorax 2010; 65:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/117\">",
"      Hansen LG, Halken S, H&oslash;st A, et al. Prediction of allergy from family history and cord blood IgE levels. A follow-up at the age of 5 years. Cord blood IgE. IV. Pediatr Allergy Immunol 1993; 4:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/118\">",
"      Halken S. Early sensitisation and development of allergic airway disease - risk factors and predictors. Paediatr Respir Rev 2003; 4:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/119\">",
"      Scirica CV, Gold DR, Ryan L, et al. Predictors of cord blood IgE levels in children at risk for asthma and atopy. J Allergy Clin Immunol 2007; 119:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/120\">",
"      Martinez FD, Wright AL, Holberg CJ, et al. Maternal age as a risk factor for wheezing lower respiratory illnesses in the first year of life. Am J Epidemiol 1992; 136:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/121\">",
"      Infante-Rivard C. Young maternal age: a risk factor for childhood asthma? Epidemiology 1995; 6:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/122\">",
"      Devereux G, Seaton A. Diet as a risk factor for atopy and asthma. J Allergy Clin Immunol 2005; 115:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/123\">",
"      McKeever TM, Britton J. Diet and asthma. Am J Respir Crit Care Med 2004; 170:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/124\">",
"      Lange NE, Rifas-Shiman SL, Camargo CA Jr, et al. Maternal dietary pattern during pregnancy is not associated with recurrent wheeze in children. J Allergy Clin Immunol 2010; 126:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/125\">",
"      Martindale S, McNeill G, Devereux G, et al. Antioxidant intake in pregnancy in relation to wheeze and eczema in the first two years of life. Am J Respir Crit Care Med 2005; 171:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/126\">",
"      Devereux G, Turner SW, Craig LC, et al. Low maternal vitamin E intake during pregnancy is associated with asthma in 5-year-old children. Am J Respir Crit Care Med 2006; 174:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/127\">",
"      Litonjua AA, Rifas-Shiman SL, Ly NP, et al. Maternal antioxidant intake in pregnancy and wheezing illnesses in children at 2 y of age. Am J Clin Nutr 2006; 84:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/128\">",
"      Camargo CA Jr, Rifas-Shiman SL, Litonjua AA, et al. Maternal intake of vitamin D during pregnancy and risk of recurrent wheeze in children at 3 y of age. Am J Clin Nutr 2007; 85:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/129\">",
"      Devereux G, Litonjua AA, Turner SW, et al. Maternal vitamin D intake during pregnancy and early childhood wheezing. Am J Clin Nutr 2007; 85:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/130\">",
"      Erkkola M, Kaila M, Nwaru BI, et al. Maternal vitamin D intake during pregnancy is inversely associated with asthma and allergic rhinitis in 5-year-old children. Clin Exp Allergy 2009; 39:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/131\">",
"      Litonjua AA, Weiss ST. Is vitamin D deficiency to blame for the asthma epidemic? J Allergy Clin Immunol 2007; 120:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/132\">",
"      Chatzi L, Torrent M, Romieu I, et al. Mediterranean diet in pregnancy is protective for wheeze and atopy in childhood. Thorax 2008; 63:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/133\">",
"      Shaheen SO, Northstone K, Newson RB, et al. Dietary patterns in pregnancy and respiratory and atopic outcomes in childhood. Thorax 2009; 64:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/134\">",
"      Jaakkola JJ, Ahmed P, Ieromnimon A, et al. Preterm delivery and asthma: a systematic review and meta-analysis. J Allergy Clin Immunol 2006; 118:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/135\">",
"      von Mutius E, Nicolai T, Martinez FD. Prematurity as a risk factor for asthma in preadolescent children. J Pediatr 1993; 123:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/136\">",
"      Frischer T, Kuehr J, Meinert R, et al. Risk factors for childhood asthma and recurrent wheezy bronchitis. Eur J Pediatr 1993; 152:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/137\">",
"      Ku MS, Sun HL, Sheu JN, et al. Neonatal jaundice is a risk factor for childhood asthma: a retrospective cohort study. Pediatr Allergy Immunol 2012; 23:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/138\">",
"      Xu B, Pekkanen J, Hartikainen AL, J&auml;rvelin MR. Caesarean section and risk of asthma and allergy in adulthood. J Allergy Clin Immunol 2001; 107:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/139\">",
"      Kero J, Gissler M, Gr&ouml;nlund MM, et al. Mode of delivery and asthma -- is there a connection? Pediatr Res 2002; 52:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/140\">",
"      McKeever TM, Lewis SA, Smith C, Hubbard R. Mode of delivery and risk of developing allergic disease. J Allergy Clin Immunol 2002; 109:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/141\">",
"      Juhn YJ, Weaver A, Katusic S, Yunginger J. Mode of delivery at birth and development of asthma: a population-based cohort study. J Allergy Clin Immunol 2005; 116:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/142\">",
"      Toll&aring;nes MC, Moster D, Daltveit AK, Irgens LM. Cesarean section and risk of severe childhood asthma: a population-based cohort study. J Pediatr 2008; 153:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/143\">",
"      Roduit C, Scholtens S, de Jongste JC, et al. Asthma at 8 years of age in children born by caesarean section. Thorax 2009; 64:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/144\">",
"      Ramsey CD, Celed&oacute;n JC. The hygiene hypothesis and asthma. Curr Opin Pulm Med 2005; 11:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/145\">",
"      Gr&ouml;nlund MM, Lehtonen OP, Eerola E, Kero P. Fecal microflora in healthy infants born by different methods of delivery: permanent changes in intestinal flora after cesarean delivery. J Pediatr Gastroenterol Nutr 1999; 28:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/146\">",
"      Bj&ouml;rkst&eacute;n B, Naaber P, Sepp E, Mikelsaar M. The intestinal microflora in allergic Estonian and Swedish 2-year-old children. Clin Exp Allergy 1999; 29:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/147\">",
"      Kalliom&auml;ki M, Kirjavainen P, Eerola E, et al. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J Allergy Clin Immunol 2001; 107:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/148\">",
"      Eggesb&oslash; M, Botten G, Stigum H, et al. Is delivery by cesarean section a risk factor for food allergy? J Allergy Clin Immunol 2003; 112:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/149\">",
"      McKeever TM, Lewis SA, Smith C, et al. Early exposure to infections and antibiotics and the incidence of allergic disease: a birth cohort study with the West Midlands General Practice Research Database. J Allergy Clin Immunol 2002; 109:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/150\">",
"      Annesi-Maesano I, Moreau D, Strachan D. In utero and perinatal complications preceding asthma. Allergy 2001; 56:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/151\">",
"      Nafstad P, Magnus P, Jaakkola JJ. Risk of childhood asthma and allergic rhinitis in relation to pregnancy complications. J Allergy Clin Immunol 2000; 106:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/152\">",
"      Werner A, Ramlau-Hansen CH, Jeppesen SK, et al. Caesarean delivery and risk of developing asthma in the offspring. Acta Paediatr 2007; 96:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/12/20682/abstract/153\">",
"      Bisgaard H, Hermansen MN, Buchvald F, et al. Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med 2007; 357:1487.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 572 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-9F539080E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_12_20682=[""].join("\n");
var outline_f20_12_20682=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENDER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EARLY ABNORMALITIES IN PULMONARY FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neonatal lung function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Airway hyperreactivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      FAMILIAL HISTORY OF ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ATOPY AND ALLERGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Atopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Allergen exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Environmental control studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RHINITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ENDOTOXIN EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OCCUPATIONAL EXPOSURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      POLLUTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Outdoor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Indoor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      RESPIRATORY INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SMOKING AND EXPOSURE TO ENVIRONMENTAL TOBACCO SMOKE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Active smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Secondhand smoke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Prenatal exposure to maternal smoking",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      OBESITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88494640\">",
"      EARLY MENARCHE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      MEDICATION USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Acetaminophen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Antibiotics during infancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11222975\">",
"      Postmenopausal hormone replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PRE- AND PERINATAL FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Maternal age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Maternal diet during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Prematurity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28536132\">",
"      Neonatal jaundice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Mode of delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34569?source=related_link\">",
"      Allergen avoidance in the treatment of asthma and allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=related_link\">",
"      Bronchoprovocation testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=related_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19653?source=related_link\">",
"      Epidemiology of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10713?source=related_link\">",
"      Genetics of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/43/19129?source=related_link\">",
"      Increasing prevalence of asthma and allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7383?source=related_link\">",
"      Natural history of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=related_link\">",
"      Secondhand smoke exposure: Effects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17304?source=related_link\">",
"      The impact of breastfeeding on the development of allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2298?source=related_link\">",
"      Virus-induced wheezing and asthma: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31193?source=related_link\">",
"      Vitamin D and extraskeletal health",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_12_20683="Usual doses antileukotriene";
var content_f20_12_20683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Usual doses of agents affecting 5-lipoxygenase pathway",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Medication",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dose form",
"      </td>",
"      <td class=\"subtitle1\">",
"       Age 0-4",
"      </td>",
"      <td class=\"subtitle1\">",
"       Age 5-11",
"      </td>",
"      <td class=\"subtitle1\">",
"       Age 12 through adult",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Montelukast",
"       </p>",
"       <p>",
"        (Singulair&reg;)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Granules: 4 mg/packet",
"       </p>",
"       <p>",
"        Tablet: 10 mg",
"       </p>",
"       <p>",
"        Chewable tablets: 4 mg, 5 mg",
"       </p>",
"      </td>",
"      <td>",
"       4 mg granules or chewable tablet once daily in evening",
"      </td>",
"      <td>",
"       5 mg chewable tablet once daily in evening",
"      </td>",
"      <td>",
"       10 mg tablet once daily in evening",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Zafirlukast",
"       </p>",
"       <p>",
"        (Accolate&reg;)",
"       </p>",
"      </td>",
"      <td>",
"       Tablets: 10 mg, 20 mg",
"      </td>",
"      <td>",
"       (Not studied)",
"      </td>",
"      <td>",
"       10 mg twice daily",
"      </td>",
"      <td>",
"       20 mg twice daily",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Zileuton",
"       </p>",
"       <p>",
"        (Zyflo CR&reg;)",
"       </p>",
"      </td>",
"      <td>",
"       Extended-release tablet: 600 mg",
"      </td>",
"      <td>",
"       (Not studied)",
"      </td>",
"      <td>",
"       (Not studied)",
"      </td>",
"      <td>",
"       1200 mg twice daily",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_12_20683=[""].join("\n");
var outline_f20_12_20683=null;
var title_f20_12_20684="Otorrhea causes";
var content_f20_12_20684=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of otorrhea in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Life-threatening conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span class=\"red\">",
"         Traumatic CSF otorrhea",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span class=\"red\">",
"         Infectious complications of acute otitis media*",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span class=\"red\">",
"         Necrotizing otitis externa",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span class=\"red\">",
"         Neoplasm",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Common conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span class=\"green\">",
"         Bacterial otitis externa",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span class=\"green\">",
"         Foreign body",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span class=\"green\">",
"         Acute otitis media with perforation of TM",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span class=\"green\">",
"         Chronic suppurative otitis media",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span class=\"green\">",
"         Cerumen",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span class=\"green\">",
"         Tympanostomy tube drainage",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Contact dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bullous myringitis with rupture of bulla",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulation tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Otomycosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        First branchial cleft cyst",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholesteatoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spontaneous CSF otorrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histiocytosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <span style=\"color:#ff0000\">",
"     Red:",
"    </span>",
"    life-threatening.",
"    <br>",
"     <span style=\"color:#008000\">",
"      Green:",
"     </span>",
"     common condition.",
"     <div class=\"footnotes\">",
"      CSF: cerebrospinal fluid; TM: tympanic membrane.",
"      <br>",
"       * Adjacent infections include mastoiditis and temporal bone osteomyelitis. Intracranial complications of acute otitis media include meningitis; brain abscess; epidural abscess; subdural empyema; and thrombosis of the lateral sinus, cavernous sinus, and/or carotid artery.",
"      </br>",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_12_20684=[""].join("\n");
var outline_f20_12_20684=null;
var title_f20_12_20685="Dobutamine stress and outcome";
var content_f20_12_20685=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dobutamine stress testing predicts outcome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 271px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 392 patients with chest pain followed for a mean of 22 months, the results from dobutamine-atropine stress technetium-99m sestamibi SPECT imaging are predictive of the risk of a cardiac event (death or nonfatal myocardial infarction). Patients who have both fixed and reversible defects have the worst outcome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Geleijnse ML, Elhendy A, van Domburg RT, et al. J Am Coll Cardiol 1996; 28:447.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_12_20685=[""].join("\n");
var outline_f20_12_20685=null;
var title_f20_12_20686="Course of IDDM";
var content_f20_12_20686=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F66417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F66417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Time course of type 1 diabetes mellitus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 290px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Time course of the development of type 1 diabetes. Genetic markers are present from birth, immune markers first appear at the time of the environmental triggering events, and sensitive metabolic markers of deficient insulin secretion begin to appear soon after the onset of beta-cell dysfunction. However, clinically evident type 1 diabetes does not occur until there has been a much greater loss of functioning beta-cell mass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_12_20686=[""].join("\n");
var outline_f20_12_20686=null;
var title_f20_12_20687="Pooled relative risk mammog";
var content_f20_12_20687=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 622px\">",
"   <div class=\"ttl\">",
"    Pooled relative risk for breast cancer mortality from mammography screening trials compared with control for women aged 39 to 49 years",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 602px; height: 291px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CNBSS-1: Canadian National Breast Screening Study-1; CrI: credible interval; HIP: Health Insurance Plan of Greater New York; %: percent.",
"     <br>",
"      * Swedish Two-County trial.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nelson HD, Tyne K, Naik A, Bougatsos B, Chan BK, Humphrey L. Screening for Breast Cancer: An Update for the US Preventive Services Task Force. AHRQ Publication No. 10-05142-EF-5, November 2009. Agency for Healthcare Research and Quality, Rockville, MD. file://www.ahrq.gov/clinic/uspstf09/breastcancer/brcanupfig1.htm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_12_20687=[""].join("\n");
var outline_f20_12_20687=null;
